

ASSOCIATE EDITOR: JUKKA HAKKOLA

Acylcarnitines: Nomenclature, Biomarkers, Therapeutic Potential, Drug Targets, and Clinical Trials

Maija Dambrova, Marina Makrecka-Kuka, Janis Kuka, Reinis Vilskersts, Didi Nordberg, Misty M. Attwood, Stefan Smesny, Zumurut Duygu Sen, An Chi Guo, Eponine Oler, Siyang Tian, Jiamin Zheng, David S. Wishart, Edgars Liepinsh, and Helgi B. Schiöth
Laboratory of Pharmaceutical Pharmacology, Latvian Institute of Organic Synthesis, Riga, Latvia (M.D., M.M.-K., J.K., R.V., E.L.); Section of Functional Pharmacology, Department of Neuroscience, Uppsala University, Uppsala, Sweden, (D.N., M.M.A., H.B.S.); Department of Psychiatry, Jena University Hospital, Jena, Germany (S.S., Z.D.S.); and Department of Biological Sciences, University of Alberta, Edmonton, Canada (A.C.G., E.O., S.T., J.Z., D.S.W.)

Abstract	507
Significance Statement	507
I. Introduction	507
II. Acylcarnitine Molecules	508
A. Repertoire of Acylcarnitines and Major Update of the HMDB Database	508
B. Classification of Acylcarnitines	509
C. Short-Chain Acylcarnitines	510
D. Medium-Chain Acylcarnitines	510
E. Long-Chain Acylcarnitines	510
F. Very Long-Chain Acylcarnitines	511
G. Unsaturated-Chain Acylcarnitines	513
H. Branched-Chain Acylcarnitines	513
I. Hydroxyl-/Dicarboxyl-Acylcarnitines	514
III. Biosynthesis and Regulation	515
A. Enzymology of Acylcarnitine Biosynthesis	515
1. Carnitine Acetyltransferase	516
2. Carnitine Octanoyltransferase	518
3. Carnitine Palmitoyltransferases	519
4. Acylcarnitine Transporters	520
B. Acylcarnitine Production Sites – Organelles	520
C. Enzymes, Transporters, and Energy Metabolism Pathways Affecting Acylcarnitine Levels	520
D. Acylcarnitine Production Sites – Tissues	522
IV. Diseases and Pathways	522
A. Biomarkers of Pathologic Conditions and Diseases	522
1. Acylcarnitines for the Diagnosis of Rare Inherited Diseases and Conditions	522
2. Long-Chain Acylcarnitine Measurements for the Diagnosis of Insulin Resistance	524
3. Incomplete Long-Chain Acylcarnitine Metabolism as a Marker of Heart Failure and a Predictor of Major Cardiovascular Events	525
B. Long-Chain Acylcarnitine Accumulation-Induced Disorders	526
1. Enzymes, Ion Channels, and (Signaling) Pathways Affected by Acylcarnitines	526
2. Detrimental Effects of Acylcarnitines in Ischemic Heart Disease and Heart Failure	527
3. Proarrhythmic Effects of Acylcarnitines	529

Address correspondence to: Helgi B. Schiöth, Professor in Pharmacology, Head, Section of Functional Pharmacology, Department of Neuroscience, Uppsala University, Box 593, 75124 Uppsala, Sweden. E-mail: helgis@bmc.uu.se; Maija Dambrova, Professor in Pharmacy, Head, Laboratory of Pharmaceutical Pharmacology, Latvian Institute of Organic Synthesis, Aizkraukles Str 21, LV1006, Riga, Latvia. E-mail: maija.dambrova@farm.osi.lv

The authors were supported by the European Union's Horizon 2020 research and innovation program [Grant 857394], Genome Canada, and the Canadian Foundation for Innovation. H.B.S. is supported by the Swedish Research Council, the Swedish Brain Foundation, and the Novo Nordisk Foundation.

The authors declare no conflicts of interest.

dx.doi.org/10.1124/pharmrev.121.000408.

4. Acylcarnitine Accumulation-Induced Complications in Rare Inherited Diseases and Conditions	529
5. Prodiabetic Effects of Acylcarnitines	530
6. Acylcarnitine Effects on Inflammation	531
7. Possible Effects of Acylcarnitines in Neurodegenerative and Neuropsychiatric Disorders	532
V. Drugs, Supplements, and Clinical Trials	533
A. The Effects of Supplementation with Acetylcarnitine and Propionylcarnitine	533
B. Carnitine Deficiency and Related Disorders	534
C. Clinical Trials	535
VI. Future Perspectives	537
Authorship Contributions	539
References	539

Abstract—Acylcarnitines are fatty acid metabolites that play important roles in many cellular energy metabolism pathways. They have historically been used as important diagnostic markers for inborn errors of fatty acid oxidation and are being intensively studied as markers of energy metabolism, deficits in mitochondrial and peroxisomal β -oxidation activity, insulin resistance, and physical activity. Acylcarnitines are increasingly being identified as important indicators in metabolic studies of many diseases, including metabolic disorders, cardiovascular diseases, diabetes, depression, neurologic disorders, and certain cancers. The US Food and Drug Administration-approved drug L-carnitine, along with short-chain acylcarnitines (acetylcarnitine and propionylcarnitine), is now widely used as a dietary supplement. In light of their growing importance, we have undertaken an extensive review of acylcarnitines and provided a detailed description of their identity, nomenclature, classification, biochemistry, pathophysiology, supplementary use, potential drug targets, and clinical trials. We also summarize these updates in the Human Metabo-

lome Database, which now includes information on the structures, chemical formulae, chemical/spectral properties, descriptions, and pathways for 1240 acylcarnitines. This work lays a solid foundation for identifying, characterizing, and understanding acylcarnitines in human biosamples. We also discuss the emerging opportunities for using acylcarnitines as biomarkers and as dietary interventions or supplements for many wide-ranging indications. The opportunity to identify new drug targets involved in controlling acylcarnitine levels is also discussed.

Significance Statement—This review provides a comprehensive overview of acylcarnitines, including their nomenclature, structure and biochemistry, and use as disease biomarkers and pharmaceutical agents. We present updated information contained in the Human Metabolome Database website as well as substantial mapping of the known biochemical pathways associated with acylcarnitines, thereby providing a strong foundation for further clarification of their physiological roles.

I. Introduction

Acylcarnitines are esters arising from the conjugation of fatty acids (i.e., acyl groups) with L-carnitine. They are widely used and produced in cellular energy metabolism pathways. The well established biologic function of acylcarnitines is to transport acyl groups from the cytosol into the mitochondrial matrix for β -oxidation, leading to the production of energy to sustain cell activity (Indiveri et al., 2011). The energy production by β -oxidation is significant, with $7n-6$ ATP molecules being produced per acylcarnitine, where n is the number of acyl- carbons (Jain et al., 2021). Over the past three decades, many additional actions and roles of acylcarnitines have been discovered. For instance,

it is now increasingly clear that long-chain acylcarnitines play a role in insulin resistance and the development of cardiovascular diseases (Adams et al., 2009; McCoin et al., 2015a; Guasch-Ferre et al., 2016; Aitken-Buck et al., 2020). The role of acylcarnitines as important diagnostic biomarkers is also growing. For example, plasma long-chain acylcarnitine measurements are widely used in newborn screening to identify inborn errors of fatty acid oxidation and to diagnose deficits in energy metabolism (Ramos-Roman et al., 2012; Knottnerus et al., 2018). Acylcarnitines are also becoming a very important group of biomolecules within the field of metabolomics, as an increasing number of diseases and nutritional states exhibit distinct acylcarnitine profiles. Interest in acylcarnitines has thus risen

ABBREVIATIONS: ACC, acetyl-CoA carboxylase; ACS, acyl-CoA synthetase; ACSL, long-chain acyl-CoA synthetase; Akt, protein kinase B; AMPK, adenosine monophosphate-activated protein kinase; CACT, carnitine/acylcarnitine translocase; CNS, central nervous system; CPT1, carnitine palmitoyltransferase 1; CPT2, carnitine palmitoyltransferase 2; CrAT, carnitine acetyltransferase; CrOT, carnitine octanoyltransferase; FAOD, fatty acid oxidation disorder; FDA, Food and Drug Administration; GTT, glucose tolerance test; HMDB, Human Metabolome Database; KO, knockout; LCHAD, long-chain 3-hydroxyacyl-CoA dehydrogenase; MCD, malonyl-CoA decarboxylase; MDD, major depressive disorder; OCT1, organic cation transporter 1; OCTN2, organic cation novel type 2 transporter; OXPHOS, oxidative phosphorylation; ^{31}P -MRS, phosphorus-31 magnetic resonance spectroscopy; PCOS, polycystic ovary syndrome, PI3K, phosphoinositide-3 kinase; PPAR- α , peroxisome proliferator-activated receptor α ; ROS, reactive oxygen species; SCD, sudden cardiac death; TMAO, trimethylamine N-oxide; VLCAD, very long-chain acyl-CoA dehydrogenase.

substantially. For example, in the past ten years, the number of publications on acylcarnitines has tripled, and the same trend can be seen in the number of acylcarnitine clinical studies that have been launched.

The first review in the area of acylcarnitines was published in 1975 with a primary focus on the role of acylcarnitines in fatty acid oxidation arising from ischemia (Hull et al., 1975). Since then, over 200 reviews have been written on or about acylcarnitines. Santra and Hendriksz (2010) published a review on the use of different acylcarnitines as vehicles to diagnose inborn errors of metabolism. Wanders et al. (2020) extended this work and addressed the involvement of acylcarnitines in inborn metabolic disorders and their utility for newborn screening. Acylcarnitines also play important roles in other metabolic disorders, including diabetes and cancer. Schooneman et al. (2013) reviewed the physiologic functions of medium- and long-chain acylcarnitines, concluding that the concentrations of different acylcarnitines correlate with a number of different metabolic disease states. McCoin et al. (2015a) published a review on long-chain acylcarnitines and their functions as both transporters in oxidative catabolism and as modulators of a number of physiologic and pathophysiological functions, such as cardiac electrophysiology, insulin signaling, cellular stress, and inflammation. Li et al. (2019) reviewed the role of acylcarnitines in hepatocellular carcinoma, a primary liver cancer, and discussed the metabolism of acylcarnitines in relation to different concentrations of short-, medium- and long-chain acylcarnitines. It was concluded that acylcarnitines could be used as both diagnostic and prognostic biomarkers for hepatocellular carcinoma. In addition to the many roles that medium- and long-chain acylcarnitines play in human physiology and pathophysiology, the smallest acylcarnitine of all, acetylcarnitine, is emerging as a useful supplemental option to alleviate the development of neurologic disorders (Maldonado et al., 2020; McCann et al., 2021).

Although acylcarnitine research is expanding and reviews on its roles in metabolic disorders continue to grow, there has been relatively little effort to comprehensively address other important issues regarding acylcarnitines. These include their nomenclature, classification, biochemistry, pathology, and use as investigative pharmaceuticals. To address these issues, we performed a systematic and comprehensive search covering all acylcarnitine-related information available through PubMed from 1975 until now. This literature survey was further complemented with information found in other databases such as PubChem, Clinicaltrials.gov, Drugbank.ca, AdisInsight, and Molecularyou.com. This consolidated information on acylcarnitines is not only presented here but has also been deposited into the

Human Metabolome Database (HMDB) (Wishart et al., 2018). In particular, the latest release of the HMDB also includes many details (structures, nomenclature, pathways, MS spectra, etc.) that could not be fully presented in this manuscript (Wishart et al., 2022). Together, these two resources should serve as a comprehensive foundation for information about acylcarnitines and should allow for regular online updates as the field continues to grow.

II. Acylcarnitine Molecules

A. Repertoire of Acylcarnitines and Major Update of the HMDB Database

The physiologic role of acylcarnitines was first discovered nearly 60 years ago in studies involving rodents (Fritz, 1959; Bremer, 1962). Since then, acylcarnitines or enzymes synthesizing acylcarnitines have been found in plants (Bourdin et al., 2007; Nguyen et al., 2016), yeasts (Hiltunen et al., 2003), arthropods (Skottene et al., 2019), and all vertebrates (Lopes-Marques et al., 2015). In that time, approximately 80 different acylcarnitines have been rigorously studied and described in the literature or cataloged in databases (Wishart et al., 2018). However, it is known that the actual number of acylcarnitines is far greater than this, as carnitine moieties can be promiscuously added to almost any organic acid. Moreover, several metabolomic studies have provided evidence that many more acylcarnitines (hundreds to thousands) likely exist in the human body (Zuniga and Li, 2011; Wishart et al., 2018; Yu et al., 2018; Blaženović et al., 2019; Yan et al., 2020). As of Jan. 2021, the HMDB contained only 146 acylcarnitines.

In the course of preparing this review, members of the HMDB curation staff extensively reviewed the extant literature for newly identified or tentatively identified acylcarnitines. Published reports have indicated that mass spectrometry-based experimental evidence exists for more than 1000 acylcarnitines (Zuniga and Li, 2011; van der Hooff et al., 2015; Yu et al., 2018; Blaženović et al., 2019; Yan et al., 2020). Based on the proposed (partial) structures and chemical formulae appearing in these papers, our HMDB team developed a computer program to generate possible linear acyl chains using experimental (formula and partial structure) constraints as well as knowledge regarding the structure of known fatty acids in the animal/plant kingdom. First, the program generated all combinations of linear, saturated, unsaturated, hydroxylated, keto- and branched-chain fatty acids ranging in size from C2 to C25. This process created more than 40,000 possible acyl chains. Then a further set of filtering steps was applied to generate more realistic and biologically feasible acyl chains that complied with the experimental observations reported in the literature (Zuniga and Li,

2011; van der Hooft et al., 2015; Yu et al., 2018; Blaženović et al., 2019; Yan et al., 2020). These included the following rules: 1) no successive carbon-carbon double bonds; 2) no double bonds, hydroxyl groups, or keto groups at the terminal carbon; 3) no hydroxyl groups at an unsaturated carbon; 4) if three carbon-carbon double bonds exist within a fatty acid, those three double bonds must adhere to two specific spacing patterns, namely, one single bond between two carbon-carbon double bonds or two single bonds between two carbon-carbon double bonds; and 5) if there are more than three carbon-carbon double bonds in the fatty acid, those isomers must be limited to those experimentally identified in the literature or databases.

This process generated 2883 fatty acid isomers. These fatty acids were then compared against known fatty acids in the HMDB, and duplicates were removed. Curators and chemists on the HMDB team then manually checked the collection for long-chain unsaturated fatty acids with multiple double bonds and kept only those that were reported in the literature or online databases to further reduce the number of fatty acids to 1096. In generating this set of fatty acyl chains, the curation team did not consider the stereo configuration (cis or trans) of these 1096 fatty acid isomers. If these cis-trans isomers were included, the total would be 4381. Using this set of 1096 computationally generated acyl groups, the HMDB team then used in-house software to create the structures in various formats (Mol, SDF, and SMILES) for 1096 acylcarnitines, all of which have now been deposited into the latest release of the HMDB. Another 36 “exotic” acylcarnitines consisting of nonlinear organic acids or dicarboxylic acids were also generated from free organic acids found in the HMDB, for which experimental evidence also supported their existence. Combined with the previously existing acylcarnitines, there are now a total of 1240 acylcarnitines in the HMDB (Fig. 1).

B. Classification of Acylcarnitines

Currently, most acylcarnitines are classified according to the chemical structure of the variable acyl moiety in the acylcarnitine molecule. As a result, the classification of acylcarnitines is often similar to the




Fig. 1. Acyl-chain categories and respective numbers of acylcarnitines in each category. The size of each mitochondrion depicts the relative abundance of short-, medium-, long- and very long-chain acylcarnitines.

classification of fatty acids (e.g., short-, medium-, long-, and very long-chain fatty acids) (Ratnayake and Galli, 2009; Kimura et al., 2020). However, it is important to note that there is also no unanimity about the classification of fatty acids, and classification methods can differ among different authors (Ratnayake and Galli, 2009; Kimura et al., 2020). Usually, the first parameter that is considered in categorizing an acylcarnitine is the length of the carbon chain. Based on the number of carbon atoms in the acyl-chain, we propose that acylcarnitines can be divided into four groups: short-chain (C2–C5), medium-chain (C6–C12), long-chain (C13–C20) and very long-chain (>C21) acylcarnitines (Fig. 2). Moreover, acylcarnitines can also be classified by the saturation degree of the fatty acid moiety: either an unsaturated or saturated fatty acid moiety. Unsaturated acylcarnitines can be further divided into monounsaturated and polyunsaturated acylcarnitines. Likewise, the cis- and trans-configurations of the fatty acid moiety can be taken into account. In addition, acylcarnitines can be classified according to the chemical structure of their acyl moiety. The majority of acylcarnitines have an aliphatic, straight-chain fatty acid moiety, but there are also acylcarnitines with branched-chain fatty acid moieties and even cyclic organic acids. Finally, the fatty acid moiety of acylcarnitines can be substituted by several other chemical groups (e.g., hydroxyl- or carboxyl groups). It should be noted that inclusion of a given acylcarnitine within a certain group can overlap with an affiliation to another chemical group. For instance, there are short-chain, branched dicarboxylic acylcarnitines (e.g., 3-methylglutaryl-carnitine) or long-chain hydroxyl-unsaturated acylcarnitines (3-hydroxyoctadecenoyl-carnitine), as well as simple acylcarnitines (acetyl-, propionyl- or palmitoyl-carnitines), which comprise the largest part of the body’s acylcarnitine pool (Fig. 2).

More rarely, acylcarnitines can be classified according to the source of the acyl moiety (Schooneman et al., 2013). Most acylcarnitines are synthesized during fatty acid metabolism (see Section III); however, several acylcarnitines (mainly branched-chain varieties) can be synthesized from degradation products of amino acids (lysine, valine, leucine, and isoleucine). Likewise, certain carbohydrate metabolic byproducts can be a source of the acyl moiety for some short-chain acylcarnitines (Topping and Clifton, 2001; Violante et al., 2013a). Other metabolic intermediates that may yield acylcarnitines are ketone bodies (Soeters et al., 2012). Acylcarnitines can also be divided into groups according to the organelles in which they are synthesized. The majority of acylcarnitines are synthesized by enzymes linked to the mitochondria, although some acylcarnitines can be products of peroxisomal metabolism (Hunt et al., 2012). Finally, acylcarnitines can be classified according to their appearance during certain physiologic processes




Fig. 2. Representative structures of various acylcarnitine classes.

or specific pathologic conditions. For instance, there are acylcarnitines (usually branched-chain acylcarnitines, long-chain dicarboxylcarnitines, or hydroxyl-acylcarnitines) that mainly appear and accumulate through acquired or inborn metabolic diseases. On the other hand, some acylcarnitines can be found in significant concentrations in the plasma/urine and tissues of healthy individuals.

C. Short-Chain Acylcarnitines

Short-chain acylcarnitines (C2–C5) have been suggested to be the most abundant group of acylcarnitines in the body, with plasma levels reaching nearly 80% or more of all acylcarnitines (Costa et al., 1997; Bene et al., 2005; Adams et al., 2009). We have provided detailed information on 50 short-chain acylcarnitines in the HMDB, which correspond to approximately 4% of the total listed acylcarnitines. C2 carnitine or acetylcarnitine is the main acylcarnitine found in plasma (Costa et al., 1997; Reuter et al., 2008; Adams et al., 2009). In addition to its important role in energy production, acetylcarnitine provides acetyl groups for the synthesis of acetylcholine (Onofrj et al., 2013). Short-chain acylcarnitines (mainly acetylcarnitine and propionylcarnitine) have been studied as supplements or experimental treatments for various diseases and pathologies. In many countries, acetylcarnitine is approved and indicated for treating several neurologic disorders (<https://go.drugbank.com/drugs/DB08842>) (see also Section V). Altered concentrations of different short-chain acylcarnitines have been demonstrated in a number of genetic diseases (Table 1); therefore, deviations from reference acylcarnitine levels have been used to diagnose inborn errors of metabolism. Moreover, abnormal levels of short-chain acylcarnitine have been identified in a

number of chronic or acquired metabolic, oncologic, and cardiovascular diseases (Table 1).

D. Medium-Chain Acylcarnitines

Medium-chain (C6–C12) acylcarnitines are much less abundant than short-chain acylcarnitines, but their number is substantially higher, with 476 now listed in the HMDB. They are typically derived from the corresponding medium-chain fatty acids by esterification with L-carnitine in a process that is described in more detail in a later section (see Section III). The other source of medium-chain acylcarnitines is peroxisomal metabolism of long-, very long-, and branched-chain fatty acids (Violante et al., 2013b; 2019). After their synthesis, medium-chain acylcarnitines are usually transported into the mitochondria and metabolized to carbon dioxide and water (Schonfeld and Wojtczak, 2016). Medium-chain acylcarnitine levels in various body fluids (e.g., plasma, urine, or serum) are invaluable markers for inherited diseases of fatty acid metabolism (Table 2). In addition, altered medium-chain acylcarnitine concentrations have been identified in other diseases, such as diabetes, cardiovascular disorders, and cancer (Table 2).

E. Long-Chain Acylcarnitines

Long-chain acylcarnitines (C13–C20) are generated as the product of L-carnitine esterification with long-chain fatty acids that are obtained from the diet or generated de novo from lipogenesis (see Section III). Among the different acylcarnitine classes, long-chain acylcarnitines have the highest number, with 533 members in the HMDB. Their main function is to ensure long-chain fatty acid transport into the mitochondria (Reuter and Evans,

TABLE 1
Short-chain acylcarnitines and diseases with altered short-chain acylcarnitine levels in blood (serum, plasma, dried blood spots) or urine

Acylcarnitine (Fatty Acid Moiety)	Sample	Increased/ decreased	Disease with Altered Acylcarnitine Concentration
Acetylcarnitine (C2:0)	Blood	Increased	Very long-chain acyl-CoA dehydrogenase deficiency (Costa et al., 1997); colorectal cancer (Ni et al., 2014); short-chain 3-hydroxyacyl-CoA dehydrogenase deficiency (Clayton et al., 2001); paclitaxel-induced neuropathy (Sun et al., 2018); type 2 diabetes (Adams et al., 2009; Mai et al., 2013; Ciborowski et al., 2015; Abu Bakar and Sarmidi, 2017); chronic heart failure (Ueland et al., 2013); ornithine transcarbamylase (Ohtani et al., 1988); prediabetes (Wang-Sattler et al., 2012; Mai et al., 2013); type 1 diabetes (Adal et al., 2006); methylmalonic acidemia (Minkler and Hoppel, 1993); myeloma (Steiner et al., 2018); diastolic heart failure (Zordoky et al., 2015)
		Decreased	3-Methyl-crotonyl-glycinuria (Thomsen et al., 2015); antiviral drug induced neuropathy (Famularo et al., 1997; James, 1997); Alzheimer's disease (Cristofano et al., 2016); major depressive disorder (Nasca et al., 2018); carnitine palmitoyltransferase 2 deficiency (Hori et al., 2010); familial Mediterranean fever (Kiykim et al., 2016); chronic fatigue syndrome (Kuratsune et al., 1998); methylmalonic acidemia (Vernez et al., 2004); hepatocellular carcinoma (Lu et al., 2016; Takaya et al., 2019); coronary artery disease (Shah et al., 2010)
Propionylcarnitine (C3:0)	Blood	Increased	Colorectal cancer (Ni et al., 2014); uterine fibroids (Wang et al., 2020); heart failure (Matsui et al., 1994); diabetes (Dellow et al., 1999); hepatocellular carcinoma (Ladep et al., 2014)
		Decreased	Carnitine palmitoyltransferase 2 deficiency (Hori et al., 2010)
		Increased	Methylmalonic acidemia/methylmalonyl-CoA mutase (Ghoraba et al., 2015; Han et al., 2015; Keyfi et al., 2019; Kang et al., 2020); propionic acidemia/mitochondrial propionyl-CoA carboxylase deficiency (Monostori et al., 2017; Curnock et al., 2020); obesity and type 2 diabetes (Libert et al., 2018); cobalamin C deficiency (Rahmandar et al., 2014); chronic heart failure (Ueland et al., 2013); diastolic heart failure (Zordoky et al., 2015); systolic heart failure (Zordoky et al., 2015)
Butyrylcarnitine (C4:0)	Urine	Decreased	Familial Mediterranean fever (Kiykim et al., 2016); type 2 diabetes (Adams et al., 2009)
		Increased	Obesity (Cho et al., 2017a)
	Blood	Decreased	Short-chain acyl-CoA dehydrogenase (Dawson et al., 1995; Young et al., 2003; van Maldegem et al., 2006; 2010; Battisti et al., 2007; Forni et al., 2010; Gallant et al., 2012; Lampret et al., 2015; An et al., 2016; Tonin et al., 2016); glutaric aciduria 2 (Forni et al., 2010; Prasad and Hussain, 2015); heart failure (Cheng et al., 2015); ethylmalonic encephalopathy (Zafeiriou et al., 2007; Drousiotou et al., 2011); nonalcoholic fatty liver disease (Kalhan et al., 2011); obesity (Butte et al., 2015); systolic heart failure (Zordoky et al., 2015)
Valerylcarnitine (C5:0)	Blood	Decreased	Celiac disease (Bene et al., 2005); acute cerebral infarction (Zhang et al., 2017b)
		Increased	Short-chain acyl-CoA dehydrogenase deficiency (Bhala et al., 1995); obesity (Cho et al., 2017a)
		Decreased	Exudative age-related macular degeneration (Chao de la Barca et al., 2020); type 2 diabetes (Mihalik et al., 2010; Sun et al., 2020); obesity (Mihalik et al., 2010); acute cerebral infarction (Zhang et al., 2017b); diastolic heart failure (Zordoky et al., 2015); systolic heart failure (Zordoky et al., 2015)
		Decreased	Pregnancy [(Bahado-Singh et al., 2014) – in serum of pregnant women with fetus with congenital heart defect]

2012). Tissue and plasma long-chain acylcarnitine levels are significantly higher in the fasted state than in the fed state (Makrecka-Kuka et al., 2017). Palmitoylcarnitine is the most abundant saturated long-chain acylcarnitine in plasma (Costa et al., 1997; Bene et al., 2005). Elevated long-chain acylcarnitine concentrations have been found in patients with inborn errors of long- or very long-chain fatty acid metabolism, although there are also inborn disorders with decreased plasma levels of long-chain acylcarnitines (Table 3). Moreover, there is a growing body of evidence that the altered levels of circulating long-chain acylcarnitines are linked to various cardiovascular diseases (Table 3). To a minor extent, altered long-chain acylcarnitine levels have been identified in patients with noncardiovascular diseases.

F. Very Long-Chain Acylcarnitines

Very long-chain acylcarnitines are acylcarnitines containing an acyl moiety with more than 20 carbon atoms, and 183 of them are now found in the HMDB. Very long-chain fatty acids are synthesized in the cytoplasm by fatty acid synthase or are absorbed from food (Sassa and Kihara, 2014). These fatty acids are too long to become involved in mitochondrial β -oxidation. As a result, peroxisomes are the main organelles where very long-chain fatty acids are metabolized. Normally, in peroxisomes very long-chain acyl moieties are cleaved into shorter fragments that form short-chain or medium-chain acylcarnitines (see Section III). These shorter acylcarnitines can then migrate into the mitochondria where they become involved in β -oxidation (Ferdinandusse et al., 2004). However, if there is an

TABLE 2
Medium-chain acylcarnitines and diseases with altered medium-chain acylcarnitine levels in blood (serum, plasma, dried blood spots) or urine

Acylcarnitine (Fatty Acid Moiety)	Sample	Increased/decreased	Disease with Altered Acylcarnitine Concentration
Caproylcarnitine (C6:0)	Blood	Increased	Psoriasis (Chen et al., 2021); cardiovascular diseases (Kukhareenko et al., 2020); Norman-Roberts syndrome (Caksen et al., 2004); type 2 diabetes (Adams et al., 2009; Mihalik et al., 2010; Batchuluun et al., 2018); carnitine palmitoyltransferase 2 deficiency (Fontaine et al., 1998); familial Mediterranean fever (Kiykim et al., 2016); multiple acyl-CoA dehydrogenase deficiency (Saral et al., 2018); cardiovascular diseases in type 2 diabetes (Zhao et al., 2020); gestational diabetes (Batchuluun et al., 2018)
	Urine	Decreased Increased	Celiac disease (Bene et al., 2005) Medium-chain acyl-CoA dehydrogenase deficiency (Bennett et al., 1990; Schmidt-Sommerfeld et al., 1992)
Octanoylcarnitine (8:0)	Blood	Increased	Glutaric aciduria 2 (Prasad and Hussain, 2015); ulcerative colitis (Kolho et al., 2017); Crohn's disease (Kolho et al., 2017); medium-chain acyl-CoA dehydrogenase deficiency (Costa et al., 1997; Rhead, 2006; Khalid et al., 2010); multiple acyl-CoA dehydrogenase deficiency (Saral et al., 2018); exfoliation syndrome (Leruez et al., 2018); gestational diabetes (Batchuluun et al., 2018); type 2 diabetes (Adams et al., 2009; Mihalik et al., 2010; Batchuluun et al., 2018); cardiovascular diseases in type 2 diabetes (Zhao et al., 2020); cardioembolic stroke, its recurrence (Seo et al., 2018); diastolic heart failure (Zordoky et al., 2015)
	Urine	Decreased Increased	Celiac disease (Bene et al., 2005); very long-chain acyl-CoA dehydrogenase deficiency (Costa et al., 1997); breast cancer (Park et al., 2019); hepatocellular carcinoma and liver cirrhosis (Kim et al., 2019); familial Mediterranean fever (Kiykim et al., 2016); human immunodeficiency virus (Waagsbo et al., 2016); pregnancy [(Bahado-Singh et al., 2014) – in serum of pregnant women with fetus with congenital heart defect]; coronary artery disease (Shah et al., 2010) Medium-chain acyl-CoA dehydrogenase deficiency (Duran et al., 1984; 1985; Tserng et al., 1990; Schmidt-Sommerfeld et al., 1992); obesity (Cho et al., 2017a); multiple acyl-CoA dehydrogenase deficiency (Sugiyama et al., 1990; Vallée et al., 1994); uterine fibroids (Wang et al., 2020)
Nonanoylcarnitine (9:0)	Blood	Decreased	Psoriasis (Ottas et al., 2017; Chen et al., 2021); pregnancy [(Bahado-Singh et al., 2014) – in serum of pregnant women with fetus with congenital heart defect]
Decanoylcarnitine (C10:0)	Urine	Decreased	Obesity (Cho et al., 2017a)
	Blood	Increased	Glutaric aciduria 2 (Prasad and Hussain, 2015); ulcerative colitis (Kolho et al., 2017); Crohn's disease (Kolho et al., 2017); obesity (Mihalik et al., 2010); medium-chain acyl-CoA dehydrogenase deficiency disorders (Woo et al., 2011); overweight (Kim et al., 2015); multiple acyl-CoA dehydrogenase deficiency (Schmidt-Sommerfeld et al., 1993; Saral et al., 2018); type 2 diabetes (Adams et al., 2009); age-related increase in alanine aminotransferase (Jung et al., 2014); prostate cancer (Zoni et al., 2019); Yin-deficiency-heat syndrome (Yi et al., 2020); cardiovascular diseases in type 2 diabetes (Zhao et al., 2020); cardioembolic stroke, its recurrence (Seo et al., 2018); diastolic heart failure (Zordoky et al., 2015)
Lauroylcarnitine (C12:0)	Urine	Decreased	Celiac disease (Bene et al., 2005); colorectal cancer (Tan et al., 2013); esophageal squamous cell carcinoma (Xu et al., 2013); inflammatory bowel disease (Danese et al., 2011); phenylketonuria (Weigel et al., 2008); intracerebral hemorrhage (Zhang et al., 2017b); pregnancy [(Bahado-Singh et al., 2014) – in serum of pregnant women with fetus with congenital heart defect]
		Increased	Overweight (Wang et al., 2011); renal cell carcinoma (Nizioł et al., 2018)
	Blood	Increased Decreased Increased	Very long-chain acyl-CoA dehydrogenase deficiency (Costa et al., 1997); Yin deficiency (Yi et al., 2020); multiple acyl-CoA dehydrogenase deficiency (Saral et al., 2018); cardiovascular diseases in type 2 diabetes (Zhao et al., 2020); diastolic heart failure (Zordoky et al., 2015) Celiac disease (Bene et al., 2005); psoriasis (Ottas et al., 2017); intracerebral hemorrhage (Zhang et al., 2017b); pregnancy [(Bahado-Singh et al., 2014) – in serum of pregnant women with fetus with congenital heart defect] Renal cell carcinoma (Nizioł et al., 2018)

inborn error of metabolism involving some peroxisomal enzymes or altered biogenesis of peroxisomes, then very long-chain acylcarnitines can accumulate (Table 4). It has been shown that in the case of X-linked adrenoleukodystrophy, there is a significantly elevated level of C26:0 acylcarnitine in plasma as well as in bloodspots (van de Beek et al., 2016). Another study demonstrated that very long-chain acylcarnitines (C22:0, C24:0, and C26:0), together with long-chain dicarboxylacylcarnitines, are elevated in

the plasma and urine of patients with peroxisomal enzyme defects (D-bifunctional protein deficiency) or peroxisomal biogenesis disorders (Zellweger spectrum disorders) (Duranti et al., 2008; Klouwer et al., 2017). In addition, elevated concentrations of very long-chain acylcarnitines have been found in patients with type 2 diabetes. This may point to some diabetes-induced dysfunction of peroxisomes (Zhang et al., 2014). On the other hand, several studies have demonstrated that

TABLE 3
Long-chain acylcarnitines and diseases with altered long-chain acylcarnitine levels in blood (serum, plasma, dried blood spots) or urine

Acylcarnitine (Fatty Acid Moiety)	Sample	Increased/decreased	Disease with Altered Acylcarnitine Concentration
Myristoylcarnitine (C14:0)	Blood	Increased	Very long-chain acyl-CoA dehydrogenase deficiency (Costa et al., 1997; Peng et al., 2013); carnitine/acylcarnitine translocase deficiency (Wasant et al., 2002); carnitine palmitoyl transferase 2 deficiency (Minkler et al., 2005); glutaric acidemia type 2 (Peng et al., 2013); sleep deprivation (Yoon et al., 2019); type 2 diabetes (Adams et al., 2009); cardiovascular diseases in type 2 diabetes (Zhao et al., 2020); cardiovascular mortality in chronic kidney disease (Kalim et al., 2013)
		Decreased	Celiac disease (Bene et al., 2005); chronic fatigue syndrome (Reuter and Evans, 2011)
Palmitoylcarnitine (C16:0)	Urine	Increased	Uterine fibroids (Wang et al., 2020)
	Blood	Increased	Very long-chain acyl-CoA dehydrogenase deficiency (Costa et al., 1997); sleep deprivation (Yoon et al., 2019); carnitine palmitoyl transferase 2 deficiency (Minkler et al., 2005); carnitine/acylcarnitine translocase deficiency (Wasant et al., 2002); type 2 diabetes (Mihalik et al., 2010; Zhang et al., 2014; Qiu et al., 2016); nonalcoholic fatty liver disease (Chen et al., 2016); obesity (Mihalik et al., 2010); pulmonary arterial hypertension (Brittain et al., 2016); chronic heart failure (Ueland et al., 2013); cardiovascular mortality in chronic kidney disease (Kalim et al., 2013); diastolic heart failure (Zordoky et al., 2015; Hunter et al., 2016); systolic heart failure (Hunter et al., 2016); increased all-cause mortality and hospitalization in heart failure patients (Ahmad et al., 2016)
		Decreased	Intracerebral hemorrhage (Zhang et al., 2017b); carnitine palmitoyltransferase 1A deficiency (Fingerhut et al., 2001); psoriasis (Chen et al., 2021)
Stearoylcarnitine (C18:0)	Feces Blood	Increased	Cirrhosis (Huang et al., 2013)
		Increased	Carnitine/acylcarnitine translocase deficiency (Wasant et al., 2002); chronic fatigue syndrome (Reuter and Evans, 2011); pulmonary arterial hypertension (Brittain et al., 2016); carnitine palmitoyltransferase 2 deficiency (Minkler et al., 2005); cardiovascular mortality in chronic kidney disease (Kalim et al., 2013); diastolic heart failure (Hunter et al., 2016); systolic heart failure (Hunter et al., 2016)
		Decreased	Intracerebral hemorrhage (Zhang et al., 2017b); carnitine palmitoyltransferase 1A deficiency (Fingerhut et al., 2001)

diabetes increases the level of peroxisomal very long-chain fatty acid catabolism (Dhaunsi and Bitar, 2004).

G. Unsaturated-Chain Acylcarnitines

Unsaturated-chain acylcarnitines are a large class of acylcarnitines that include acylcarnitines with differing lengths of an unsaturated fatty acid moiety (Table 5). There are 716 of these acylcarnitines in the HMDB, whereas there are only 526 saturated fatty acid acylcarnitines in the HMDB. It has been shown that unsaturated-chain acylcarnitines can be synthesized by human cells from the corresponding fatty acid (Chegary et al., 2009). In addition, human cells contain enzymes that can convert saturated fatty acids into unsaturated fatty acids (Igal and Sinner, 2021). Thus, unsaturated fatty acids for the esterification with L-carnitine can be synthesized endogenously and consumed via the diet. Altered unsaturated-chain fatty acid levels have been documented in inborn metabolic disorders as well as in a number of acquired diseases (Table 5).

H. Branched-Chain Acylcarnitines

The main source of short- to medium-length branched-chain acylcarnitines is from the catabolism of branched-chain amino acids (e.g., valine, leucine,

and isoleucine). However, dietary and microbial sources can also lead to branched-chain acylcarnitines. We cataloged 347 branched-chain and 895 aliphatic straight-chain acylcarnitines in the HMDB. Among those derived from branched-chain amino acids, the corresponding amino acids are first deaminated to alpha-keto acids and then decarboxylated to form acyl-CoA derivatives, which can be further transformed into the corresponding acylcarnitines (Neinast et al., 2019). Branched-chain amino acids are converted to branched-chain fatty acids mainly by mitochondrial enzymes (Brosnan and Brosnan, 2006; Crown et al., 2015), and the synthesis of branched-chain acylcarnitines is catalyzed by carnitine acetyltransferase (CrAT, Enzyme Commission (EC) number, EC:2.3.1.7) (Violante et al., 2013a) or peroxisomal carnitine octanoyltransferase (CrOT, EC:2.3.1.137), which accepts longer branched-chain fatty acids as substrates (Ferdinandusse et al., 1999).

The accumulation of branched-acylcarnitines (i.e., isovalerylcarnitine, or 2-methylbutyrylcarnitine) in the blood has been observed in a number of inborn errors of branched-chain amino acid catabolism (Table 6), such as short-/branched-chain acyl-CoA dehydrogenase (EC:1.3.99) deficiency (Porta et al., 2019) and isovaleryl-CoA dehydrogenase (EC:1.3.8.4) deficiency

TABLE 4

Very long-chain acylcarnitines and diseases with altered very long-chain acylcarnitine levels in blood (serum, plasma, dried blood spots) or urine

Acylcarnitine (Fatty Acid Moiety)	Sample	Increased/decreased	Disease with Altered Acylcarnitine Concentration (Reference)
Behenylcarnitine (C22:0)	Blood	Decreased	Acute cerebral infarction (Zhang et al., 2017b)
	Urine	Increased	Zellweger syndrome (Duranti et al., 2008); infantile Refsum disease (Duranti et al., 2008); D-bifunctional protein deficiency (Duranti et al., 2008)
Lignoceroylcarnitine (C24:0)	Blood	Increased	Type 2 diabetes (Zhang et al., 2014)
	Urine	Decreased Increased	Cardiovascular diseases in type 2 diabetes (Zhao et al., 2020) Zellweger syndrome (Duranti et al., 2008); infantile Refsum disease (Duranti et al., 2008); type 2 diabetes (Zhang et al., 2014)
Cerotoylcarnitine (C26:0)	Blood	Increased	Zellweger syndrome (Klouwer et al., 2017), X-linked adrenoleukodystrophy (van de Beek et al., 2016), cardiovascular mortality in chronic kidney disease (Kalim et al., 2013)
	Urine	Increased	Zellweger syndrome (Duranti et al., 2008); infantile Refsum disease (Duranti et al., 2008)

(also known as isovaleric acidemia) (Roe et al., 1984). Another inborn error of metabolism, known as isobutyryl-CoA dehydrogenase (EC:1.3.99) deficiency, elevates the level of isobutyryl-carnitine concentrations in plasma (Pedersen et al., 2006).

Phytanic acid and pristanic acid are the main sources of long-chain branched-acylcarnitines. These acids can be obtained through the consumption of dairy products, ruminant animal fats, and certain fish (Hellgren, 2010). The metabolism of phytanic and pristanic acid occurs mainly in the liver and kidney tissue peroxisomes where peroxisomal α -oxidation of phytanoyl-CoA yields pristanoyl-CoA that can be further β -oxidized (Wierzbicki, 2007). It is hypothesized that the synthesis of these long-chain acylcarnitines is catalyzed by peroxisomal CrOT (Herzog et al., 2017), as phytanic and pristanic acids are poor substrates for carnitine palmitoyltransferase 1 (CPT1, EC:2.3.1.21) (Singh and Poulos, 1995).

It has been suggested that phytanoyl- and pristanoyl-carnitines could serve as markers for the diagnosis of inborn peroxisomal disorders. However, a recent study demonstrated that although the plasma concentration of both acylcarnitines can be elevated, they both lack sensitivity and specificity for the conclusive diagnosis of peroxisomal disorders, including Refsum disease and alpha-methylacyl-CoA racemase (EC:5.1.99.4) deficiency (Herzog et al., 2017). Interestingly, decreased circulating branched acylcarnitine levels have been observed in some gastrointestinal disorders and in traumatic brain injury (Table 6).

I. Hydroxyl-/Dicarboxyl-Acylcarnitines

Hydroxyl-/dicarboxyl-acylcarnitines are a large class of acylcarnitines that, due to their diversity, can be divided into several groups according to their acyl chain length. We compiled data for 380 hydroxyl-acylcarnitines and 218 dicarboxyl-acylcarnitines in the HMDB. The acylcarnitine with the shortest acyl chain of this group is malonylcarnitine. This compound accumulates in patients suffering from malonic aciduria due to the absence of functional

malonyl-CoA decarboxylase (MCD, EC:4.1.1.9). This leads to a subsequent elevation of malonyl-CoA, which can be converted to its carnitine derivative (Liu et al., 2016). Short-chain hydroxyl acylcarnitines (e.g., 3-hydroxybutyrylcarnitine) can be formed from 3-hydroxybutyryl-CoA (Soeters et al., 2012). 3-Hydroxybutyrylcarnitine has been associated with fasting and ketosis but also with insulin resistance and type 2 diabetes (Soeters et al., 2012). Other short-chain (C3–C5) dicarboxyl-acylcarnitines are catabolic products of amino acid metabolism (Tuncel et al., 2018; Chen et al., 2020) or the Krebs cycle (Rizzo et al., 2014). Some short-chain dicarboxyl-acylcarnitines can be synthesized from long-chain dicarboxylic acids by peroxisomes (Ferdinandusse et al., 2004). In addition, a certain portion of medium-chain dicarboxyl-acylcarnitines can be synthesized by peroxisomes by cleaving longer-chain dicarboxyl-acylcarnitines (Ferdinandusse et al., 2004). Other medium-chain dicarboxyl-acylcarnitines can be synthesized from hydroxyl-/dicarboxyl-fatty acids, which are formed from hydroxyl-/dicarboxyl-acyl-CoA due to incomplete β -oxidation along with subsequent omega-oxidation (Ribel-Madsen et al., 2016).

It has been shown that long-chain dicarboxyl-acylcarnitines are elevated in the urine in patients with inborn peroxisomal disorders (Table 7). The fatty acid moiety for the synthesis of long-chain dicarboxyl-acylcarnitines can be obtained from fatty acid omega-oxidation (Wanders et al., 2011). However, it is not clear which enzymes and organelles synthesize long-chain dicarboxyl-acylcarnitines. A recent study using primary rat cardiomyocytes and an in vivo mouse model showed that both mitochondria and peroxisomes contribute to dicarboxylic acid metabolism. In the same study, oxidation of dicarboxylic acids in mouse liver homogenate was inhibited by the CPT1 inhibitor etomoxir, underlining the importance of mitochondrial metabolism in this process (Bharathi et al., 2020). Another study demonstrated that longer dicarboxyl-acylcarnitines were excreted in the urine of patients with peroxisomal biogenesis disorders due to dysfunctional peroxisomes (Duranti et al., 2008). Therefore, it can be hypothesized that peroxisomal dysfunction leads to the accumulation of

TABLE 5

Unsaturated-chain acylcarnitines and diseases with altered unsaturated-chain acylcarnitine levels in blood (serum, plasma, dried blood spots) or urine

Acylcarnitine (Fatty Acid Moiety)	Sample	Increased/decreased	Disease with Altered Acylcarnitine Concentration
Butenylcarnitine (C4:1)	Blood	Increased	Maternal obesity/prepregnant obesity of mothers (Schlueter et al., 2020)
Hexenylcarnitine (C6:1)	Blood	Increased	Obesity in adolescence (Cho et al., 2017a)
Decenylcarnitine (C10:1)	Blood	Decreased	Adolescent idiopathic scoliosis (Sun et al., 2016b)
		Increased	Overweight (Kang et al., 2018)
Decadienylcarnitine (C10:2)	Blood	Decreased	Schizophrenia (Cao et al., 2020); familial Mediterranean fever (Kiykim et al., 2016)
		Increased	2,4-Dienoyl-CoA reductase deficiency (Roe et al., 1990; Kimura et al., 2004; Miinalainen et al., 2009)
Dodecenylcarnitine (C12:1)	Blood	Decreased	Familial Mediterranean fever (Kiykim et al., 2016); schizophrenia (Cao et al., 2020)
		Increased	Mitochondrial dysfunction in diabetes patients (Abu Bakar and Sarmidi, 2017); childhood obesity (Wahl et al., 2012)
Tetradecenylcarnitine (C14:1)	Blood	Decreased	Placental abruption (Gelaye et al., 2016) – increase in dodecanoylcarnitine/dodecenoylcarnitine ratio (C12/C12:1)
		Increased	Very long-chain acyl-CoA dehydrogenase deficiency (Wood et al., 2001; Shigematsu et al., 2003; Tajima et al., 2008; Laforet et al., 2009; Hisahara et al., 2015; Lepori et al., 2018); trifunctional protein (mitochondrial long-chain ketoacyl-CoA thiolase) deficiency (Das et al., 2006); mitochondrial dysfunction in diabetes patients (Abu Bakar and Sarmidi, 2017); nonalcoholic fatty liver disease (Chen et al., 2016); insulin resistance, type 2 diabetes (Mai et al., 2013)
Tetradecadienylcarnitine (C14:2)	Blood	Increased	Insulin resistance, type 2 diabetes (Mai et al., 2013) Alzheimer's disease (Huo et al., 2020)
Hexadecenylcarnitine (C16:1)	Blood	Decreased	Childhood obesity (Wahl et al., 2012)
		Increased	Familial Mediterranean fever (Kiykim et al., 2016)
Octadecenylcarnitine (C18:1)	Blood	Increased	Carnitine palmitoyltransferase 2 deficiency (Gempel et al., 2001; 2002; Minkler et al., 2005; Brucknerova et al., 2008; Illsinger et al., 2008; Tajima et al., 2017); cardiovascular mortality in incident dialysis patients (Kalim et al., 2013); schizophrenia (Cao et al., 2020); succinic semialdehyde dehydrogenase deficiency (Kirby et al., 2020); neonatal macrosomia (Wright and Baker, 2020); liver cirrhosis (Miyaaki et al., 2020); carnitine/acylcarnitine translocase deficiency (Iacobazzi et al., 2004); ischemia/reperfusion (Shah et al., 2012; Rizza et al., 2014); increased all-cause mortality and hospitalization in heart failure patients (Ahmad et al., 2016)
Octadecadienylcarnitine (C18:2)	Blood	Increased	Parkinson's disease (Chang et al., 2018); chronic heart failure (Ahmad et al., 2016; Hunter et al., 2016); carnitine/acylcarnitine translocase deficiency (Iacobazzi et al., 2004); ischemia/reperfusion (Shah et al., 2012; Rizza et al., 2014); increased all-cause mortality and hospitalization in heart failure patients (Ahmad et al., 2016)

dicarboxyl-fatty acids, which are converted to long-chain dicarboxyl-acylcarnitines in the mitochondria and excreted via urine. Increased dicarboxyl-acylcarnitine concentrations in blood and urine have also been noted in a number of acquired diseases (Table 7).

III. Biosynthesis and Regulation

A. Enzymology of Acylcarnitine Biosynthesis

Acylcarnitines in the body are generally produced by conjugating a fatty acid with L-carnitine through the help of the carnitine acyltransferase system. Under normal conditions, carnitine homeostasis is maintained by three mechanisms: 1) biosynthesis, 2) uptake from dietary sources, and 3) reuptake from the glomerular filtrate in kidney proximal tubules via organic cation novel type 2 transporter (OCTN2)-mediated transport. The regulation of carnitine homeostasis has been extensively reviewed previously, and readers are referred to

the papers by Rebouche (2004), Strijbis et al. (2010), and Longo et al. (2016) for an in-depth understanding.

Carnitine is required as a substrate for the function of carnitine acyltransferases to generate acylcarnitines. As a result, decreasing carnitine availability is often used to treat disorders related to acylcarnitine accumulation in the body. For fatty acids to be incorporated into acylcarnitines by carnitine acyltransferases, fatty acids first need to be activated to their respective acyl-CoA esters with the help of acyl-CoA synthetases (ACS). The function, regulation and composition of the ACS family have been extensively reviewed elsewhere (Grevengoed et al., 2014). The ACS family includes multiple short-chain (ACSS), medium-chain (ACSM), and long-chain (ACSL) members. It should be noted that the specific loss of long-chain ACS (acyl-CoA synthetase long-chain family member 1; ACSL1, EC:6.2.1.3) activity in mouse liver tissues results in a decrease in long-chain acylcarnitines and an increase in medium-chain acylcarnitine content due to the upregulation of peroxisomal fatty acid oxidation (Li et al.,

TABLE 6

Branched-chain acylcarnitines and diseases with altered branched-chain acylcarnitine levels in blood (serum, plasma, dried blood spots) or urine

Acylcarnitine (Fatty Acid Moiety)	Sample	Increased/decreased	Disease with Altered Acylcarnitine Concentration
Isobutyrylcarnitine (C4:0 M)	Blood	Increased	Isobutyryl-CoA dehydrogenase deficiency (Forni et al., 2010); glutaric aciduria type 2 (Forni et al., 2010); ethylmalonic encephalopathy (Forni et al., 2010); gestational diabetes (Roy et al., 2018)
	Urine	Decreased Increased	Traumatic brain injury (Jeter et al., 2013) Glutaric aciduria type 2 (Sugiyama et al., 1990); multiple acyl-CoA dehydrogenase deficiency (Kidouchi et al., 1988); acute coronary syndrome (Wang et al., 2018)
Isovalerylcarnitine (C5:0 I)	Blood	Increased	Isovaleric acidemia (Shigematsu et al., 2007; Forni et al., 2010; Couce et al., 2017; Lin et al., 2020); glutaric aciduria type 2 (Forni et al., 2010); 3-hydroxy-3-methylglutaryl-CoA lyase deficiency (Ma et al., 2011; Václavík et al., 2020); cardiovascular diseases (Kukhareenko et al., 2020); acute kidney injury (Wan et al., 2019)
		Decreased	Daytime sleepiness (Pak et al., 2018); inflammatory bowel disease (Danese et al., 2011); ulcerative colitis (Bene et al., 2006); traumatic brain injury (Jeter et al., 2013)
	Urine	Increased	Glutaric aciduria type 2 (Shimizu et al., 1991); multiple acyl-CoA dehydrogenation deficiency (Kidouchi et al., 1988)
2-Methylbutyrylcarnitine (C5:0 M)	Blood	Increased	Short/branched-chain acyl-CoA dehydrogenase deficiency/2-methylbutyryl-CoA dehydrogenase deficiency (Madsen et al., 2006; Forni et al., 2010); glutaric aciduria type 2 (Forni et al., 2010); gout (Huang et al., 2020); nonalcoholic steatohepatitis (Kalhan et al., 2011)
		Decreased	Pediatric obesity (Farook et al., 2015); traumatic brain injury (Jeter et al., 2013)
Methylcrotonylcarnitine (C5:1 I)	Blood	Increased	3-methylcrotonyl-CoA carboxylase deficiency (van Hove et al., 1995); 3-hydroxy-3-methylglutaryl-CoA lyase deficiency (Václavík et al., 2020)
Tiglylcarnitine (C5:1 M)	Blood	Increased	Beta ketothiolase deficiency/acetyl-CoA acetyltransferase 1 gene mutation (Millington et al., 1987; Fukao et al., 2003; Wen et al., 2016); short-chain enoyl-CoA hydratase deficiency (Pajares et al., 2020)
		Decreased	Familial Mediterranean fever (Kiykim et al., 2016); Lewis lung carcinoma (Wu et al., 2018); metabolic syndrome, type 2 diabetes, cardiovascular diseases (Yu et al., 2014)
Pristanoyl-carnitine	Blood	Increased	Alpha-methylacyl-CoA racemase deficiency (Herzog et al., 2017)
Phytanoyl-carnitine	Blood	Increased	Refsum disease (Herzog et al., 2017); rhizomelic chondrodysplasia punctata (Herzog et al., 2017)

2009). Overexpression of ACSL1 and ACSL4 (acyl-CoA synthetase long-chain family member 4, EC:6.2.1.3) has been shown to increase acylcarnitine levels in human colorectal cancer cells (Sánchez-Martínez et al., 2017) and in primary cultured Schwann cells isolated from rat sciatic nerve tissues (Hinder et al., 2014).

Carnitine acyltransferases each support the transfer of acyl groups with different chain lengths to carnitine to form short-, medium-, and long-chain acylcarnitines (Figs. 3 and 4). Moreover, acyltransferases ensure the reversible shuttling of acyl groups between free CoA and carnitine. Thus, CrAT (EC:2.3.1.7) is mostly responsible for the synthesis of both short- (up to C5) and branched-chain acylcarnitines. However, the human enzyme can also effectively synthesize acylcarnitines with carbon chain lengths up to C8 and, to a slightly lesser extent, up to C10 (Violante et al., 2013a). Human CrOT (EC:2.3.1.137) is mostly responsible for the synthesis of medium-chain (C6–C12) and branched-chain acylcarnitines in peroxisomes (Ferdinandusse et al., 1999). CPT1 (EC:2.3.1.21, which has three tissue-specific isoforms; see Section III.A.3) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Human liver CPT1 can also synthesize acylcarnitines from acyl-CoAs with a carbon length starting from C6 (Finocchiaro et al.,

1990), whereas equivalent rat liver and avian muscle enzymes have been shown to produce acylcarnitines from very long-chain unsaturated acyl-CoAs (Gavino et al., 2003; Price et al., 2011). Mitochondrial carnitine/acylcarnitine translocase (CACT, SLC25A20) shuttles long-chain acylcarnitines inside the mitochondrial matrix, where carnitine palmitoyltransferase 2 (CPT2, EC:2.3.1.21) converts these acylcarnitines back to their respective long-chain acyl-CoA (Rufer et al., 2009).

1. Carnitine Acetyltransferase. Mammalian carnitine acetyltransferase, or CrAT, is found in the mitochondrial matrix, the peroxisomal matrix, the endoplasmic reticulum, and the nucleus (Markwell et al., 1973; Ramsay et al., 2001). Recently, its activity has also been reported in the cytosol of mouse cardiomyocytes (Altamimi et al., 2018). In the mitochondria CrAT regulates the acetyl-CoA/free CoA ratio to prevent depletion of free CoA. For example, during intensive physical exercise when overproduction of acetyl-CoA occurs in muscle tissue, this process ensures replenishment of free CoA to facilitate pyruvate metabolism, but when the physical load ends, transacetylation of acetylcarnitine provides acetyl-CoA for the Krebs cycle (Stephens et al., 2007). The main function of CrAT in peroxisomes is to aid in the export of products of peroxisomal β -oxidation (Westin et al., 2008). In the murine cardiomyocyte cytosol, the

TABLE 7
Hydroxyl-/dicarboxyl-chain acylcarnitines and diseases with altered hydroxyl-/dicarboxyl-chain acylcarnitine levels in blood (serum, plasma, dried blood spots) or urine

Acylcarnitine (Fatty Acid Moiety)	Sample	Increased/ decreased	Disease with Altered Acylcarnitine Concentration
3-Hydroxy-propionylcarnitine (C3-OH)	Urine	Decreased	Obesity (Cho et al., 2017a); systolic heart failure (Zordoky et al., 2015)
	Blood	Increased	
Malonylcarnitine (C3-DC)		Decreased	Malonyl-CoA decarboxylase deficiency (Santer et al., 2003; Ficicioglu et al., 2005); propofol infusion syndrome (Wolf et al., 2001); short-chain enoyl-CoA hydratase mutation (Pajares et al., 2020); type 2 diabetes (Mai et al., 2013); methylmalonic acidemia (Maeda et al., 2007)
		Increased	Familial Mediterranean fever (Kiykim et al., 2016); cleft lip (Hozyasz et al., 2010); obesity (Libert et al., 2018); acute cerebral infarction (Zhang et al., 2017b)
Methylmalonylcarnitine (C3:0 DC M)	Urine	Increased	Malonyl-CoA decarboxylase deficiency (Yano et al., 1997); methylmalonic acidemia (Maeda et al., 2007)
	Blood	Increased	Methylmalonyl-CoA epimerase deficiency/methylmalonic acidemia (Maeda et al., 2007; Waters et al., 2016); familial Mediterranean fever (Kiykim et al., 2016); cobalamin C deficiency (Rahmandar et al., 2014)
		Decreased	Melanoma (Bayci et al., 2018); Intracerebral hemorrhage (Zhang et al., 2017b)
		Increased	Methylmalonyl-CoA epimerase deficiency/methylmalonic acidemia (Maeda et al., 2007; Waters et al., 2016)
3-Hydroxybutyrylcarnitine (C4-OH)	Blood	Increased	Short-chain L-3-hydroxyacyl-CoA dehydrogenase deficiency (Clayton et al., 2001; Hussain et al., 2005); prediabetes (Zhong et al., 2017); type 2 diabetes (Zhong et al., 2017); metallosis (Stepien et al., 2018); mitochondrial acetoacetyl-CoA thiolase deficiency (Catanzano et al., 2010); heart failure (Cheng et al., 2015)
		Decreased	Psoriasis (Chen et al., 2021)
Succinylcarnitine (C4-DC)	Urine	Increased	Renal cell carcinoma (Nizioł et al., 2018)
	Blood	Increased	Succinyl-CoA ligase deficiency (Van Hove et al., 2010; Jaber et al., 2013)
Glutaryl carnitine (C5-DC)	Blood	Increased	Multiple acyl-CoA dehydrogenase deficiency (Saral et al., 2018); glutaric acidemia type 1 (Couce Pico et al., 2008; Lee et al., 2013; Mohamed et al., 2015; Numata-Uematsu et al., 2017); renal insufficiency (Hennermann et al., 2009)
		Decreased	Familial Mediterranean fever (Kiykim et al., 2016)
	Urine	Increased	Multiple acyl-CoA dehydrogenase deficiency (Sakuma et al., 1991); glutaric acidemia type 1 (Korman et al., 2007; Couce Pico et al., 2008; Kim et al., 2014)
		Decreased	3-Hydroxy-3-methylglutaryl-CoA lyase deficiency (Roe et al., 1986; Santarelli et al., 2013; Václavík et al., 2020); acute kidney injury (Wan et al., 2019); pulmonary arterial hypertension (Mey et al., 2020)
Methylglutaryl carnitine (C5-M-DC)	Blood	Increased	Traumatic brain injury (Jeter et al., 2013); metabolic syndrome (Gong et al., 2020)
		Decreased	3-Methylglutaconic aciduria (Jooste et al., 1994); acute coronary syndrome (Wang et al., 2018)
3-Hydroxyvalerylcarnitine (C5-OH)	Urine	Increased	3-Hydroxy-3-methylglutaryl-coenzyme A lyase deficiency (Grunert et al., 2017); holocarboxylase synthetase deficiency (Donti et al., 2016)
	Blood	Decreased	Psoriasis (Chen et al., 2021)
3-Hydroxy-isovalerylcarnitine (C5-OH-I)	Blood	Increased	3-Methylcrotonyl-CoA carboxylase deficiency (van Hove et al., 1995); 3-hydroxy-3-methylglutaryl-CoA lyase deficiency (Bischof et al., 2004; Santarelli et al., 2013; Dos Santos Mello et al., 2015; Václavík et al., 2020); 3-methylglutaconic aciduria type 1 (Tavasoli et al., 2017); Leigh syndrome (Balasubramaniam et al., 2017); holocarboxylase synthetase deficiency (Yokoi et al., 2009)
		Decreased	Traumatic brain injury (Jeter et al., 2013)
	Urine	Increased	3-Methylcrotonyl-CoA carboxylase deficiency (van Hove et al., 1995); multiple carboxylase deficiency (Nakanishi and Shimizu, 1993; Maeda et al., 2008); biotin deficiency (Stratton et al., 2011)
		Decreased	Mitochondrial acetoacetyl-CoA thiolase deficiency (Catanzano et al., 2010); mitochondrial 2-methylacetoacetyl-CoA thiolase deficiency (Ngu et al., 2008)
2-Methyl-3-hydroxy-butyrylcarnitine (C5-OH-M)	Blood	Increased	3-Hydroxy-3-methylglutaryl-CoA lyase deficiency (Václavík et al., 2020)
3-Methylglutaconylcarnitine (C5:1-M-DC)	Blood	Increased	3-Methylglutaconic aciduria (Jooste et al., 1994)
3-Hydroxy-3-methylglutaryl-carnitine (C5:1-M-OH-DC)	Blood	Increased	3-Hydroxy-3-methylglutaryl-CoA lyase deficiency (Václavík et al., 2020)
3-Hydroxy-hexanoylcarnitine (C6-OH)	Urine	Increased	Metabolic syndrome (Esperanza et al., 2020)
	Blood	Increased	Pulmonary arterial hypertension (Mey et al., 2020)
Adipylcarnitine (C6-DC)	Blood	Increased	Glutaric aciduria type 1 (Matsumoto et al., 1990); 3-hydroxy-3-methylglutaryl-CoA lyase deficiency (Grunert et al., 2017)
	Urine	Increased	Glutaric aciduria type 1 (Matsumoto et al., 1990)
Dehydroadipylcarnitine (C6:1-DC)	Urine	Decreased	Diastolic heart failure (Zordoky et al., 2015)
	Blood	Increased	Psoriasis (Ottas et al., 2017)
Suberylcarnitine (C8-DC)	Blood	Increased	Pulmonary arterial hypertension (Mey et al., 2020); type 2 diabetes (Adams et al., 2009)
Dodecanedioylcarnitine (C12-DC)	Blood	Increased	Chronic fatigue syndrome (Reuter and Evans, 2011)
	Urine	Increased	Carnitine palmitoyltransferase 2 deficiency (Fontaine et al., 1998)

(continued)

TABLE 7—Continued

Acylcarnitine (Fatty Acid Moiety)	Sample	Increased/ decreased	Disease with Altered Acylcarnitine Concentration
3-Hydroxy-tetradecanoylcarnitine (C14-OH)	Blood	Increased	Cardiovascular diseases in type 2 diabetes (Zhao et al., 2020)
Tetradecanedioylcarnitine (C14-DC)	Urine	Increased	Zellweger syndrome (Duranti et al., 2008); infantile Refsum disease (Duranti et al., 2008); D-bifunctional protein deficiency (Duranti et al., 2008)
3-Hydroxy-tetradecenoylcarnitine (C14:1-OH)	Blood	Decreased	Psoriasis (Chen et al., 2021); coronary artery disease (Shah et al., 2010)
	Urine	Increased	Obstructive sleep apnea (Cho et al., 2017b); mitochondrial trifunctional protein deficiency (Park et al., 2009)
3-Hydroxy-hexadecanoylcarnitine (C16-OH)	Blood	Increased	Type 2 diabetes (Mai et al., 2013; Zhang et al., 2014; Hameed et al., 2020); long-chain 3-hydroxy acyl-CoA dehydrogenase deficiency (Karall et al., 2015); mitochondrial trifunctional protein deficiency (Park et al., 2009)
		Decreased	Psoriasis (Chen et al., 2021)
3-Hydroxy-hexadecenoylcarnitine (C16:1-OH)	Blood	Increased	Diastolic heart failure (Hunter et al., 2016); systolic heart failure (Hunter et al., 2016)
		Decreased	Intracerebral hemorrhage (Zhang et al., 2017b); psoriasis (Chen et al., 2021); coronary artery disease (Shah et al., 2010)
Hexadecanedioylcarnitine (C16-DC)	Blood	Increased	Peroxisomal biogenesis disorders (Rizzo et al., 2003)
	Urine	Increased	Zellweger syndrome (Duranti et al., 2008); infantile Refsum disease (Duranti et al., 2008); D-bifunctional protein deficiency (Duranti et al., 2008)
3-Hydroxysteroylcarnitine (C18-OH)	Blood	Increased	Coronary artery disease (Shah et al., 2010)
3-Hydroxyoleylcarnitine (C18:1-OH)	Blood	Increased	Chronic fatigue syndrome (Reuter and Evans, 2011); mitochondrial trifunctional protein deficiency (Park et al., 2009); psoriasis (Chen et al., 2021)
Octadecanedioylcarnitine (C18-DC)	Blood	Increased	Peroxisomal biogenesis disorders (Rizzo et al., 2003)
	Urine	Increased	Zellweger syndrome (Duranti et al., 2008); infantile Refsum disease (Duranti et al., 2008); D-bifunctional protein deficiency (Duranti et al., 2008)

reverse activity of CrAT might be related to providing acetyl-CoA for the biosynthesis of malonyl-CoA to inhibit fatty acid oxidation (Altamimi et al., 2018). It is also known that CrAT, by decreasing the availability of acetyl-CoA in the presence of carnitine overload (or when overexpressed), can alleviate inactivation of pyruvate dehydrogenase and increase glucose utilization in primary human skeletal myocytes (Noland et al., 2009). This can facilitate insulin secretion in β cells (Berdous et al., 2020). During ischemia, the lack of oxygen limits mitochondrial β -oxidation and respiration in isolated rat hearts, leading to the accumulation of both short-/long-chain acylcarnitines and acyl-CoA intermediates along with the corresponding decrease in free CoA (Whitmer et al., 1978). Although limited reserves of cytosolic CoA are likely converted to acyl-CoAs under acute stress conditions, preserving CrAT activity is crucial to ensure repletion of free CoA inside the mitochondria to support energy metabolism as long as possible.

2. Carnitine Octanoyltransferase. Carnitine octanoyltransferase, or CrOT, is found only in peroxisomes, and similar to CrAT, this enzyme aids the export of products of peroxisomal β -oxidation (Westin et al., 2008). The highest activity of CrOT is toward C4–C12 containing acylcarnitines as indicated by studies using rat and mouse liver enzymes (Fig. 4), whereas the activity rapidly decreases for chains with more than 14 carbons (Miyazawa et al., 1983; Farrell et al., 1984). It is interesting to note that although CrOT can use C10-CoA and 4,8-dimethylnonoyl-CoA (a C11-CoA product of peroxisomal oxidation of

pristanic acid) to produce the respective acylcarnitines, the human enzyme is inactive against 2,6-dimethylheptanoyl-CoA (C9-CoA), which is produced when C11-CoA is further β -oxidized (Ferdinandusse et al., 1999). Peroxisomes, via the help of CrOT, can partially contribute to medium-chain acylcarnitine production from the metabolism of medium- and long-chain fatty acids. Peroxisomes can also contribute to the oxidation of these fatty acids under normoxic conditions in isolated perfused rat hearts (Bian et al., 2005), particularly when mitochondrial fatty acid oxidation is impaired or overloaded as shown in a study using human skin fibroblasts (Violante et al., 2013b). Studies in isolated rat hearts indicate that peroxisomal fatty acid oxidation can provide more than 50% of the acetyl groups that are used to produce malonyl-CoA (Reszko et al., 2004). Moreover, the study of intact isolated rat hearts indicates that acetyl-CoA molecules formed from fatty acids that undergo the first steps of oxidation only in peroxisomes are used for malonyl-CoA biosynthesis but are not transferred to the mitochondria in detectable amounts (Bian et al., 2005). Similar to CPT1, CrOT contains a malonyl-CoA-sensitive domain and can be inhibited by malonyl-CoA at physiologic concentrations (ABhaird and Ramsay, 1992; Morillas et al., 2002). More than 30 years ago, it was suggested that the inhibition of rat liver peroxisomal long- and medium-chain acyltransferase (i.e., CrOT) by malonyl-CoA could be important for the regulation of mitochondrial fatty acid oxidation (Derrick and Ramsay, 1989). This is likely true for peroxisomal fatty acid oxidation itself, as the overexpression of the CrOT gene in human

hepatic cancer cell lines results in an increase in CrOT activity and subsequent upregulation of enzymes that encode peroxisomal fatty acid oxidation. Conversely, small interfering RNA-induced knockdown of CrOT has been shown to result in decreased mRNA levels of key proteins of fatty acid metabolism in peroxisomes (Le Borgne et al., 2011). Overexpression of CrOT leads to a decrease in medium- and very long-chain fatty acid levels, whereas long-chain fatty acid levels are not affected. Furthermore, hepatic cancer cells with CrOT knockdown demonstrate an increase in medium-chain fatty acid levels (Le Borgne et al., 2011). Moreover, CrOT overexpression can result in an increase in the mRNA levels of key proteins involved in peroxisomal fatty acid metabolism but not mitochondrial CPT1 and acyl-CoA thioesterase. Notably, the redirection of myocardial fatty acid oxidation from the mitochondria to peroxisomes decreases ischemic damage in isolated rat hearts and improves recovery during reperfusion (Liepinsh et al., 2013).

3. Carnitine Palmitoyltransferases. Carnitine palmitoyltransferase 1 (CPT1) is the only carnitine acyltransferase with three isoforms (CPT1A, liver isoform; CPT1B, muscle isoform; and CPT1C, brain isoform). Each of these isoforms is specific for different tissue types. The heart is one of the tissues where both CPT1A and CPT1B are present. Although liver and muscle isoforms share a high degree of sequence homology, they differ significantly in their physiologic response to and regulation by malonyl-CoA and carnitine. A seminal paper by McGarry and colleagues (1983) describes, in great detail, the differences between the liver and muscle isoforms of CPT1 from rats, dogs, and humans. The Michaelis–Menten constant (K_m) of carnitine for CPT1 ranges from 32 and 39 μM in rat and human liver tissues to 500–600 μM in human, rat, and dog skeletal muscles to 197 and 695 μM in rat and dog cardiac tissues, respectively. The muscle isoform has a low affinity for carnitine, and the opposite is true for the liver isoform (McGarry et al., 1983; Distler et al., 2009). The IC_{50} for malonyl-CoA of CPT1 in human and rat liver tissue is in the low micromolar range (1.6–2.7 μM), whereas it is in the low to medium nanomolar range in rat and dog cardiac tissues (25–100 nM) and rat, dog, and human skeletal muscle (17–34 nM) (McGarry et al., 1983). This high affinity toward the physiologic inhibitor malonyl-CoA means that muscle and cardiac tissues are more sensitive to malonyl-CoA than liver tissues (Bird and Saggerson, 1984). During fasting, when the malonyl-CoA tissue content decreases by factors of 4.4-, 3.3-, and 3-fold in liver, cardiac, and muscle tissues, respectively (McGarry et al., 1983), the activity of CPT1 increases only in the liver and not in cardiac tissues (Paulson et al., 1984; Bonnefont et al., 2004). On the other hand, a diet rich in carbohydrates activates insulin signaling. As a result, adenosine

monophosphate-activated protein kinase (AMPK) is inhibited, and the production of malonyl-CoA by acetyl-CoA carboxylase (ACC, EC:6.4.1.2) is increased, leading to the inhibition of liver CPT1 activity, which facilitates liponeogenesis. Unlike heart and muscle tissues that predominantly express the ACC2 isoform, liver tissue expresses both ACC1 and ACC2, with the latter being responsible for malonyl-CoA synthesis (Munday, 2002). In a fasted state, the activity of ACC is inhibited via phosphorylation by AMPK. When the inhibitory activity of malonyl-CoA is averted, hepatic fatty acid β -oxidation is increased and triacylglycerol accumulation is prevented (Akkaoui et al., 2009). Within cardiac tissues, when the sensitivity of CPT1B toward malonyl-CoA is reduced, cardiac fatty acid utilization is increased (van Weeghel et al., 2018). Together, the interplay between malonyl-CoA and CPT1 is crucial for regulating long-chain fatty acid oxidation rates in liver, heart, and muscle tissues. Missense mutations may result in a deficiency of CPT1A that leads to partial or even complete loss of enzymatic activity (Gobin et al., 2003). This deficiency is characterized by life-threatening hypoketotic hypoglycemia and fasting intolerance (Bennett et al., 2004; Stoler et al., 2004).

The brain isoform of rat CPT1C has a 2-fold lower K_m than CPT1A for carnitine and a 5-fold higher K_m for palmitoyl-CoA, but its catalytic activity is up to 320-fold lower (Sierra et al., 2008). Although the exact role of CPT1C in brain tissue remains to be elucidated, recent studies have demonstrated that CPT1C and the availability of malonyl-CoA are required for proper axon growth by regulating anterograde transport of late endosomes and lysosomes (Palomo-Guerrero et al., 2019). Moreover, CPT1C is involved in the regulation of ceramide metabolism. Thus, the overexpression of this enzyme results in increased ceramide levels. Furthermore, it has been shown that a deficit of CPT1C diminishes ceramide levels and results in altered dendritic spine morphology and impaired spatial learning in mice (Carrasco et al., 2012). Overall, CPT1 enzymes are key regulators of long-chain acylcarnitine availability and thus have served as the primary target for altering long-chain acylcarnitine levels. Strategies to treat these CPT1-related conditions include increasing malonyl-CoA levels via inhibition of MCD (Fillmore and Lopaschuk, 2014) using CPT1 inhibitors, which have been proven effective in treating ischemic heart disease in an in vivo pig model (Cheng et al., 2006). Direct inhibition of CPT1 with pharmacological agents such as etomoxir (etomoxiryl-CoA) (Lopaschuk et al., 1988) or decreasing the availability of substrate (carnitine) by using OCTN2 inhibitors such as meldonium or methyl-GBB (Liepinsh et al., 2015) have also been explored as cardioprotective strategies in rat (in vivo) and isolated heart ischemia-reperfusion injury models.

CPT2 is another isoform of carnitine palmitoyltransferase that is located on the matrix side of the

inner mitochondrial membrane and is tasked with converting long-chain acylcarnitines back to the respective long-chain acyl-CoAs. CPT2 is not sensitive to malonyl-CoA and catalyzes the transfer of the acyl group of long-chain acylcarnitines onto CoA. Data obtained from rat liver mitochondria suggest that CPT2 aids in the export of long-chain acyl-CoA esters from the mitochondria (Ventura et al., 1998) and can synthesize C8–C20 acylcarnitines (Fig. 4). On the other hand, human CPT2 has virtually no activity in handling shorter acyl-CoAs or very long-chain acyl-CoAs or acyl-CoAs derived from branched-chain amino acid metabolism (Violante et al., 2010). Although this activity could potentially remove toxic long-chain acyl-CoA esters from the mitochondrial matrix, it could also lead to the accumulation of long-chain acylcarnitines in the mitochondrial intermembrane space.

4. Acylcarnitine Transporters. The transporter CACT catalyzes the equimolar exchange of long-chain acylcarnitines for carnitine to ensure long-chain acylcarnitine transfer across the inner mitochondrial membrane (Murthy and Pande, 1984) via a ping-pong mechanism with one binding site alternately exposed to each side of the membrane. Moreover, carnitine uniport is also possible (Palmieri, 1994). Another transporter, human OCTN2 or SLC22A5, is involved not only in the transport of carnitine but also in the transport of acetylcarnitine (Wu et al., 1999). In rodents, OCTN2 also ensures the transport of acetylcarnitine across the blood-brain barrier (Kido et al., 2001). More recently, in a study using a mouse acylcarnitine transporter, it was shown that organic cation transporter 1 (OCT1, SLC22A1) is involved in the hepatic efflux of short-chain (C2–C6) acylcarnitines (Fig. 4) and participates in the regulation of plasma short-chain acylcarnitine levels (Kim et al., 2017). It remains to be determined which transport proteins (Table 8), if any, are involved in the efflux/transport of medium- and long-chain acylcarnitines.

B. Acylcarnitine Production Sites – Organelles

Based on the locations of carnitine acyltransferases and their contribution to the overall pool of acylcarnitines, two distinct sites of acylcarnitine production can be identified from an organelle perspective: the mitochondria and peroxisomes. As highlighted in Section III.A.1, due to the presence of CrAT, both organelles can generate acetylcarnitine from acetyl-CoA. Acetyl-CoA itself is a product of multiple catabolic reactions and is predominantly generated in the mitochondrial matrix by glycolysis, β -oxidation, and the catabolism of branched-chain amino acids (Pietrocola et al., 2015). Although CrAT in peroxisomes aids the export of acetyl moieties via acetylcarnitine (Westin et al., 2008), the reverse activity of CrAT in the cytosol ensures that acetyl moieties are used for the biosynthesis of malonyl-CoA (Altamimi et al., 2018). Studies using rodent peroxisomes and rodent mitochondria indicate that on

average, peroxisomal contributions to the oxidation of C16–C24 saturated and unsaturated fatty acids are 15%–31%, 14%–46%, and 18%–38% in rat liver, cardiac, and muscle tissues, respectively (Reubsæet et al., 1989). Comparable findings have been reported for pig liver, kidney, and cardiac tissues (Yu et al., 1997). In other words, acetylcarnitine of peroxisomal origin contributes to the overall pool of acetylcarnitine to a lesser extent than acetylcarnitine derived from mitochondria. Peroxisomal metabolism of pristanic acid and odd-chain fatty acids serves as a source for propionyl-CoA, which is subsequently converted to propionyl-carnitine by CrAT to exit peroxisomes (Jakobs and Wanders, 1995). Peroxisomal metabolism of long- and very long-chain fatty acids usually results in the production of C12–C14 chain length acyl-CoAs (Reszko et al., 2004), whereas metabolism of octanoate usually involves shortening by two acetyl moieties (Kasumov et al., 2005). As a result, peroxisomes can also contribute to the production of butylcarnitine and C12- to C14-acylcarnitine pools. Since peroxisomes do not have CPT1 and CrOT has a strong preference for acyl-CoAs with chain lengths of up to C14 (Miyazawa et al., 1983; Farrell et al., 1984), it is unlikely that peroxisomes could produce meaningful amounts of any acylcarnitines with acyl moieties longer than C14. When peroxisomes oxidize medium-chain fatty acids such as lauric acid (C12), C12-, C10-, C8- and C6-acylcarnitines are formed and exported (Violante et al., 2019). This, in turn, means that mitochondria serve as the main source for acylcarnitines with carbon chain lengths of C16 and above. Mitochondria do not have CrOT, meaning that their acylcarnitine production is limited to acyl moieties with chain lengths preferred by CrAT and CPT1/2 (Fig. 4). Nevertheless, human CrAT can convert acyl-CoAs with chain lengths up to C10 to the respective acylcarnitines (Violante et al., 2013a), whereas CPT1 can produce acylcarnitines from saturated fatty acids with chain lengths starting from C6 to C18 (Finocchiaro et al., 1990; Schaefer et al., 1997). CPT1 can also produce acylcarnitines from unsaturated fatty acids (Price et al., 2011), including very long-chain polyunsaturated fatty acids (Gavino et al., 2003). As a result, mitochondria take part in the production of acylcarnitines with virtually every chain length.

C. Enzymes, Transporters, and Energy Metabolism Pathways Affecting Acylcarnitine Levels

The modulation of fatty acid metabolism typically changes the content of acylcarnitines as well as their metabolism in mitochondria (Fig. 5). Physiologically, energy metabolism is regulated during the fed-fasted cycle via activation of AMPK or insulin signaling pathways. AMPK stimulates fatty acid metabolism, whereas insulin-mediated signaling inhibits fatty acid metabolism by affecting CPT1-dependent acylcarnitine synthesis. CPT1 activity in insulin-sensitive tissues is regulated via




Fig. 3. Generalized model of acylcarnitine synthesis, transport and metabolism in (A) peroxisomes and (B) mitochondria. Acylcarnitines are generated in the mitochondria and peroxisomes of various tissues. BC, branched chain; FATP1, long-chain fatty acid transport protein 1; LC, long chain; MC, medium chain; MITO, mitochondria; mt- β -ox, mitochondrial fatty acid β -oxidation; PEX, peroxisomes; pex- α/β -ox, peroxisomal fatty acid α - or β -oxidation; TCA cycle, tricarboxylic acid cycle; VLC, very long-chain.

changes in the malonyl-CoA level (McGarry et al., 1977). Accordingly, a low malonyl-CoA content leads to increased CPT1 activity and an increased acylcarnitine synthesis rate. Malonyl-CoA is generated by ACC and degraded by MCD. The activity of ACC is inhibited by the AMPK-mediated phosphorylation of enzyme, whereas inactivation of AMPK turns ACC into the dephosphorylated state and increases enzyme activity (Dyck and Lopaschuk, 2006). The activation of insulin signaling prevents ACC phosphorylation and thus stimulates malonyl-CoA synthesis followed by CPT1 inhibition (Witters and Kemp, 1992). Malonyl-CoA-mediated decarboxylation is catalyzed by MCD, which converts malonyl-CoA into acetyl-CoA. Improvement in insulin sensitivity by insulin mimetics such as glucagon-like peptide 1 could accelerate insulin action and support the insulin-induced reduction in fatty acid metabolism. In contrast, negative regulation of the phosphoinositide-3 kinase/protein kinase B (PI3K/Akt) pathway by activation of various phosphatases, such as protein tyrosine phosphatase 1B, protein phosphatase 2A, and phosphatase and tensin homolog, could potentially increase the acylcarnitine content and fatty acid metabolism rate (Liao and Hung, 2010).

Long-chain acylcarnitine synthesis is dependent on CPT1 expression and the availability of substrates. For instance, muscle-specific CPT1 knockout (KO) mice (Wicks et al., 2015) have lower medium- and long-chain acylcarnitine contents in their muscle tissue. Likewise, pharmacological inhibition of CPT1 by the drug oxfenicine results in a lower long-chain

acylcarnitine content in heart tissues (Kennedy et al., 2000; Karwi et al., 2020). Additionally, the availability of carnitine significantly influences the acylcarnitine synthesis rate and content of acylcarnitines in plasma and tissues (Rahbeeni et al., 2002; Liepinsh et al., 2015). Stimulation of fatty acid metabolism in mitochondria has been considered as strategy to reduce long-chain acylcarnitine levels. Thus, when decreased CPT1-dependent acylcarnitine production is accompanied by preserved or stimulated mitochondrial β -oxidation, the mitochondria are further protected against lipid overload-induced accumulation of long-chain acylcarnitines (Liepinsh et al., 2015; Makrecka-Kuka et al., 2020a). Similarly, the regulation of mitochondrial fatty acid oxidation is mediated by sirtuins (a well conserved family of signaling proteins involved in metabolic regulation), which change the acetylation/deacetylation balance of mitochondrial proteins (Matsushima and Sadoshima, 2015). Thus, long-chain acyl-CoA dehydrogenase (LCAD), an important enzyme in mitochondrial β -oxidation, is hyperacetylated in the absence of sirtuin 3 and results in an increased content of long-chain acylcarnitines (Hirschey et al., 2010). In the sirtuin 5 KO mouse model, impaired β -oxidation and increased contents of medium- and long-chain acylcarnitines in the liver and muscles were also observed (Rardin et al., 2013). Overall, inhibiting acylcarnitine synthesis and the stimulation of mitochondrial fatty acid β -oxidation are important mechanisms for the prevention of acylcarnitine accumulation.




Fig. 4. Enzyme and transporter preferences for acylcarnitines of various chain lengths (C2–C23). Shading represents the enzyme/transporter preference for specific acylcarnitine lengths. Based on the literature data, a darker area indicates a higher preference for a specific acylcarnitine, whereas a lighter area indicates a lower preference for a specific acylcarnitine or limited data availability.

D. Acylcarnitine Production Sites – Tissues

Plasma concentrations of acylcarnitines are frequently used as markers to diagnose inborn fatty acid oxidation defects and other diseases leading to incomplete fatty acid metabolism (Rinaldo et al., 2008; Wanders et al., 2020). Acylcarnitines of differing chain lengths may appear in the plasma as a result of efflux from different organs or tissues. The heart, skeletal muscle, and liver all contain various acylcarnitine species. Therefore, these tissues could be proposed as the main contributors to the plasma acylcarnitine pool. Increased plasma concentrations of medium- and long-chain acylcarnitines are observed in the fasted state due to increased lipolysis and fatty acid oxidation rates when compared with the fed state (Liepinsh et al., 2014; Makrecka et al., 2014). Similar differences in the acylcarnitine content between different nutritional states are detected in metabolically flexible tissues such as the heart and muscles but not in the liver (Schooneman et al., 2014; Makrecka-Kuka et al., 2017). Moreover, the content of long- and medium-chain acylcarnitines in rodent plasma is comparable with that in heart tissue, indicating that the heart is a major contributor to plasma acylcarnitine concentration changes, particularly for medium- and long-chain acylcarnitines (Makrecka-Kuka et al., 2017). This allows one to use plasma long-chain acylcarnitine concentrations as indicators of cardiac acylcarnitine content and mitochondrial functionality. Although skeletal muscles have an energy metabolism pattern similar to that of the heart, multiple studies in rodents (Makrecka-Kuka et al., 2017), pigs (Schooneman et al., 2015), and humans (Xu et al., 2016) have shown that there is no significant contribution (efflux) of long-chain acylcarnitines from skeletal muscle to the plasma. Indeed, in studies involving fasted mice, it was found that the muscle tissue content of long-chain acylcarnitines increased during exercise but the plasma concentration did not change (Makrecka-Kuka et al., 2017). Even though the liver is the main source of circulating acetyl- and propionyl-carnitine (Schooneman et al., 2015; Xu et al., 2016), it does not contribute

to the long-chain acylcarnitine blood pool, even when liver CPT2 is absent and the liver tissue content of acylcarnitines is increased (Lee et al., 2016). Skeletal muscles in humans have been shown to contribute to the plasma pool of C8–C12 (C12:1) acylcarnitines during exercise, but not during the resting state (Xu et al., 2016). The cardiac content of medium-chain acylcarnitines is significantly higher than that of the muscles and the heart contributes significantly more to the plasma concentration of medium-chain acylcarnitines at a resting state (Makrecka-Kuka et al., 2017). Thus during the exercise, both the heart and skeletal muscles appear to contribute to the plasma medium-chain acylcarnitine pool (Xu et al., 2016; Zhang et al., 2017a). Overall, it can be concluded that the heart is the main contributor to the long-chain acylcarnitine pool in plasma and that skeletal muscles and the heart contribute to the medium-chain acylcarnitine pool, whereas the liver is the main contributor to the short-chain acylcarnitine pool in plasma.

IV. Diseases and Pathways

A. Biomarkers of Pathologic Conditions and Diseases

1. Acylcarnitines for the Diagnosis of Rare Inherited Diseases and Conditions. Inherited fatty acid oxidation disorders (FAODs) may be diagnosed if any part of the mitochondrial fatty acid transport, or the short-, medium- or long-chain fatty acid β -oxidation pathways have been adversely affected. The FAODs related to the transport of long-chain acylcarnitines across the mitochondrial inner membrane (CACT deficiency) and conversion of acylcarnitines back to the respective acyl-CoAs (CPT2 deficiency) have been previously described (Houten et al., 2016; Vishwanath, 2016; Marsden et al., 2021). Defects in enzymes involved in mitochondrial β -oxidation such as very long-chain acyl-CoA dehydrogenase (VLCAD), long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD), and mitochondrial trifunctional protein deficiency are often characterized by elevated long- and very long-chain acylcarnitine levels. These conditions have been extensively reviewed before,

TABLE 8
 Proteins directly involved in acylcarnitine biosynthesis and transport or directly affected by acylcarnitines

Protein and Identifier (UniProt ID for Human Protein)	Involvement	Localization	Reference
Carnitine acetyltransferase (CrAT) EC 2.3.1.7 (UniProtKB: P43155)	Catalyzes the reversible transfer of acyl groups (up to C4) from carnitine to CoA and regulates the acyl-CoA/CoA ratio and availability of free CoA during intensified fatty acid metabolism.	Mitochondrial matrix, peroxisomal matrix, endoplasmic reticulum, nucleus, and cardiomyocyte cytosol	Wu et al., 2003; Hsiao et al., 2004; Stephens et al., 2007
Carnitine octanoyltransferase (CrOT) EC 2.3.1.137 (UniProtKB: Q9UKG9)	Catalyzes reversible transfer of acyl groups (C6–12, can go up to C16) from CoA to carnitine. Metabolism of branched chain fatty acids.	Peroxisomal matrix	Ferdinandusse et al., 1999; Jogl et al., 2005
Carnitine palmitoyltransferase 1 (CPT1) EC 2.3.1.21	Catalyzes reversible transfer of the acyl group of long-chain fatty acid-CoA conjugates onto carnitine. Broad specificity to acyl group, over the range of C8–C18, optimal substrate palmitoyl-CoA. Forward reaction inhibited by palmitoylcarnitine and malonyl-CoA.	Outer mitochondrial membrane	McGarry and Brown, 1997
CPT1A – liver isoform UniProtKB: P50416	Expressed in most tissues. Low K_m value for carnitine, sensitive to malonyl-CoA.	Outer mitochondrial membrane	
CPT1B – muscle isoform UniProtKB: Q92523	Highest expression in heart and skeletal muscle, no expression in liver and kidney. High K_m value for carnitine, sensitive to malonyl-CoA.	Outer mitochondrial membrane	
CPT1C – brain isoform UniProtKB: Q8TCG5	Highest expression in brain and testis. Catalytic activity negligible but can bind malonyl-CoA.	Outer mitochondrial membrane	Price et al., 2002; Wolfgang et al., 2006; Sierra et al., 2008
Carnitine palmitoyltransferase 2 (CPT2) EC 2.3.1.21 (UniProtKB: P23786)	Regulates energy homeostasis and involved in ceramide biosynthesis and regulation. Catalyzes the transfer of the acyl group of long-chain fatty acid-carnitine conjugates onto CoA. Loss of CPT2 disables the mitochondrial oxidation of long-chain fatty acids.	Conflicting reports on localization in mitochondria or endoplasmic reticulum	
Carnitine/acylcarnitine translocase (CACT) (UniProtKB: O43772)	Transport of acylcarnitines and carnitine across the mitochondrial inner membrane to and from mitochondrial matrix. Support of mitochondrial fatty acid-oxidation pathway.	Inner mitochondrial membrane	Pereyra et al., 2017
Organic cation transporter 1 (OCT1) SLC22A1 (UniProtKB: O15245)	Involved in hepatic acylcarnitine efflux. Associated with serum acylcarnitine levels.	Cell membrane	Console et al., 2014
Organic cation novel type 2 transporter (OCTN2) SLC22A5 (UniProtKB: O76082)	Involved in transport of acetylcarnitine.	Cell membrane	Kim et al., 2017
			Kido et al., 2001; Kobayashi et al., 2007




Fig. 5. Enzymes, transporters and signaling pathways as potential targets to decrease the acylcarnitine content. Arrows indicate enzymatic reaction or transport; T-shaped arrows indicate inhibition. The interrupted arrow indicates indirect activation by the PI3K/Akt signaling pathway. FA, fatty acids; FATP1, long-chain fatty acid transport protein 1; IRS, insulin receptor substrate; LC, long chain; mt- β -ox, mitochondrial fatty acid β oxidation; PI3K, phosphoinositide 3-kinase; TCA cycle, tricarboxylic acid cycle.

and readers are referred to the papers of Houten et al. (2016), Vishwanath (2016), and Marsden et al. (2021) for an in-depth understanding.

CACT-mediated transport is an essential step in the long-chain fatty acid β -oxidation pathway. Carnitine-acylcarnitine translocase deficiency is a rare autosomal recessive disease characterized by mutations in the CACT gene (SLC25A20). This condition may result in hypoketotic hypoglycemia, elevated creatine kinase and transaminases, dicarboxylic aciduria, very low free carnitine, and marked elevation of long-chain acylcarnitines (Rubio-Gozalbo et al., 2004). This can lead to cardiac complications (cardiac arrhythmia, cardiomyopathy, and heart block), muscle weakness, and seizures (Vitoria et al., 2015). Another condition called CPT2 deficiency is the most common of the rare disorders related to the metabolism of long-chain fatty acid oxidation. Particularly rare are lethal neonatal and severe infantile forms of CPT2 deficiency. On the other hand, the more common and milder version of this disease is the muscle form of CPT2 deficiency (Joshi and Zierz, 2020). It should be noted that severe carnitine deficiency and increased long-chain acylcarnitine levels are characteristic of this disorder. Long- and medium-chain acylcarnitine

levels are used for the diagnosis of not only CACT disorders but also CPT2 and several β -oxidation enzyme deficiencies (Fig. 6 and Table 3).

2. Long-Chain Acylcarnitine Measurements for the Diagnosis of Insulin Resistance. Although acylcarnitines have long been used to diagnose inherited metabolic disorders, they are also being studied for the diagnosis of acquired metabolic disorders such as diabetes and insulin resistance. Currently, glucose and glycated hemoglobin A1c are the main diagnostic markers of type 2 diabetes used in clinical practice (Inzucchi et al., 2015; American Diabetes Association, 2017). Recently, assessments of triglycerides and total cholesterol have been included as markers of diabetes progression and therapeutic efficacy (American Diabetes Association, 2017). Other circulating lipid metabolites have not yet been accepted into clinical practice as markers of insulin resistance. Given the role of insulin in the suppression of lipid metabolism, it would be reasonable to evaluate insulin sensitivity by measuring the levels of fatty acid metabolism intermediates. In this regard, long-chain acylcarnitines appear to be promising biomarkers.

Energy metabolism is significantly changed during fed and fasted cycles, as it depends on the

availability of energy substrates in the circulation. The utilization of fatty acids dominates in a fasted state, whereas insulin-sensitive tissues switch to carbohydrate metabolism in a fed state in response to the increased availability of glucose. Long-chain acylcarnitines are produced from long-chain fatty acids in skeletal muscles and the heart. However, only the heart is thought to be the main contributor to the plasma long-chain acylcarnitine pool (Koves et al., 2008; Makrecka-Kuka et al., 2017). Activation of insulin signaling decreases CPT1 activity and thus reduces the long-chain acylcarnitine content in muscle and cardiac tissues (Mihalik et al., 2010). The inability to reduce fatty acid metabolism in a fed state is a metabolic inflexibility caused by insulin resistance (Goodpaster and Sparks, 2017; Smith et al., 2018). The plasma concentrations of long-chain acylcarnitines reflect the changes in acylcarnitine tissue contents in the fed and fasted states and thus can serve as a valuable marker of tissue-specific insulin sensitivity (Makarova et al., 2019). Importantly, insulin levels in a fasted state are substantially lower than those in a fed state. Therefore, the measurement of plasma acylcarnitine concentrations in the fasted state does not characterize insulin sensitivity. Accordingly, high concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance. This is a result of insulin's inability to inhibit CPT1-dependent fatty acid metabolism in the heart (Ngu et al., 2008; Ramos-Roman et al., 2012). In patients with type 2 diabetes, insulin resistance usually presents in the heart and skeletal muscle concurrently. Thus, long-chain acylcarnitine measurements might be useful for the diagnosis of insulin resistance in skeletal muscles (Paternostro et al., 1996; Luong et al., 2021).

In the clinical setting, the postprandial state is not well defined. Therefore, the oral glucose tolerance test (GTT) or a controlled high carbohydrate-containing meal is better suited for diagnosing diabetes, prediabetes, or insulin sensitivity. The GTT is widely accepted as a diagnostic method, and measurements of acylcarnitines before and after glucose administration are feasible in clinical situations (Jagannathan et al., 2020). GTT measurements characterize either mitochondrial energy status in the fasted state or in the insulin-mediated transition from a fasted to a postprandial state. The concept that insulin-resistant subjects are not able to adequately decrease long-chain acylcarnitine plasma concentrations during an insulin clamp or a standard meal has been validated in several clinical studies (Mihalik et al., 2010; Bouchouirab et al., 2018). Thus, measurements of plasma long-chain acylcarnitine levels during GTT and insulin clamp tests are suitable for evaluating insulin sensitivity in both muscle tissues and the heart.

3. Incomplete Long-Chain Acylcarnitine Metabolism as a Marker of Heart Failure and a Predictor of Major Cardiovascular Events. Oxidative phosphorylation (OXPHOS) in the mitochondria is the central energy production pathway of the heart. As a result, mitochondrial dysfunction has been considered to be an important reason for contractile failure in the heart. Long-chain fatty acids are the main energy substrates for oxidative metabolism in the heart, and fatty acid metabolism is primarily affected when there is reduced mitochondrial OXPHOS capacity. Insufficient fatty acid metabolism in the mitochondria results in a decreased ATP generation rate and persistent energy deficiency. AMPK can sense an increased AMP/ATP ratio and stimulate CPT1 activity. Since acylcarnitine accumulation does not induce any feedback inhibition of CPT1, acylcarnitine levels can increase significantly over time as the pathology progresses. During the progression of heart failure, cardiac metabolism switches to other available energy substrates, but these derangements do not affect acylcarnitine production. Heart tissues are suggested to be the main contributors to the plasma long-chain acylcarnitine pool (Makrecka-Kuka et al., 2017); therefore, long-chain acylcarnitine measurements in plasma are particularly suitable for the diagnosis of cardiac diseases related to mitochondrial dysfunction.

During fasting, plasma concentrations of medium- and long-chain acylcarnitines are continuously increasing in tissues and plasma as a result of stimulated intracellular fatty acid metabolism, which is proportional to the duration of the fast (Elizondo et al., 2020; Hung et al., 2020). This is a result of the low concentrations of insulin in the circulation, the limited availability of glucose as a metabolic substrate, and the stimulation of intracellular fatty acid metabolism. Increased fatty acid availability and facilitated CPT1 activity are appropriate metabolic conditions for the evaluation of mitochondrial capacity to metabolize fatty acids. In situations where β -oxidation and OXPHOS capacity are not capable of utilizing high amounts of synthesized acylcarnitines, elevated levels of medium- and long-chain acylcarnitines will appear in the plasma (Adams et al., 2009; Elizondo et al., 2020). Overall, a fasted state (or being on a ketogenic diet) is the most appropriate condition for the diagnosis of mitochondrial dysfunction in the heart.

Several studies have measured increased levels of circulating long-chain acylcarnitines in patients with chronic heart failure (Ueland et al., 2013; Ahmad et al., 2016; Hunter et al., 2016; Ruiz et al., 2017). In all studies with heart failure patients, elevated circulating levels of long-chain acylcarnitines were independently associated with adverse clinical outcomes. In the clinical trial HF-ACTION, higher plasma concentrations of long-chain acylcarnitines were independently associated with lower peak Vo_2 as well as both




Fig. 6. Enzymes and transporters related to the development of FAOD and the accumulation of acylcarnitines. Red arrows indicate reverse flux of acyl moieties and efflux of acylcarnitines. The main enzymes and transporters related to FAOD are marked in blue. ACAD9, acyl-CoA dehydrogenase family member 9; ECH, enoyl-CoA hydratase; ETFQO, electron transfer flavoprotein-ubiquinone oxidoreductase; LCKAT/MCKAT, long-/medium-chain 3-keto-thiolase, MCHAD/SCHAD, medium-/short-chain 3-hydroxyacyl-CoA dehydrogenase.

the primary and secondary clinical endpoints of the parent trial (Ahmad et al., 2016). In particular, plasma levels of C16, C18:1, and C18:2 acylcarnitines were significantly higher in patients with end-stage heart failure. In patients who underwent left ventricular assist device placement, plasma levels of long-chain acylcarnitines were decreased. Increased long-chain acylcarnitine concentrations reflect dysfunctional fatty acid metabolism in mitochondria and probably in peroxisomes (Houten et al., 2016). This suggests an important mechanism contributing to global lipid perturbations in humans with heart failure. Overall, long-chain acylcarnitines appear to be promising biomarkers for diagnosis or therapeutic interventions in patients with heart failure.

Multiple metabolomic profiling studies have been performed to identify biomarkers that predict major cardiovascular events (Shah et al., 2012; Rizza et al., 2014). A metabolomic profiling study identified medium- and long-chain acylcarnitines as biomarkers that could predict major cardiovascular events in elderly people (Shah et al., 2012). In another study, aging, mitochondrial dysfunction, and increased levels of long-chain acylcarnitines (evaluated by metabolomic profiling) were associated with major cardiovascular events, independent of standard predictors (Shah et al., 2012). Therefore, higher levels of plasma long-chain acylcarnitines can be a predictor for an increased risk of major cardiovascular events.

B. Long-Chain Acylcarnitine Accumulation-Induced Disorders

1. Enzymes, Ion Channels, and (Signaling) Pathways Affected by Acylcarnitines. Certain pathologic states are linked to inappropriate regulation of long-chain acylcarnitine synthesis or incomplete metabolism (McCoin et al., 2015a). This leads to an accumulation of long-chain acylcarnitines that may interact with several cytosolic and mitochondrial enzymes, ion channels, and signaling pathways (Fig. 7). The long-chain acylcarnitine palmitoylcarnitine has been shown to decrease OXPHOS-dependent mitochondrial respiration with complex I/III and complex II substrates in a dose-dependent manner. It has also been shown to induce mitochondrial membrane hyperpolarization and the subsequent production of reactive oxygen species (ROS) (Liepinsh et al., 2016). Palmitoylcarnitine can also induce mitochondrial damage leading to apoptotic cell death via activation of the caspase pathway (Mutomba et al., 2000; McCoin et al., 2015b). At physiologically relevant concentrations, palmitoylcarnitine was able to significantly decrease mitochondrial pyruvate and lactate oxidation (Makrecka et al., 2014) and to impact cellular energy metabolism pathways through dephosphorylation of the insulin receptor and protein kinase B (Akt) (Vilks et al., 2021).

The sodium-potassium exchanger [(Na⁺/K⁺)-ATPase, EC 7.2.2.13, multiple isoforms] is inhibited by long-chain acylcarnitines (Adams et al., 1979; Lamers et al.,

1984; Mészáros and Pappano, 1990). Moreover, the activity of the sarco/endoplasmic reticulum Ca^{2+} -ATPase (SERCA, EC 7.2.2.10, multiple isoforms) is increased in the presence of long-chain acylcarnitine concentrations below 20 μM and decreased when long-chain acylcarnitine concentrations are above 20 μM . This means that long-chain acylcarnitines facilitate Ca^{2+} release from the sarcoplasmic reticulum (Adams et al., 1979; Dumonteil et al., 1994; Yamada et al., 2000; McCoin et al., 2015b). In addition, it has been shown that extracellular long-chain acylcarnitines interact with the extracellular site of the voltage-gated potassium channel ionic current carried by hERG channels (I_{HERG}) (Kv11.1, KCNH2) to increase the I_{HERG} amplitude (Ferro et al., 2012). Although it is clear that long-chain acylcarnitines affect cardiac excitation-contraction coupling (Aitken-Buck et al., 2020), it remains to be determined whether they have a relevant pathologic meaning (e.g., leading to a proarrhythmic action). These effects are further discussed in the following sections as risk factors for cardiometabolic diseases.

2. Detrimental Effects of Acylcarnitines in Ischemic Heart Disease and Heart Failure. The high energy demand and limited glucose availability in the heart ensure that fatty acid metabolism is the predominant energy production mechanism for this organ (Stanley et al., 2005). In the postprandial and fasted states, 60%–95% of the heart's ATP is produced from fatty acid oxidation, respectively (Liepinsh et al., 2014). The content of acylcarnitines fully depends on their production and utilization rates. Therefore, if stimulated fatty acid flux and accelerated synthesis of acylcarnitines are not fully coupled with oxidation, then acylcarnitines will accumulate in cardiac mitochondria and other intracellular compartments. Acylcarnitine accumulation to relatively high levels can be considered a normal physiologic response to fasting or starving. For example, during the fasted state, the acylcarnitine content in the heart can be elevated by 5-fold compared with the fed state (Makrecka et al., 2014). The content of acylcarnitines increases even further in the case of prolonged fasting or starvation (Soeters et al., 2009). In a healthy heart, an increase in long-chain acylcarnitines does not lead to mitochondrial or cardiac damage; however, in the fasted state, cardiac oxygen utilization efficiency is significantly reduced (Liepinsh et al., 2014; Makrecka-Kuka et al., 2020c). In patients, fasting- and starvation-induced accumulation of long-chain acylcarnitines might lead to more pronounced cardiac damage in cases of ischemia (Liepinsh et al., 2014). Likewise, in patients with insulin resistance, the increased risk of heart disease (Peters et al., 2015) might be linked to higher levels of long-chain acylcarnitines in the heart.

During ischemia, the low oxygen availability in the heart limits mitochondrial β -oxidation (Fillmore et al.,

2014), and incompletely metabolized fatty acids, along with respective acyl-CoAs and acylcarnitines, start to accumulate. Energetic deficiencies in the ischemic heart stimulate a number of energy production pathways, including long-chain fatty acid uptake and the corresponding long-chain acylcarnitine synthesis in mitochondria by CPT1. Accordingly, high CPT1 (A and B isoforms) activity in cardiac tissues results in an increased long-chain acylcarnitine production rate (Liepinsh et al., 2016). At the same time, within the ischemic mitochondrial matrix, the long-chain acylcarnitine utilization rate is substantially reduced because of limited CPT2 activity and subsequent β -oxidation. For their proper functioning, CPT2 and β -oxidation enzymes need a sufficient amount of free CoA as a cofactor; however, during ischemia, the acyl-CoA/CoA ratio is significantly increased, leading to a deficiency of free CoA (Whitmer et al., 1978). Additionally, oxygen deficiency induces the accumulation of NADH and FADH_2 , which leads to inhibition of β -oxidation enzymes (Neely and Feuvray, 1981; Jaswal et al., 2011). Altogether, long-chain acylcarnitines accumulate in ischemic mitochondria because of stimulated synthesis and a limited utilization rate.

Multiple studies have noted the accumulation of fatty acid metabolites in the infarcted heart (Idell-Wenger et al., 1978; Whitmer et al., 1978; Corr et al., 1984; Ford et al., 1996). Moreover, there is direct evidence that long-chain acylcarnitine accumulation reaches levels in cardiac mitochondria that induced detrimental effects in an isolated rat heart infarction study (Liepinsh et al., 2016). The mechanisms of mitochondrial dysfunction induced by long-chain acylcarnitines have been described in several studies (Siliprandi et al., 1992; Korge et al., 2003; Tominaga et al., 2008). The main detrimental effects of long-chain acylcarnitine in mitochondria are related to the inhibition of OXPHOS, further resulting in inhibited ATP synthase activity and increased ROS production (Tominaga et al., 2008; Dambrova et al., 2021). This is supported by the finding that the highest measured levels of long-chain acylcarnitines are bound to the mitochondrial membranes and localized in the intermembrane space (Liepinsh et al., 2016). In addition to the direct effects on mitochondrial OXPHOS, long-chain acylcarnitines inhibit pyruvate and lactate metabolism in cardiac mitochondria (Makrecka et al., 2014). Overall, long-chain acylcarnitine accumulation is very harmful to mitochondrial functioning and is likely a factor that contributes to the energetic crisis in the myocardium during ischemia-reperfusion.

The amphiphilic nature of long-chain acylcarnitines and their nonspecific interaction with membranes have been widely studied (McCoin et al., 2015a). However, the presumptive nonspecific actions ascribed to long-chain acylcarnitines are somewhat doubtful




Fig. 7. Enzymes, ion channels, and (signaling) pathways affected by long-chain acylcarnitines in myocytes. Arrows indicate enzymatic reaction or transport; T-shaped arrows indicate inhibition. FA, fatty acids; FATP1, long-chain fatty acid transport protein 1; IRS, insulin receptor substrate; LC, long chain; mt- β -ox, mitochondrial fatty acid β oxidation; PDC, pyruvate dehydrogenase complex; TCA cycle, tricarboxylic acid cycle.

because fatty acid-binding proteins are present in various intracellular and extracellular compartments and protect cardiomyocytes and mitochondria against the amphiphilic effects of long-chain acylcarnitines (Liepinsh et al., 2016). However, for in vitro studies, the role of fatty acid-binding proteins as factors limiting long-chain acylcarnitine toxicity effects has to be taken into account. Fatty acid-binding proteins scavenge fatty acids and metabolic intermediates to reduce their free fraction and deliver intermediates only for specific reactions in the appropriate target proteins, thus preventing nonspecific toxic reactions (Glatz and vanderVusse, 1996; Neess et al., 2015). In the circulation, the free fraction of long-chain acylcarnitines is very low because they are tightly bound to serum albumin. In the cell cytosol, the high abundance of fatty acid-binding proteins could be responsible for the handling of fatty acids and long-chain acylcarnitines (Liepinsh et al., 2016). In myoglobin-rich tissues, long-chain (C12–C18) acylcarnitines can also bind to oxymyoglobin and participate in the regulation of long-chain acylcarnitine pools (Chintapalli et al., 2016; 2018). Currently, the protective effects of binding proteins have not been studied in detail, and

such assumptions are based on indirect evidence. Depending on whether an individual is in the fed or fasted state, long-chain acylcarnitine concentrations in the heart vary between 10 and 50 μ M. The effects of long-chain acylcarnitines on ion channels, insulin signaling enzymes, pyruvate metabolism, and OXPHOS in mitochondria are typically found to occur between 5 and 20 μ M if tested in the absence of cytosol or serum albumin. The addition of cytosolic fractions significantly limits the detrimental action of long-chain acylcarnitines on mitochondrial functionality (Liepinsh et al., 2016), which suggests the presence of protective proteins in the cytosol. Importantly, if fatty acids and long-chain acylcarnitines compete for the same binding protein, an increased level of fatty acids during starving and ischemia results in an increased free fraction of long-chain acylcarnitines. Since deoxymyoglobin has limited acylcarnitine binding compared with oxymyoglobin, it has also been hypothesized that this could contribute to the higher free acylcarnitine levels during hypoxia (Chintapalli et al., 2016; 2018). Therefore, conditions with increased fatty acid flux and hypoxia can be harmful because of the higher possibility of nonspecific actions of long-chain acylcarnitines.

3. *Proarrhythmic Effects of Acylcarnitines.* Most sudden cardiac deaths (SCDs) are caused by arrhythmias, particularly ventricular fibrillation. The majority of cases of SCD occur in patients who do not have traditional risk factors for arrhythmia (Srinivasan and Schilling, 2018). During cardiac ischemia and reperfusion, the concentration of long-chain acylcarnitines is markedly elevated and therefore associated with life-threatening arrhythmias (Aitken-Buck et al., 2020). Long-chain acylcarnitines can interfere with excitation-contraction coupling, cause arrhythmias, and reduce the conductivity between cardiac cells; reviews are available in McCoin et al. (2015a) and Aitken-Buck et al. (2020). It has been demonstrated that attenuation of increasing long-chain acylcarnitine levels during hypoxia through CPT1 inhibition is able to protect against hypoxia-mediated alterations in cardiomyocyte action potentials (Knabb et al., 1986). Several mechanisms of long-chain acylcarnitine interference have been proposed, including direct channel interaction (Yamada et al., 1994), nonselective permeabilization of the sarcolemma (Liu et al., 1991), reduction in gap junction permeability, and interference with calcium release from the sarcoplasmic reticulum (Liu et al., 1991). Furthermore, an extracellular increase in long-chain acylcarnitine levels has been shown to induce arrhythmias at the single-cell level (Wu and Corr, 1992). It must be noted that all of these observed effects of long-chain acylcarnitines strongly depend on the employed concentrations. It is therefore not well defined which of the long-chain acylcarnitine effects achieved at certain concentrations in vitro and ex vivo can be attributed to effects during ischemia in vivo.

Despite the strong indications that long-chain acylcarnitines interfere with cellular electrophysiology and excitation-contraction coupling and even though long-chain acylcarnitines promote arrhythmias in animal models, the targeting of long-chain acylcarnitine concentrations as an antiarrhythmic treatment strategy has not been tested in the clinic. Taking into account that there are clinically approved compounds that can be used for reducing long-chain acylcarnitine concentrations in humans, it would be reasonable to explore whether these compounds could find a new use in a patient group at high risk of cardiac arrhythmia during ischemia.

4. *Acylcarnitine Accumulation-Induced Complications in Rare Inherited Diseases and Conditions.* Several inborn errors of metabolism involve fatty acid metabolism defects and the accumulation of acylcarnitines (McCoin et al., 2015a). Altered energy metabolism and marked accumulation of long-chain acylcarnitines in the blood and many tissues have been observed in a number of rare inborn disorders, such as CACT, CPT2, VLCAD, LCHAD, and mitochondrial trifunctional protein deficiency. The enzymes associated with these deficiencies are involved in the transport and metabolism of long-

chain acylcarnitines and facilitate mitochondrial fatty acid β -oxidation. Long-chain acylcarnitine accumulation is not present in all FAODs; it is present only when there is an enzyme deficiency in the fatty acid mitochondrial metabolism pathway downstream of CPT1 (A and B isoforms).

The clinical phenotypes seen in FAODs are heterogeneous and of different severity even when the same fatty acid oxidation gene is deficient (Baruteau et al., 2013; Joshi et al., 2014). Considerable effort has been devoted to identifying discriminating biochemical factors determining the more severe phenotypes and to identifying pathologic mechanisms leading to disease complications. Energy deficiency in the heart and muscles is considered the main reason for acute and long-term complications of fatty acid oxidation deficiencies. Often, acute onset of the metabolic crisis and clinical symptoms appear when patients are in a fasted state or during exercise (Joshi et al., 2014). Thus, certain adaptation mechanisms can compensate for a single gene deficiency and exhibit a normal metabolic phenotype despite fatty acid metabolism having an essential role in energy production in the heart and skeletal muscle. To a large extent, compensation for deficiencies in fatty acid mitochondrial metabolism is possible because of the switch to carbohydrate oxidation, which replaces fatty acids as energetic substrates. Additionally, during carbohydrate intake, activation of insulin signaling limits long-chain acylcarnitine synthesis (Elizondo et al., 2020). Instead, during prolonged fasting and exercise, the limited availability of glucose cannot match the energy demand and fully compensate for fatty acid metabolism deficiency (Houten et al., 2016). During fasting and exercise, a marked increase in the content of long-chain acylcarnitines is a physiologic response, and cells and mitochondria can usually tolerate elevated levels of acylcarnitines (Xu et al., 2016). In patients with inherited deficiencies in mitochondrial fatty acid metabolism, increased production is not coupled with acylcarnitine metabolism, and long-chain acylcarnitines accumulate, often substantially exceeding tolerable baseline levels (Chace et al., 2001; McHugh et al., 2011). Since the high content of long-chain acylcarnitines induces harmful effects on the mitochondria and energy metabolism pathways, long-chain acylcarnitines are involved in the induction of an energetic crisis (McCoin et al., 2015a).

More than 50% of patients with these conditions exhibit cardiac complications, including cardiomyopathy, arrhythmias, and SCD (Bonnet et al., 1999). The same cardiovascular events are linked to excessive accumulation of acylcarnitines in experimental and clinical studies in subjects without an inherited deficiency. In patients with deficiencies of primary carnitine carriers, CPT1, and medium-chain acyl-CoA

dehydrogenase, long-chain acylcarnitines do not accumulate and arrhythmias are not observed (Bonnet et al., 1999). In the postmortem blood specimen samples from deceased patients with mitochondrial fatty acid oxidation deficiencies, the level of long-chain acylcarnitines was up to 100 times greater than the levels observed in acquired cardiac disorders (Chace et al., 2001; McHugh et al., 2011). In comparison, during myocardial infarction, mitochondrial long-chain acylcarnitine levels are increased 2- to 4-fold (Liepinsh et al., 2016). Patients with heart failure were found to have 2-fold higher concentrations of circulating long-chain acylcarnitine than control subjects (Ruiz et al., 2017). This evidence confirms that the long-chain acylcarnitine accumulation has a distinct role in the pathologic mechanism of cardiovascular complications.

The main treatment currently available for FAODs is a dietary intervention to limit long-chain fatty acids and increase consumption of carbohydrates to ensure adequate energy production (Spiekerkoetter et al., 2009). This treatment strategy could also affect long-chain acylcarnitine production because of reduced long-chain fatty acid flux and activated insulin signaling. Additionally, these dietary interventions might be based on diet supplementation with medium-chain fatty acid triglycerides, which are known to improve cardiac parameters but do not reduce rhabdomyolytic crises in FAOD patients (Gillingham et al., 2017; Vockley et al., 2021). Fatty acids with an uneven number of carbons might be beneficial because they replenish the Krebs cycle.

A less studied compensatory mechanism is the redistribution of fatty acid metabolism from mitochondria to peroxisomes. Long- and very long-chain fatty acids can be metabolized in peroxisomes, and in case of limited mitochondrial metabolism, peroxisomal proliferation and fatty acid oxidation are stimulated via activation of the peroxisome proliferator-activated receptor gamma coactivator 1/peroxisome proliferator-activated receptor α (PGC1/PPAR- α) pathway (Liepinsh et al., 2013; Wicks et al., 2015). Peroxisomes shorten (very) long-chain fatty acids down to chain lengths C6, thereby generating acetyl-CoA and acetylcarnitine, which increases acetyl group availability for metabolism in the Krebs cycle. At the same time, this process reduces the mitochondrial load of long-chain acylcarnitines. Additionally, in patients with at least some residual fatty acid oxidation enzyme activity, stimulation of fatty acid metabolism by PPAR-agonists might be beneficial. Indeed, bezafibrate treatment in CPT2-deficient patients reduced the average C16+C18:1 level from 38.39 to 7.73 M with a concomitant decrease in creatine kinase levels (Yamada et al., 2018). However, PPAR- α agonists are not effective in all patients because stimulation of fatty acid flux via CPT1 might induce additional acylcarnitine

accumulation, especially in patients with a lack of residual mitochondrial enzyme activity (Yamada et al., 2018).

Despite early diagnosis and dietary therapy, a significant number of patients with FAODs still develop symptoms, which underlines the need for additional individualized treatment strategies. Targeted long-chain acylcarnitine-lowering strategies are currently not used for the treatment of mitochondrial FAODs. Promising results have been obtained in a recent *in vitro* study using the drug etomoxir. The reduced long-chain acylcarnitine production by etomoxir rescues the proarrhythmia defects in human induced pluripotent stem cells derived from fibroblasts of patients with VLCAD deficiency (Knottnerus et al., 2020). In patients with blocked mitochondrial fatty acid oxidation, the reduction in long-chain acylcarnitine synthesis appears to ensure certain benefit. Novel diagnostic methods using detailed functional studies in fibroblasts would help in the design of individualized treatments for patients with mitochondrial fatty acid oxidation deficiencies.

5. Prodiabetic Effects of Acylcarnitines. Insulin resistance, which is the main feature of type 2 diabetes, involves inappropriate glucose and fatty acid metabolism. Disturbances in glucose metabolism can be induced by a high fatty acid load in the diet, which results in the accumulation of lipid metabolites. Among the fatty acid intermediates involved in the development of insulin resistance are long-chain acylcarnitines. However, this is not widely acknowledged (Schooneman et al., 2013; McCoin et al., 2015a). Generally, the increased levels of long-chain acylcarnitines have been viewed as a marker of incomplete mitochondrial metabolism of fatty acids that activate proinflammatory pathways implicated in insulin resistance (Adams et al., 2009). However, because long-chain acylcarnitine-induced effects on insulin signaling were previously demonstrated (Aguer et al., 2015; Liepinsh et al., 2017; Blackburn et al., 2020; Vilks et al., 2021), an increased intracellular content of long-chain acylcarnitines results in feedback inhibition of insulin action (Fig. 7). Thus, insulin- and AMPK-mediated regulation of CPT1 activity has significant physiological impacts, and long-chain acylcarnitines are beginning to emerge as important metabolites involved in the regulation of energy metabolism. Long-chain acylcarnitines are also very active intermediates and effectively inhibit pyruvate and lactate oxidation in mitochondria. This compromises glucose metabolism in models of isolated rat cardiac mitochondria (Makrecka et al., 2014), cells in culture (Aguer et al., 2015), and *ex vivo* isolated rat hearts (Makrecka et al., 2014). It has been hypothesized that in the fasted state, long-chain acylcarnitines inhibit glucose uptake and metabolism to reduce the risk of hypoglycemia and generate

energy from existing lipid stores (Liepinsh et al., 2017). Thus, long-chain acylcarnitines are important players in metabolism with important roles in the development of insulin resistance.

In several studies, it has been confirmed that long-chain acylcarnitines are not only markers for incomplete fatty acid oxidation but are also actively involved in the regulation of carbohydrate and lipid metabolism (Makrecka et al., 2014; Aguer et al., 2015; Liepinsh et al., 2017; Blackburn et al., 2020). The acute and chronic administration of palmitoylcarnitine in vivo inhibits the activation of insulin signaling and insulin-dependent glucose uptake in murine muscles (Liepinsh et al., 2017). Increased levels of long-chain acylcarnitines in muscle-specific CPT2 KO mice ($SK^{-/-}$) were shown to significantly reduce Akt Ser473 phosphorylation in liver and adipose tissue, whereas in muscles from high-fat diet (HFD)-fed mice, a marked decrease in Akt Ser473 phosphorylation in $Sk^{-/-}$ mice compared with wild-type mice ($Sk^{+/+}$) was observed (Pereyra et al., 2020). Recently, it was discovered that long-chain acylcarnitines induce dephosphorylation of the insulin receptor through increased activity of protein tyrosine phosphatase 1B (Vilks et al., 2021). The same study reported that palmitoylcarnitine decreases Akt phosphorylation independent of the insulin receptor phosphorylation level. Thus, the mechanism behind long-chain acylcarnitine action in muscles appears to involve the activated dephosphorylation of the insulin receptor and Akt. Importantly, increased levels of insulin in vitro and in vivo can suppress the long-chain acylcarnitine effects on Akt phosphorylation (Liepinsh et al., 2017). This explains how, in the transition from a fasted to a fed state, increased levels of insulin overcome the effects of long-chain acylcarnitine and enable insulin signaling, which enhances glucose metabolism and inhibits fatty acid metabolism (Soeters et al., 2009; Consitt et al., 2016). In addition, to support the transition from fatty acid metabolism to glucose metabolism and to overcome transient insulin insensitivity in the muscles and heart, long-chain acylcarnitines appear to stimulate insulin release (Soni et al., 2014; Liepinsh et al., 2017) via suppression of Akt signaling in insulin-releasing cells (Vilks et al., 2021).

In healthy subjects, the increased concentration of insulin effectively inhibits long-chain acylcarnitine production via the increased tissue content of malonyl-CoA (Koves et al., 2008; Ussher et al., 2009). If insulin fails to inhibit long-chain acylcarnitine production in the fed state, it results in disturbances in glucose uptake and oxidation. In the early stage of insulin resistance, elevated levels of insulin can compensate for insulin resistance and thereby overcome the long-chain acylcarnitine-induced effects. In the later stages of insulin resistance, the inability of insulin to inhibit long-chain acylcarnitine production is accompanied by

an increased concentration of long-chain acylcarnitines, which further stimulates the progression of glucose intolerance. Thus, the increased tissue content of long-chain acylcarnitines accelerates the progression of insulin resistance.

6. Acylcarnitine Effects on Inflammation. Inflammation is one of the key pathologies for many diseases and disorders, including insulin resistance, cardiomyopathy, organ rejection, and central nervous system (CNS)-related disorders. It has been previously demonstrated that when present in sufficiently high concentrations, palmitoylcarnitine ($\geq 10\text{--}25\ \mu\text{M}$) promotes inflammation and oxidative stress in C2C12 myotubes and murine monocytes (Adams et al., 2009; Aguer et al., 2015; McCoin et al., 2015b). More recently, it was shown that the loss of CPT2 and subsequent endogenous accumulation of long-chain acylcarnitines does not affect palmitate-induced inflammation in C2C12 myotubes (Blackburn et al., 2020), suggesting that skeletal muscle cell inflammation cannot be attributed to the accumulation of long-chain acylcarnitine alone. However, the inhibition of CPT2 in vivo by aminocarnitine exacerbates inflammation in cardiac tissues in classic models of lipopolysaccharide-induced endotoxemia in mice (Makrecka-Kuka et al., 2020b). This suggests that further upregulation of inflammation in the case of endotoxemia or sepsis could be related to the accumulation of long-chain acylcarnitines.

In murine monocyte/macrophage cell lines, acylcarnitines activate proinflammatory signaling pathways in an acyl-chain length (C10–C18)-dependent and a concentration-dependent (5–25 μM) manner (Adams et al., 2009; Rutkowsky et al., 2014). In addition, it has been suggested that the long-chain acylcarnitine-induced proinflammatory response is mediated not through the Toll-like receptor but downstream of the myeloid differentiation factor 88 (MyD88) component (Rutkowsky et al., 2014). In FAOD patients with increased levels of long-chain acylcarnitines several changes in inflammatory proteins were observed. These included modestly increased plasma concentrations of IFN- γ and IL-8 and a decreased concentration of IL-10, an inflammation-dampening cytokine (McCoin et al., 2019). These findings suggest that long-chain acylcarnitines could take part in the activation of inflammatory signaling. It has also been shown that an excess of long-chain acylcarnitines, in combination with insufficient β -oxidation, promotes Th17 inflammation in patients with type 2 diabetes (Nicholas et al., 2019). Overall, these data suggest that the accumulation of long-chain acylcarnitines induces inflammation, thus potentiating the progression of diseases such as diabetes. Likewise, a drug-induced reduction in acylcarnitine availability has been shown to decrease the accumulation of macrophages and monocytes in atherosclerotic lesions. This also decreases the level of circulating inflammatory

cytokines in an experimental model of atherosclerosis (Vilskersts et al., 2015). Moreover, enforced expression of CPT1A and increased fatty acid oxidation in murine macrophage cell lines have been shown to result in attenuated proinflammatory processes (Malandrino et al., 2015). This is likely related to the reduced accumulation of acylcarnitines in cells. Taken together, these findings suggest that the enzymes and proteins involved in long-chain acylcarnitine transport and production could serve as potential drug targets to attenuate inflammatory processes in chronic disorders.

Taking into account the growing significance of immunometabolism, it is intriguing to consider the role of acylcarnitines in the immune cell response. It should be noted that to date, studies on immune cells have mainly been focused on the investigation of fatty acid oxidation per se but not on the possible role of fatty acid metabolites, such as acylcarnitines, in immune cell functioning. Historically, it has been suggested that fatty acid oxidation is necessary for macrophage anti-inflammatory (M2) phenotype regulation (Vats et al., 2006). Follow up studies in primary rodent cells and human T cells and cultured human cells using etomoxir, an irreversible CPT1A inhibitor, demonstrated interesting off-target effects (Divakaruni et al., 2018; Raud et al., 2018) and brought into question whether fatty acid oxidation is essential for human macrophage M2 polarization (Namgaladze and Brune, 2014). Moreover, later studies have shown that CPT2 deletion in bone marrow-derived macrophages derived from mice does not affect polarization toward an M2 (anti-inflammatory) phenotype (Nomura et al., 2016). Overall, the current thinking in the immunometabolism field suggests that the anti-inflammatory macrophage response is more robustly supported by mitochondrial OXPHOS than by fatty acid oxidation. Interestingly, none of the above-mentioned studies measured acylcarnitine profiles. High concentrations of etomoxir are known to induce the accumulation of long-chain acylcarnitines in the rat myocardium (Lopaschuk et al., 1988), which could further inhibit mitochondrial OXPHOS (Liepinsh et al., 2016). Thus, it could be hypothesized that etomoxir-induced mitochondrial dysfunction in macrophages could be secondary to the accumulation of long-chain acylcarnitines and that the accumulation of fatty acid metabolites could attenuate macrophage polarization to the M2 phenotype. However, this idea needs to be tested.

Interestingly, higher concentrations of circulating long- and medium-chain acylcarnitines have been found in sepsis nonsurvivors (Langley et al., 2013; Puskarich et al., 2018). This suggests the possible role of acylcarnitines in immune cell proinflammatory activation. However, data on the roles of fatty acid oxidation and long-chain acylcarnitines in the

proinflammatory response are lacking. Given that the accumulation of long-chain acylcarnitines inhibits pyruvate metabolism and phosphorylation of Akt in rodent mitochondria and murine myoblasts (Makrecka et al., 2014; Liepinsh et al., 2017), it might be suggested that the availability of acylcarnitines could determine the energy metabolism pattern in immune cells and thus direct immune cell activation toward a proinflammatory phenotype.

7. Possible Effects of Acylcarnitines in Neurodegenerative and Neuropsychiatric Disorders. Fatty acid oxidation is not the primary energy production pathway in the brain (Schonfeld and Reiser, 2013). However, the role of fatty acid oxidation and acylcarnitines, especially long- and medium-chain acylcarnitines, in the progression of CNS-related disorders is increasingly being studied. A growing number of studies have observed unique acylcarnitine signatures in patients with neurodegenerative and neuropsychiatric disorders. In clinical studies, higher levels of circulating long- and medium-chain acylcarnitines have been found in patients with Alzheimer's disease (van der Velpen et al., 2019). Moreover, higher levels of long-chain acylcarnitines are associated with disease progression (Chatterjee et al., 2021) and with cognitive impairment (Toledo et al., 2017). However, in larger cohorts, it has been shown that the higher serum levels of medium- and long-chain acylcarnitines actually predicted a lower risk of Alzheimer's disease incidence (Huo et al., 2020). Furthermore, clinical trials of patients with Parkinson's disease have consistently shown that circulating levels of long-chain acylcarnitines are decreased (Saiki et al., 2017; Chang et al., 2018; Molsberry et al., 2020). In both schizophrenia and psychosis patients, the levels of C3-carnitine and palmitoylcarnitine in the circulation were decreased (Kriisa et al., 2017; Cao et al., 2019). The levels of individual long-chain acylcarnitines in those patients do not follow the same pattern. Thus, for patients with schizophrenia, the levels of the majority of long- and medium-chain acylcarnitines are decreased (Cao et al., 2019), whereas for patients with psychosis, an increase in long-chain acylcarnitines was found (Kriisa et al., 2017). Overall, the metabolomic analysis of acylcarnitines in patients with CNS-related disorders has consistently identified alterations in circulating acylcarnitines. However, it is not clear whether acylcarnitine levels in the circulation could correspond to acylcarnitine levels in brain tissues or if an altered acylcarnitine profile in the plasma indicates possible crosstalk in neurodegenerative and neuropsychiatric disorders.

Interestingly, although fatty acid oxidation is not the main energy source for neuronal tissues, key enzymes involved in acylcarnitine synthesis, specifically CPT1, ACC, and MCD, are highly expressed in the

hypothalamus (Sorensen et al., 2002; Lopez et al., 2006; Santos et al., 2013; Jernberg et al., 2017). This result suggests a possible involvement of acylcarnitine availability in the hypothalamic regulation of energy homeostasis. Previous studies have shown that the inhibition or genetic ablation of the acylcarnitine synthesizing enzyme CPT1 induces a reduction in food intake (Obici et al., 2003; Wolfgang et al., 2006; 2008). This finding implies that acylcarnitines could be involved in the regulation of nutrient sensing. Overall, these data suggest that acylcarnitine availability or content in the brain could alter energy metabolism in peripheral tissues (e.g., muscle and liver) by regulating hypothalamic nutrient sensing. Thus, it is more likely that changes in the circulating acylcarnitine profile are not directly driven by changes in the acylcarnitine profile in neuronal tissues; rather, these changes represent energy metabolism alterations in peripheral tissues.

In brain tissues, the acylcarnitine synthesis and turnover rate is extremely low compared with other tissues (Schonfeld and Reiser, 2013). Thus, disturbances in acylcarnitine metabolism might induce changes in the neuronal acylcarnitine content/profile and subsequent alterations in signaling pathways only over the long term. In general, the pathogenesis of many CNS-related disorders involves mitochondrial dysfunction and inflammation (Lucas et al., 2006; Golpich et al., 2017; Skaper et al., 2018). It has been shown that the accumulation of long-chain acylcarnitines in mitochondria induces disturbances in OXPHOS, stimulates ROS production in the heart (Tominaga et al., 2008; Liepinsh et al., 2016), and potentially promotes inflammation (Rutkowski et al., 2014; Makrecka-Kuka et al., 2020b). Similarly, in the brain, the long-term accumulation of long-chain acylcarnitines could promote or enhance mitochondrial dysfunction along with inflammation-related disturbances.

V. Drugs, Supplements, and Clinical Trials

A. The Effects of Supplementation with Acetylcarnitine and Propionylcarnitine

A number of recent patient studies have presented interesting and compelling relationships between acetylcarnitine deficiency and several mental illnesses, including depression, schizophrenia, attention deficit hyperactivity disorder, and autism spectrum disorder (Van Oudheusden and Scholte, 2002; Frye et al., 2013; Nasca et al., 2018; Cao et al., 2019). Most of these articles argue for the possibility of using acylcarnitine measurements for diagnosing and acylcarnitine supplements for treating mental disorders. Short-chain acylcarnitines (i.e., acetylcarnitine and propionylcarnitine) are the most abundant group of acylcarnitines in the body and the most commonly used supplements (Tables 9 and 10). Altered levels of different short-chain

acylcarnitines have been demonstrated in a number of inherited diseases and in many different mental illnesses (Nasca et al., 2018; Table 1). Beyond its important role in general metabolism, acetylcarnitine provides acetyl groups for the synthesis of acetylcholine (Onofrij et al., 2013). Acetylcarnitine supplementation has been suggested to enhance cholinergic neurotransmission (Nalecz et al., 2004; Jones et al., 2010) and has been shown to increase the norepinephrine and serotonin contents in murine brains (Smeland et al., 2012). These results suggest that acetylcarnitine supplements could affect a number of different types of mental illness both directly, by compensating for carnitine deficiency, and indirectly, by enhancing cholinergic neurotransmission. A list of clinical studies reported a positive effect of acetylcarnitine on the outcome of neuropsychiatric conditions and metabolic diseases, as shown in Table 9. Such nutritional supplementation is considered a treatment option for several conditions, including schizophrenia (Bruno et al., 2016), autism spectrum disorder (Ziats et al., 2015), attention deficit hyperactivity disorder (Van Oudheusden and Scholte, 2002; Abbasi et al., 2011), and alcohol use disorder (Martinotti et al., 2011) (see the more comprehensive list in Fig. 8). However, the most studied condition associated with acetylcarnitine supplementation is major depressive disorder (MDD), which has been assessed in multiple clinical trials (see Section V).

It is well established that many current antidepressant treatment strategies do not provide an adequate treatment response in a substantial number of patients (Trivedi et al., 2006; Bauer et al., 2013). This is manifested by a treatment response that is only achieved after many weeks and by side effects of the medications that can cause low compliance, prompting alternative treatments for MDD. A recent meta-analysis investigated the effect of acetylcarnitine on depressive symptoms across 12 randomized controlled trials (Veronese et al., 2018). This report shows a significant decrease in depressive symptoms in the acetylcarnitine supplementation as a monotherapy intervention compared with placebo or with no intervention. Moreover, the incidence of adverse effects under acetylcarnitine treatment was found to be similar to placebo and much lower (79%) than under standard antidepressants, whereas the effectiveness of acetylcarnitine monotherapy was found to be comparable to standard antidepressants (Veronese et al., 2018). In contrast, a randomized controlled trial by Brennan and colleagues (2013) studying a combination of acetylcarnitine and alpha-lipoic acid in 40 depressed patients with bipolar affective disorder did not show a significant antidepressant effect. Accordingly, the Canadian Network for Mood and Anxiety Treatments, which has produced clinical guidelines for the management of adults with MDD (2016),

recommends acetylcarnitine monotherapy as third-line therapy for mild to moderate MDD (Ravindran et al., 2016) but not in the depression phase of bipolar affective disorders (Yatham et al., 2018). In Brennan's study, brain levels of high-energy phosphate were evaluated phosphorus-31 magnetic resonance spectroscopy (^{31}P -MRS) in a subgroup of participants. Corresponding to the negative finding in terms of clinical effects, ^{31}P -MRS failed to detect a significant change from baseline at weeks 1 and 12 of acetylcarnitine and alpha-lipoic acid treatment (Brennan et al., 2013). In contrast, a preliminary study reported that the antidepressant effect of acetylcarnitine in two geriatric patients with MDD was associated with the normalization of high-energy phosphate levels in prefrontal regions (Petegrew et al., 2002). Acetylcarnitine was also found to be effective in dysthymia both in the general adult population and in elderly patients (Bella et al., 1990; Zanardi and Smeraldi, 2006; Bersani et al., 2013).

Acetylcarnitine was shown to be effective not only in treating MDD but also in reducing the severity of depressive symptoms accompanying other diseases (Table 9). A randomized controlled trial comparing the antidepressant agent duloxetine to acetylcarnitine in patients with fibromyalgia reported that acetylcarnitine improved depressive symptoms and pain (Leombruni et al., 2015). A meta-analysis investigated the effectiveness of acetylcarnitine treatment in reducing depressive symptoms in Alzheimer's disease when used as an adjunct to Alzheimer's disease medication (Meister et al., 2016). By analyzing 34 studies and 4769 patients with persistent depressive symptoms, lower rates of adverse events and increased adherence to drug therapy in the group that received adjunct acetylcarnitine were reported (Meister et al., 2016).

In summary, acetylcarnitine supplementation seems to decrease depressive symptoms compared with placebo or no intervention in patients with MDD. Moreover, acetylcarnitine shows a better tolerance rate and seems to be a better candidate as a rapid-acting antidepressant. However, findings on the effectiveness of acetylcarnitine supplementation in other psychiatric disorders are not consistent across studies.

Long-term supplementation with carnitine has been suggested to positively affect physical performance (Karllic and Lohninger, 2004). Theoretically, supplementation should increase the muscle carnitine content and subsequently improve fatty acid oxidation and exercise function in humans (Gnoni et al., 2020). As might be expected, carnitine supplementation also induces certain effects on the concentrations of serum acylcarnitines. Metabolomic studies have shown that carnitine supplementation increased a broad range of acylcarnitine concentrations in patients with septic shock (Puskarich et al., 2018). Carnitine supplementation has also increased postexercise acetylcarnitine concentrations and

reduced long-chain acylcarnitine species in patients with impaired glucose tolerance (Bruls et al., 2019). It has been reported that decreased long-chain acylcarnitine levels have been found after carnitine supplementation (Böhles et al., 1987). However, the role of carnitine in the generation of the proatherogenic metabolite trimethylamine N-oxide (TMAO) and the associated longitudinal effects on the cardiovascular system still need to be critically assessed (Sawicka et al., 2020). Overall, considering that the global market of carnitine supplements is very large, estimated to be nearly 170 million USD in 2018 with a yearly growth of 5% (<https://www.grandviewresearch.com/industry-analysis/l-carnitine-market>), the effect of carnitine supplementation on acylcarnitine metabolism warrants more consideration.

In addition to the positive effects of carnitine and acetylcarnitine, a number of studies also report positive outcomes of propionylcarnitine supplementation (Table 10). For example, propionylcarnitine has been used, together with acetylcarnitine, as a supplement for the treatment of sexual dysfunction and depressed moods in older males (Cavallini et al., 2004). Other studies have reported positive effects in treating several different vascular diseases, intermittent claudication, colitis, and ischemia (Table 10). Propionylcarnitine, a carnitine donor, is believed to interact with CACT and to increase fatty acid transport across the mitochondrial membrane (Heggermont et al., 2016). It also stimulates energy production in ischemic muscles by increasing Krebs cycle flux (Wiseman and Brogden, 1998).

B. Carnitine Deficiency and Related Disorders

L-carnitine (levocarnitine) supplementation has long been used to treat carnitine deficiencies arising from inborn errors associated with its uptake and transport. Carnitine has also been used to reduce body weight and prevent the development of certain cardiometabolic diseases, especially cardiomyopathy and diabetes (Fig. 8). Long-term supplementation with carnitine has been shown to positively affect physical performance, but its role in the generation of proatherogenic metabolite TMAO and associated longitudinal effects on the cardiovascular system still need to be critically assessed (Sawicka et al., 2020). As expected, carnitine supplementation induces certain effects on serum acylcarnitines. Metabolomic studies have shown that carnitine supplementation increased a broad range of acylcarnitine concentrations in patients with septic shock (Puskarich et al., 2018). Carnitine supplementation has also increased postexercise acetylcarnitine concentrations and reduced long-chain acylcarnitine species in patients with impaired glucose tolerance (Bruls et al., 2019). Decreased long-chain acylcarnitine levels have even been found after carnitine supplementation (Böhles et al., 1987). Overall, given the amount of money spent on carnitine supplements, the effect of carnitine

TABLE 9
Effects of acetylcarnitine supplementation

Disease/Condition	Positive Outcome of Supplementation	Negative/Neutral Effect
Peripheral nervous system diseases	De Grandis et al., 1995; Onofrj et al., 1995; Scarpini et al., 1997; Grandis, 1998; Hart et al., 2004; Bianchi et al., 2005; Ghirardi et al., 2005a,b; Herzmann et al., 2005; Maestri et al., 2005; Flatters et al., 2006; Osio et al., 2006; Youle and Osio, 2007; Memeo and Loiero, 2008; Xiao and Bennett, 2008; Traina et al., 2009; Valcour et al., 2009; Campone et al., 2013; Li et al., 2016; Sun et al., 2016a; Cruccu et al., 2017	Hershman et al., 2013; 2018; Callander et al., 2014; Curran et al., 2019
Alzheimer's disease	Bonavita, 1986; Battistin et al., 1989; Bella et al., 1990; Passeri et al., 1990; Rai et al., 1990; Spagnoli et al., 1991; Parnetti et al., 1993; Pettegrew et al., 1995; Thal et al., 1996; Brooks et al., 1998; Bianchetti et al., 2003; Chan et al., 2008; 2010; Remington et al., 2009; 2015a,b; 2016; Gavrilova et al., 2011; Bersani et al., 2013; Jeong et al., 2017	Campi et al., 1990; Thal et al., 2000
Cognitive dysfunction	Herrmann et al., 1990; Lino et al., 1992; Chan et al., 2010; Amen et al., 2011; Remington et al., 2015a,b	
Dementia	Passeri et al., 1988; Battistin et al., 1989; Gambi et al., 1989; Goety et al., 1990; Sinforiani et al., 1990; Salvioli and Neri, 1994; Remington et al., 2016; Yang et al., 2018	Pueschel, 2006
Multiple sclerosis	Famularo et al., 1999; Tomassini et al., 2004; Maestri et al., 2005	
Neurodegenerative diseases	Calabrese et al., 2003	
Pain	Onofrj et al., 1995; Scarpini et al., 1997; Biagiotti and Cavallini, 2001; De Grandis and Minardi, 2002; Herzmann et al., 2005; Sima et al., 2005; Osio et al., 2006; Rossini et al., 2007; Youle and Osio, 2007; Memeo and Loiero, 2008; Xiao and Bennett, 2008; Janiri et al., 2009; Valcour et al., 2009;	
Depressive disorder	Malaguarnera et al., 2011b; Leombruni et al., 2015; Park et al., 2016; Cruccu et al., 2017	Tomassini et al., 2004; Brennan et al., 2013
Fatigue, dystrophy	Tempesta et al., 1987; Guarnaschelli et al., 1988; Bella et al., 1990; Cipolli and Chiari, 1990; Garzya et al., 1990; Salvioli and Neri, 1994; Pettegrew et al., 2002; Cavallini et al., 2004; Zanardi and Smeraldi, 2006; Rossini et al., 2007; Malaguarnera et al., 2011a; Bersani et al., 2013; Leombruni et al., 2015; Suzuki et al., 2019	Ledinek et al., 2013; Marti-Carvajal et al., 2019
Ischemia	Vermeulen and Scholte, 2004; Rossini et al., 2007; Malaguarnera et al., 2008; 2011b,c; 2014; Benedini et al., 2009; Hoffman et al., 2010; Sun et al., 2016a; Pereira et al., 2018	
Nerve degeneration	Postiglione et al., 1990; Gasparetto et al., 1991; Postiglione et al., 1991; Corbucci et al., 1992; Adembri et al., 1994	
Diabetic neuropathies	Hart et al., 2002	
Neuralgia	De Grandis and Minardi, 2002; Sima et al., 2005	
Hyperammonemia	Memeo and Loiero, 2008; Valcour et al., 2009; Xiao et al., 2012; Callander et al., 2014; Curran et al., 2016; Cruccu et al., 2017	Hershman et al., 2013; 2018
Type 2 diabetes	Siciliano et al., 2006; Malaguarnera et al., 2011c; Suzuki et al., 2017	
	Giancaterini et al., 2000; Turpeinen et al., 2000; Ruggenenti et al., 2009; Fernandez et al., 2013; Li et al., 2016	Parvanova et al., 2018; Condorelli et al., 2019; Rolim et al., 2019

supplementation on acylcarnitine metabolism warrants more consideration.

C. Clinical Trials

To assess the state of acylcarnitines currently registered in clinical studies, ClinicalTrials.gov was searched

using the keywords 'acylcarnitine' and 'levocarnitine' without any date constraints. ClinicalTrials.gov is the official US database of privately and publicly funded clinical studies and holds information on nearly 370,000 trials (<https://clinicaltrials.gov>). Additionally, the scientific literature published in PubMed (<https://pubmed.ncbi.nlm>

.nih.gov) was searched using the keyword ‘acylcarnitine’ with the clinical trials filter. The results from these methods were manually curated and classified.

In total, 190 clinical studies were identified. These included 126 interventional studies that used levocarnitine as a primary pharmacological intervention and 72 other clinical trials that used acylcarnitine levels as biomarkers or outcome measurements (previously discussed). The 64 trials using acylcarnitine biomarkers can be divided into six different types of studies: pharmacological interventions (58%), nutritional diet interventions (20%), behavioral interventions (12%), nutritional supplementation studies (6%), observational studies (2%), and procedural studies (2%) (Fig. 8A). These studies investigated acylcarnitine levels as biomarkers for different conditions (20 studies) and as study outcome measurements (40 studies). Although the use of acylcarnitines as biomarkers or outcome measures in drug and nutritional diet studies has been discussed previously, it is interesting to note that ~5% of the clinical trials investigated acylcarnitines in behavioral interventions for these purposes. The eight behavioral studies evaluated acylcarnitine levels in exercise, lifestyle, and weight loss interventions as biomarkers for fatty acid oxidation or future markers for weight loss or to assess acylcarnitine levels as outcome measures.

The use of direct carnitine supplementation with the US Food and Drug Administration (FDA)-approved levocarnitine is being investigated in 126 interventional studies. Levocarnitine was first approved in 1985 and is indicated for persons with certain types of carnitine-related metabolic disorders. It is the only treatment with a direct connection to carnitine-acylcarnitine homeostasis. These interventional studies assessed the use of carnitine for treating conditions such as carnitine deficiencies in patients undergoing hemodialysis, peripheral vascular diseases, complications from prematurity, glucose intolerance, hepatic disease, and a number of different neurologic disorders, including neuromuscular, neuropsychiatric, and neuropathic (Fig. 8D). The dominant categories of conditions treated with carnitine were cardiovascular disease (11 studies), infections including viral infections and sepsis (14 studies), neuromuscular disorders (11 studies), and renal disease (14 studies) (Fig. 8D). Furthermore, as discussed in Section IV, lower levels of acetylcarnitine, which is a metabolite of carnitine, are linked with depression disorders (Nasca et al., 2018), and acetylcarnitine has been recommended as an interventional treatment (Table 9). Although we did not identify any current clinical studies registered in ClinicalTrials.gov that investigate acetylcarnitine as an interventional therapy, two studies were identified that are assessing acetylcarnitine levels as a biomarker in mood disorders—one is investigating the mechanism of action of ketamine (NCT00088699) and another is predicting

depression recovery after antidepressant use (NCT00590863).

Two clinical trials are using levocarnitine to develop a standard of care in cases of phosphide poisoning (NCT03953248 and NCT04509258). This specific use of the drug is unique in comparison with other trials focusing on specific diseases or conditions. The two phosphide poisoning trials are in phase I and phase IV, respectively, but neither of the two trials have yet published any results. The impetus for the use of levocarnitine for treating phosphide toxicity comes from a rat study that was published in 2015 that demonstrated how phosphide toxicity triggers oxidative stress and further mitochondrial dysfunction. This toxicity could potentially be limited by the use of levocarnitine (Baghaei et al., 2016). Another distinctive condition being studied in clinical trials is polycystic ovary syndrome (PCOS). A 2015 study evaluated PCOS and found that it is associated with modified mitochondrial OXPHOS and often insulin resistance, which affect acylcarnitine metabolism (Cree-Green et al., 2019). Therefore, treatment with levocarnitine supplementation may attenuate symptoms of this disease. Six clinical trials have begun since 2016, representing 15% of all levocarnitine trials in this period.

In addition to the FDA-approved L-carnitine formulation levocarnitine and acetylcarnitine, 22 FDA-approved drugs and one investigational drug are in trials where acylcarnitines are being assessed as biomarkers for different conditions (12 studies) or as primary or secondary study outcome measures (19 studies; two studies are not specified, and one study uses acylcarnitine levels for inclusion/exclusion criteria). Acylcarnitines are already in use as biomarkers for insulin resistance and cardiovascular events (Davies et al., 2014; Albert and Tang, 2018). Furthermore, they are being investigated as potential diagnostic markers for the progression of depression, liver disease, propionic and methylmalonic acidemias, diabetes, and energy storage diseases. In addition, studies with acylcarnitines as outcome measures are also being explored for patients with myopathies, inborn errors of metabolism, cardiovascular disease, heart failure and heart defects, sepsis, and Klinefelter syndrome. Interestingly, a new study has been initiated that involves assessing the change in C14:1 long-chain acylcarnitines as a primary outcome measure after testosterone cypionate treatment in male infants born with the most common chromosomal abnormality, XXY, also known as Klinefelter syndrome.

Diabetes, insulin resistance, and obesity are the most common conditions in studies where acylcarnitines are being used as biomarkers for outcome measures. In particular, they are being assessed in studies with antihyperglycemic drugs as well as nutritional diet and behavioral




Fig. 8. Clinical trials involving acylcarnitines and L-carnitine. We identified 64 trials using keyword searches with the term *acylcarnitine* in ClinicalTrials.gov and PubMed with the clinical trials filter. In addition, eight studies assessing L-carnitine (levocarnitine) were identified, but these studies are investigated separately in (D). The data were subsequently manually curated and classified into different categories, such as the type of clinical study, condition/diagnosis and drug classes. (A) Type of clinical study as defined in ClinicalTrials.gov with the number of clinical trials identified in each category. Study types included observational, procedural, nutritional supplementation (nutritional suppl.), behavioral interventions, nutritional diet interventions, and drug studies. Percent and number of clinical trials in parentheses. (B) Condition/diagnosis of the participants. The data show several deficiencies (grouped as Deficiency), such as carnitine deficiency, vitamin B6 deficiency, malnutrition, and infant nutrition disorders. Energy storage diseases include glucose transporter type 1 deficiency syndrome, glucose intolerance, and glycogen storage disease type V. Fatty acid oxidation disorders (FAODs) include long-chain fatty acid transport deficiency, carnitine palmitoyl transferase type 1A (CPT1A) deficiency, and trifunctional protein deficiency. The category “Other” represents polycystic ovary syndrome (PCOS), inborn errors of metabolism, sepsis, complications from premature birth, and Klinefelter syndrome. Type 2 diabetes (T2DM), insulin resistance (IR), and obesity are an often-combined study group in clinical trials and are thereby counted together as one category. Acidemias represent both propionic acidemia and methylmalonic acidemia. (C) Drug classes. The “Other” group includes drugs that act as analgesics, growth hormone receptor antagonists, hepatoprotectants, amino acid analogs, and antihypertensives. (D) Additionally, we identified 126 trials using keyword searches with the term *levocarnitine* in ClinicalTrials.gov. Conditions treated with levocarnitine with the number of studies in each category. Fertility-related disorders include polycystic ovary syndrome (PCOS) and male infertility. Type 2 diabetes (T2DM), glucose intolerance (GI), insulin resistance (IR), and obesity are an often-combined study group in clinical trials and are thereby counted together as one category. Cardiovascular disease (CVD) includes heart failure, vascular disease, atherosclerosis, heart septal defects, arterial disease, and coronary artery disease. Neuromuscular disorders include spinal muscular atrophy, sarcopenia, postpoliomyelitis syndrome, and muscle soreness. Infections are represented by sepsis and viral infections. In addition to these dominant conditions in the figure, there are three studies in the areas of neurodegenerative disorders, including progressive supranuclear palsy, Alzheimer’s disease, and multiple sclerosis. Neuropsychiatric disorders (three studies) include attention deficit hyperactivity disorder, bipolar disorder, and autism. Other studies were related to prematurity, thyroid-related disease, fatigue, ulcerative colitis, and toxicity (three studies each) and central nerve injury, carnitine-related deficiency, Sjogren’s syndrome, sleep apnea, thalassemia, chronic pancreatitis, migraine, and dyslipidemia (one study each).

interventional trials (NCT00047437 and NCT01373814). Some of the most common classes of pharmacological therapies, including carnitine supplements and medium-chain fatty acid triglycerides [for example, triheptanoin, a triglyceride used to treat long-chain FAODs (Shirley, 2020)], coincide with several of the most prevalent disorders, including deficiency disorders and energy storage diseases (Fig. 8C).

The use of acylcarnitines as interventional treatments and as both diagnostic biomarkers and primary and secondary outcome measurements is clearly expanding. Indeed, acylcarnitines are being assessed in a variety of study types and conditions—beyond simple carnitine deficiency and metabolic disorders—to help

diagnose different stages of disease (NCT02426775, NCT02856555, and NCT00088699). This robust utilization of acylcarnitines signifies an increasing understanding of their beneficial uses and a growing interest in them for drug discovery.

VI. Future Perspectives

This review provides a comprehensive overview of the identity, nomenclature, classification, biochemistry, pathophysiology, supplementary use, pharmacological use, potential pharmaceutical agents, and clinical trials for acylcarnitines. Our substantial update of the HMDB with regard to detailed data on

TABLE 10
Effects of propionylcarnitine supplementation

Disease/Condition	Positive Outcome of Supplementation	Negative/Neutral Effect
Depressive disorder Erectile dysfunction	Cavallini et al., 2004 Gentile et al., 2004; 2009; Cavallini et al., 2005; Morano et al., 2007; Gianfrilli et al., 2012	
Penile induration Ulcerative colitis	Cavallini et al., 2002 Gasbarrini et al., 2003; Mikhailova et al., 2011; Scioli et al., 2014	Safarinejad et al., 2007
Peripheral arterial disease	Scanlon, 1985; Bolognesi et al., 1995; Taylor et al., 1996; Capecchi et al., 1997; Cittanti et al., 1997; Di Marzo et al., 1999; Loffredo et al., 2006; 2013; Santo et al., 2006; Signorelli et al., 2006a,b; De Marchi et al., 2012	
Intermittent claudication	Brevetti et al., 1995; 1997; Taylor et al., 1996; Dal Lago et al., 1999; Di Marzo et al., 1999; De Barker et al., 2001; Hiatt et al., 2001; Strano, 2002; Marchi et al., 2012; Luo et al., 2013	Hiatt et al., 2011
Ischemia	Chiddo et al., 1991; Greco et al., 1992; Lagioia et al., 1992	
Heart failure	Mancini et al., 1992; Anand et al., 1998	The Investigators of the Study, 1999 (no effect on exercise duration)
Diabetes mellitus Peripheral vascular diseases	Greco et al., 1992 (diabetic angiopathy) Greco et al., 1992; Pola et al., 1992; Allegra et al., 2008; Riccioni et al., 2008	
Reperfusion injury	Lango et al., 2005	

acylcarnitines provides a strong foundation for further clarification of the physiologic roles of acylcarnitines. However, it is also clear that the identity and physiologic role of many recently identified acylcarnitines are obscure and that the majority of acylcarnitines recently added to the HMDB are not linked to any specific physiologic function, illustrating the complex task ahead. This review also clarifies several issues regarding the nomenclature of acylcarnitines. For example, we formalized the definition of the acyl-chain lengths among acylcarnitines corresponding to short-chain, medium-chain, long-chain, and very long-chain acylcarnitines. The presently used classification is derived from the respective fatty acid classes (Ratnayake and Galli, 2009; Kimura et al., 2020), but its relation to acylcarnitine-specific target proteins and transporters remains obscure (Figs. 3 and 4). It is likely that further development of other classification categories will be needed as many of the long-chain and branched-chain acylcarnitines seem to be present in much higher numbers than previously anticipated (Fig. 1). We aim to do this in collaboration with the HMDB as well as other open sources that are lacking more detailed information on a variety of acylcarnitines.

As part of this review, we have also provided substantial mapping of the known biochemical pathways associated with acylcarnitines, providing a framework for basic physiologic functions (Figs. 5 and 7). The concepts illustrated in these pathways have been extended to all acylcarnitine pathways in the HMDB. However, it is clear that much more work is needed to clarify the many pathologic processes associated with

acylcarnitine deficiencies and how individual genotypic differences affect how these pathways actually work. Understanding acylcarnitine metabolic and signaling pathways provides a better rationale for selecting targets for therapeutic interventions. It is also helpful to explain how many current drugs such as metformin, various statins, liraglutide, and triheptanoin and various supplements interfere with acylcarnitine metabolism.

The importance of acylcarnitines as biomarkers is clearly growing (Wanders et al., 2020; McCann et al., 2021), and the list of different diseases linked with altered levels of different acylcarnitines (see Tables 1–7) is increasing. Significant progress in the breadth and depth of acylcarnitine measurements by metabolomic studies has illustrated how different acylcarnitines are affected in different disease states. However, more information is needed to determine what “normal” levels are (i.e., changes in acylcarnitines in the fed/fasted cycle and the impact of nutrition/diets) to better define their validity as biomarkers and ascertain possible drug targets. Nevertheless, based on the wealth of data already at hand, it is reasonable to conclude that acylcarnitines play a role in many diseases.

This observation is also supported by the many clinical trials that make use of acylcarnitines as biomarkers in both pharmacological and dietary intervention studies (see Fig. 8). Interestingly, there are a number of behavioral intervention studies that use acylcarnitines as biomarkers. The role of acylcarnitines as biomarkers for inborn errors of fatty acid oxidation is clear, but there is increasing interest in using acylcarnitines as

biomarkers for acquired metabolic and cardiovascular diseases. This is demonstrated by the fact that long-chain acylcarnitine measurements have been shown to be particularly useful for the diagnosis of insulin resistance. Likewise, the byproducts of incomplete long-chain acylcarnitine metabolism appear to offer interesting biomarkers for heart failure and represent potential predictors of major cardiovascular events (Ruiz-Canela et al., 2017; Albert and Tang, 2018).

Another important area that is emerging is the use of acylcarnitines as biomarkers for low-grade inflammation. Inflammation is increasingly considered to be an underlying cause not only of metabolic disorders, cardiovascular diseases, and many cancers but also of several CNS disorders, including depression and autism spectrum disorder (Traina, 2016; Kepka et al., 2021). The need for new biomarkers for psychiatric disorders is great, and this could be a field that will attract significant attention in the future. Overall, there is a clear need for more systematic and standardized approaches to measure and analyze acylcarnitines. This strategy will enable a more comprehensive and sophisticated analysis of acylcarnitine data. Indeed, the use of advanced analytical methods such as artificial intelligence and machine learning, with their superior pattern recognition abilities, should lead to even more robust biomarker discoveries concerning acylcarnitines.

The use of L-carnitine (levocarnitine) as both a drug and a supplement is rapidly growing. The vast dietary supplement industry associated with short-chain acylcarnitines (acetylcarnitine and propionylcarnitine) has been driven by numerous reports that acetylcarnitine deficiency might lead to different conditions, including neurologic and psychiatric diseases (Virmani and Binienda, 2004; Pennisi et al., 2020). Unfortunately, detailed biologic investigations assessing the widespread use or benefits of such supplementation are lacking. This may be because these supplements are both cheap (not patent protected) and not considered drugs. As such, they do not require complex clinical trials nor are there studies motivated by the high earning potential that often drives such trials. Nevertheless, there are many clinical trials that have been initiated with L-carnitine as a primary pharmacological agent in interventional studies. Hopefully, these trials will garner more attention, whereas the consequences related to overall acylcarnitine metabolism may need more attention.

Key proteins within the biochemical pathways associated with acylcarnitine transport, synthesis, and utilization are gaining interest as potential drug targets. Table 8 lists several of the proteins that are involved in acylcarnitine biosynthesis and transport. OCTN2, MCD, and CPT1 are now widely considered potential drug targets for cardiometabolic diseases (Fig. 5). There are, however, arguments that the development of drugs targeting acylcarnitine

transport or metabolism could lead to potential side effects because acylcarnitines play such key roles in physiologic energy metabolism pathways and reflect general mitochondrial and peroxisomal metabolism reactions. A better understanding of the transport of unmetabolized acylcarnitines into the circulation is clearly warranted as this would lead to a better understanding of their role in pathology and their potential for drug development. In general, the role of circulating acylcarnitines needs further attention at both the physiologic and molecular levels. More studies are also needed to understand the molecular mechanisms regarding acylcarnitine actions in different organ systems before we will be able to fully interpret the cascade of metabolomic studies linking acylcarnitines to specific disorders. Nevertheless, it is already clear that controlling the levels of long-chain acylcarnitines will be an important goal for the treatment of inherited diseases of fatty acid oxidation, diabetes/insulin resistance, and cardiovascular diseases (Pallares-Mendez et al., 2016; Wanders et al., 2020; McCann et al., 2021).

In summary, controlling the levels of acylcarnitines either through drugs that target their synthesis and transport or through dietary interventions and supplements (such as acetylcarnitine and propionylcarnitine) appear to have wide-ranging and significant effects on human health.

Authorship Contributions

Participated in research design: Dambrova, Makrecka-Kuka, Kuka, Vilskersts, Wishart, Liepinsh, Schiöth.

Performed data analysis: Dambrova, Makrecka-Kuka, Kuka, Vilskersts, Nordberg, Attwood, Smesny, Sen, Guo, Oler, Tian, Zheng, Liepinsh.

Wrote or contributed to the writing of the manuscript: Dambrova, Makrecka-Kuka, Kuka, Vilskersts, Attwood, Smesny, Wishart, Liepinsh, Schiöth.

References

- Abbasi SH, Heidari S, Mohammadi MR, Tabrizi M, Ghaleiha A, and Akhondzadeh S (2011) Acetyl-L-carnitine as an adjunctive therapy in the treatment of attention-deficit/hyperactivity disorder in children and adolescents: a placebo-controlled trial. *Child Psychiatry Hum Dev* **42**:367–375.
- A'Bháird NN and Ramsay RR (1992) Malonyl-CoA inhibition of peroxisomal carnitine octanoyltransferase. *Biochem J* **286**:637–640.
- Abu Bakar MH and Sarmidi MR (2017) Association of cultured myotubes and fasting plasma metabolite profiles with mitochondrial dysfunction in type 2 diabetes subjects. *Mol Biosyst* **13**:1838–1853.
- Adal E, Koyuncu G, Aydin A, Celebi A, Kavunoglu G, and Cam H (2006) Asymptomatic cardiomyopathy in children and adolescents with type 1 diabetes mellitus: association of echocardiographic indicators with duration of diabetes mellitus and metabolic parameters. *J Pediatr Endocrinol Metab* **19**:713–726.
- Adams RJ, Cohen DW, Gupte S, Johnson JD, Wallick ET, Wang T, and Schwartz A (1979) In vitro effects of palmitylcarnitine on cardiac plasma membrane Na,K-ATPase, and sarcoplasmic reticulum Ca²⁺-ATPase and Ca²⁺ transport. *J Biol Chem* **254**:12404–12410.
- Adams SH, Hoppel CL, Lok KH, Zhao L, Wong SW, Minkler PE, Hwang DH, Newman JW, and Garvey WT (2009) Plasma acylcarnitine profiles suggest incomplete long-chain fatty acid beta-oxidation and altered tricarboxylic acid cycle activity in type 2 diabetic African-American women. *J Nutr* **139**:1073–1081.
- Adembri C, Domenici LL, Formigli L, Brunelleschi S, Ferrari E, and Novelli GP (1994) Ischemia-reperfusion of human skeletal muscle during aortoliac surgery: effects of acetylcarnitine. *Histol Histopathol* **9**:683–690.
- Aguer C, McCain CS, Knotts TA, Thrush AB, Ono-Moore K, McPherson R, Dent R, Hwang DH, Adams SH, and Harper ME (2015) Acylcarnitines: potential implications for skeletal muscle insulin resistance. *FASEB J* **29**:336–345.

- Ahmad T, Kelly JP, McGarrah RW, Hellkamp AS, Fiuza M, Testani JM, Wang TS, Verma A, Samsky MD, Donahue MP, et al. (2016) Prognostic implications of long-chain acylcarnitines in heart failure and reversibility with mechanical circulatory support. *J Am Coll Cardiol* **67**:291–299.
- Aitken-Buck HM, Krause J, Zeller T, Jones PP, and Lamberts RR (2020) Long-chain acylcarnitines and cardiac excitation-contraction coupling: links to arrhythmias. *Front Physiol* **11**:577856.
- Akkaoui M, Cohen I, Ensouc C, Lenoir V, Sournac M, Girard J, and Prip-Buus C (2009) Modulation of the hepatic malonyl-CoA-carnitine palmitoyltransferase 1A partnership creates a metabolic switch allowing oxidation of de novo fatty acids. *Biochem J* **420**:429–438.
- Albert CL and Tang WHW (2018) Metabolic biomarkers in heart failure. *Heart Fail Clin* **14**:109–118.
- Allegra C, Antignani PL, Schachter I, Koverech A, Messano M, and Virmani A (2008) Propionyl-L-carnitine in Leriche-Fontaine stage II peripheral arterial obstructive disease. *Ann Vasc Surg* **22**:552–558.
- Altamimi TR, Thomas PD, Darwesh AM, Fillmore N, Mahmoud MU, Zhang L, Gupta A, Al Batran R, Seubert JM, and Lopaschuk GD (2018) Cytosolic carnitine acetyltransferase as a source of cytosolic acetyl-CoA: a possible mechanism for regulation of cardiac energy metabolism. *Biochem J* **475**:959–976.
- Amen DG, Wu JC, Taylor D, and Willeumier K (2011) Reversing brain damage in former NFL players: implications for traumatic brain injury and substance abuse rehabilitation. *J Psychoactive Drugs* **43**:1–5.
- American Diabetes Association (2017) 2. Classification and diagnosis of diabetes. *Diabetes Care* **40** (Suppl 1):S11–S24.
- An SJ, Kim SZ, Kim GH, Yoo HW, and Lim HH (2016) Compound heterozygous mutations of ACADS gene in newborn with short chain acyl-CoA dehydrogenase deficiency: case report and literature review. *Korean J Pediatr* **59** (Suppl 1): S45–S48.
- Anand I, Chandrashekhyan Y, De Giuli F, Pasini E, Mazzeletti A, Confortini R, and Ferrari R (1998) Acute and chronic effects of propionyl-L-carnitine on the hemodynamics, exercise capacity, and hormones in patients with congestive heart failure. *Cardiovasc Drugs Ther* **12**:291–299.
- Baghaei A, Solgi R, Jafari A, Abdolghaffari AH, Golaghaei A, Asghari MH, Baeri M, Ostad SN, Sharifzadeh M, and Abdollahi M (2016) Molecular and biochemical evidence on the protection of cardiomyocytes from phosphine-induced oxidative stress, mitochondrial dysfunction and apoptosis by acetyl-L-carnitine. *Environ Toxicol Pharmacol* **42**:30–37.
- Bahado-Singh RO, Ertl R, Mandal R, Bjorndahl TC, Syngelaki A, Han B, Dong E, Liu PB, Alpay-Savasan Z, Wishart DS and Nicolaidis KH (2014) Metabolomic prediction of fetal congenital heart defect in the first trimester. *Am J Obstet Gynecol* **211**:240.e1–240.e14.
- Balasubramaniam S, Lewis B, Mock DM, Said HM, Tarailo-Graovac M, Mattman A, van Karnebeek CD, Thorburn DR, Rodenburg RJ, and Christodoulou J (2017) Leigh-like syndrome due to homoplasmic m.8993T>G Variant with hypocitrullinemia and unusual biochemical features suggestive of multiple carboxylase deficiency (MCD). *JIMD Rep* **33**:99–107.
- Barker GA, Green S, Askew CD, Green AA, and Walker PJ (2001) Effect of propionyl-L-carnitine on exercise performance in peripheral arterial disease. *Med Sci Sports Exerc* **33**:1415–1422.
- Baruteau J, Sachs P, Broué P, Brivet M, Abdoul H, Vianey-Saban C, and Ogier de Baulny H (2013) Clinical and biological features at diagnosis in mitochondrial fatty acid beta-oxidation defects: a French pediatric study of 187 patients. *J Inheret Metab Dis* **36**:795–803.
- Batchuluun B, Al Rijjal D, Prentice KJ, Eversley JA, Burdett E, Mohan H, Bhattacharjee A, Gunderson EP, Liu Y, and Wheeler MB (2018) Elevated medium-chain acylcarnitines are associated with gestational diabetes mellitus and early progression to type 2 diabetes and induce pancreatic β -cell dysfunction. *Diabetes* **67**:885–897.
- Battisti C, Forte F, Molinelli M, Funghini S, Pasquini E, Tassinari M, Dotti MT, and Federico A (2007) A new case of short-chain acyl-CoA dehydrogenase deficiency: clinical, biochemical, genetic and (1)H-NMR spectroscopic studies. *Neurol Sci* **28**:328–330.
- Battistini L, Pizzolato G, Dam M, Da Col C, Perlotto N, Saitta B, Borsato N, Calvani M, and Ferlin G (1989) Single-photon emission computed tomography studies with ^{99m}Tc-hexamethylpropyleneamine oxime in dementia: effects of acute administration of L-acetylcarnitine. *Eur Neurol* **29**:261–265.
- Bauer M, Pfennig A, Severus E, Whybrow PC, Angst J, and Möller HJ; World Federation of Societies of Biological Psychiatry. Task Force on Unipolar Depressive Disorders (2013) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. *World J Biol Psychiatry* **14**:334–385.
- Bayci AWL, Baker DA, Somerset AE, Turkoglu O, Hothem Z, Callahan RE, Mandal R, Han B, Bjorndahl T, Wishart D, et al. (2018) Metabolomic identification of diagnostic serum-based biomarkers for advanced stage melanoma. *Metabolomics* **14**:105.
- Bella R, Biondi R, Raffaele R, and Pennisi G (1990) Effect of acetyl-L-carnitine on geriatric patients suffering from dysthymic disorders. *Int J Clin Pharmacol Res* **10**:355–360.
- Bene J, Komlósi K, Gasztonyi B, Juhász M, Tulassay Z, and Melegh B (2005) Plasma carnitine ester profile in adult celiac disease patients maintained on long-term gluten free diet. *World J Gastroenterol* **11**:6671–6675.
- Bene J, Komlósi K, Havasi V, Talián G, Gasztonyi B, Horváth K, Mózsik G, Hunyady B, Melegh B, and Figler M (2006) Changes of plasma fasting carnitine ester profile in patients with ulcerative colitis. *World J Gastroenterol* **12**:110–113.
- Benedini S, Perseghin G, Terruzzi I, Scifo P, Invernizzi PL, Del Maschio A, Lazzarin A and Luzi L (2009) Effect of L-acetylcarnitine on body composition in HIV-related lipodystrophy. *Horm Metab Res* **41**:840–845.
- Bennett MJ, Boriack RL, Narayan S, Rutledge SL, and Raff ML (2004) Novel mutations in CPT 1A define molecular heterogeneity of hepatic carnitine palmitoyltransferase I deficiency. *Mol Genet Metab* **82**:59–63.
- Bennett MJ, Coates PM, Hale DE, Millington DS, Pollitt RJ, Rinaldo P, Roe CR, and Tanaka K (1990) Analysis of abnormal urinary metabolites in the newborn period in medium-chain acyl-CoA dehydrogenase deficiency. *J Inheret Metab Dis* **13**:707–715.
- Berdous D, Berney X, Sanchez-Archidona AR, Jan M, Roujeau C, Lopez-Mejia IC, Mynatt R, and Thorens B (2020) A genetic screen identifies Crat as a regulator of pancreatic beta-cell insulin secretion. *Mol Metab* **37**:100993.
- Bersani G, Mecco G, Denaro A, Liberati D, Colletti C, Nicolai R, Bersani FS and Koverech A (2013) L-acetylcarnitine in dysthymic disorder in elderly patients: a double-blind, multicenter, controlled randomized study vs. fluoxetine. *Eur Neuropsychopharmacol* **23**:1219–1225.
- Bhala A, Willi SM, Rinaldo P, Bennett MJ, Schmidt-Sommerfeld E, and Hale DE (1995) Clinical and biochemical characterization of short-chain acyl-coenzyme A dehydrogenase deficiency. *J Pediatr* **126**:910–915.
- Bharathi SS, Zhang Y, Gong Z, Muzumdar R, and Goetzman ES (2020) Role of mitochondrial acyl-CoA dehydrogenases in the metabolism of dicarboxylic fatty acids. *Biochem Biophys Res Commun* **527**:162–166.
- Biagiotti G and Cavallini G (2001) Acetyl-L-carnitine vs tamoxifen in the oral therapy of Peyronie's disease: a preliminary report. *BJU Int* **88**:63–67.
- Bian F, Kasumov T, Thomas KR, Jobbins KA, David F, Minkler PE, Hoppel CL, and Brunengraber H (2005) Peroxisomal and mitochondrial oxidation of fatty acids in the heart, assessed from the ¹³C labeling of malonyl-CoA and the acetyl moiety of citrate. *J Biol Chem* **280**:9265–9271.
- Bianchetti A, Rozzini R, and Trabucchi M (2003) Effects of acetyl-L-carnitine in Alzheimer's disease patients unresponsive to acetylcholinesterase inhibitors. *Curr Med Res Opin* **19**:350–353.
- Bianchi G, Vitali G, Caraceni A, Ravaglia S, Capri G, Cundari S, Zanna C, and Gianni L (2005) Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-L-carnitine. *Eur J Cancer* **41**:1746–1750.
- Bird MI and Saggerson ED (1984) Binding of malonyl-CoA to isolated mitochondria. Evidence for high- and low-affinity sites in liver and heart and relationship to inhibition of carnitine palmitoyltransferase activity. *Biochem J* **222**:639–647.
- Bischof F, Nägele T, Wanders RJ, Trefz FK, and Melms A (2004) 3-hydroxy-3-methylglutaryl-CoA lyase deficiency in an adult with leukoencephalopathy. *Ann Neurol* **56**:727–730.
- Blackburn ML, Ono-Moore KD, Sobhi HF, and Adams SH (2020) Carnitine palmitoyltransferase 2 knockout potentiates palmitate-induced insulin resistance in C₂C₁₂ myotubes. *Am J Physiol Endocrinol Metab* **319**:E265–E275.
- Blazenović I, Kind T, Sa MR, Ji J, Vaniya A, Wancewicz B, Roberts BS, Torbašinović H, Lee T, Mehta SS, et al. (2019) Structure annotation of all mass spectra in untargeted metabolomics. *Anal Chem* **91**:2155–2162.
- Böhles H, Noppeney T, Akcetin Z, Rein J, and von der Emde J (1987) The effect of preoperative L-carnitine supplementation on myocardial metabolism during aorto-coronary bypass surgery. *Z Kardiol* **76** (Suppl 5):14–18.
- Bolognesi M, Amodio P, Merkel C, Godi L, and Gatta A (1995) Effect of 8-day therapy with propionyl-L-carnitine on muscular and subcutaneous blood flow of the lower limbs in patients with peripheral arterial disease. *Clin Physiol* **15**:417–423.
- Bonavita E (1986) Study of the efficacy and tolerability of L-acetylcarnitine therapy in the senile brain. *Int J Clin Pharmacol Ther Toxicol* **24**:511–516.
- Bonnefont JP, Djouadi F, Prip-Buus C, Gobin S, Munnich A, and Bastin J (2004) Carnitine palmitoyltransferases 1 and 2: biochemical, molecular and medical aspects. *Mol Aspects Med* **25**:495–520.
- Bonnet D, Martin D, Villain E, Jouve P, Rabier D, Brivet M, and Saudubray JM; Pascale De Lonlay (1999) Arrhythmias and conduction defects as presenting symptoms of fatty acid oxidation disorders in children. *Circulation* **100**:2248–2253.
- Bouchouirab FZ, Fortin M, Noll C, Dubé J, and Carpentier AC (2018) Plasma palmitoyl-carnitine (AC16:0) is a marker of increased postprandial nonesterified incomplete fatty acid oxidation rate in adults with type 2 diabetes. *Can J Diabetes* **42**:382–388.e1.
- Bourdin B, Adenier H, and Perrin Y (2007) Carnitine is associated with fatty acid metabolism in plants. *Plant Physiol Biochem* **45**:926–931.
- Bremer J (1962) Carnitine in intermediary metabolism. The metabolism of fatty acid esters of carnitine by mitochondria. *J Biol Chem* **237**:3628–3632.
- Brennan BP, Jensen JE, Hudson JI, Coit CE, Beaulieu A, Pope Jr HG, Renshaw PF, and Cohen BM (2013) A placebo-controlled trial of acetyl-L-carnitine and α -lipoic acid in the treatment of bipolar depression. *J Clin Psychopharmacol* **33**:627–635.
- Brevetti G, Diehm C, and Lambert D (1999) European multicenter study on propionyl-L-carnitine in intermittent claudication. *J Am Coll Cardiol* **34**:1618–1624.
- Brevetti G, Perna S, Sabbá C, Martone VD, and Condorelli M (1995) Propionyl-L-carnitine in intermittent claudication: double-blind, placebo-controlled, dose titration, multicenter study. *J Am Coll Cardiol* **26**:1411–1416.
- Brevetti G, Perna S, Sabbá C, Martone VD, Di Iorio A, and Barletta G (1997) Effect of propionyl-L-carnitine on quality of life in intermittent claudication. *Am J Cardiol* **79**:777–780.
- Brittain EL, Talati M, Fessel JP, Zhu H, Penner N, Calcutt MW, West JD, Funke M, Lewis GD, Gerszten RE, et al. (2016) Fatty acid metabolic defects and right ventricular lipotoxicity in human pulmonary arterial hypertension. *Circulation* **133**:1936–1944.
- Brooks 3rd JO, Yesavage JA, Carta A, and Bravi D (1998) Acetyl L-carnitine slows decline in younger patients with Alzheimer's disease: a reanalysis of a double-blind, placebo-controlled study using the trilinear approach. *Int Psychogeriatr* **10**:193–203.
- Brosnan JT and Brosnan ME (2006) Branched-chain amino acids: enzyme and substrate regulation. *J Nutr* **136** (Suppl 1):207S–211S.

- Brucknerova I, Bzduch V, Behulova D, Ferianec V, Dubovicky M, Ujhazy E, and Mach M (2008) Reversible asphyxial status in a newborn due to neonatal form of carnitine palmitoyltransferase II deficiency. *Neuroendocrinol Lett* **29**:627–630.
- Bruls YM, de Ligt M, Lindeboom L, Phielix E, Havekes B, Schaart G, Kornips E, Wildberger JE, Hesselink MK, Muoio D, et al. (2019) Carnitine supplementation improves metabolic flexibility and skeletal muscle acetylcarnitine formation in volunteers with impaired glucose tolerance: a randomised controlled trial. *EBioMedicine* **49**:318–330.
- Bruno A, Pandolfo G, Crucitti M, Lorusso S, Zoccali RA, and Muscatello MR (2016) Acetyl-L-carnitine augmentation of clozapine in partial-responder schizophrenia: a 12-week, open-label uncontrolled preliminary study. *Clin Neuropharmacol* **39**:277–280.
- Butte NF, Liu Y, Zakeri IF, Mohney RP, Mehta N, Voruganti VS, Göring H, Cole SA, and Comuzzie AG (2015) Global metabolomic profiling targeting childhood obesity in the Hispanic population. *Am J Clin Nutr* **102**:256–267.
- Cakcen H, Tuncer O, Kirimi E, Fryns JP, Uner A, Unal O, Cinal A, and Odabaş D (2004) Report of two Turkish infants with Norman-Roberts syndrome. *Genet Couns* **15**:9–17.
- Calabrese V, Scapagnini G, Ravagna A, Bella R, Butterfield DA, Calvani M, Pennisi G, and Giuffrida Stella AM (2003) Disruption of thiol homeostasis and nitrosative stress in the cerebrospinal fluid of patients with active multiple sclerosis: evidence for a protective role of acetylcarnitine. *Neurochem Res* **28**:1321–1328.
- Callander N, Markovina S, Eickhoff J, Hutson P, Campbell T, Hematti P, Go R, Hegeman R, Longo W, Williams E, et al. (2014) Acetyl-L-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin Oncology Network. *Cancer Chemother Pharmacol* **74**:875–882.
- Campi N, Todeschini GP, and Scarzella L (1990) Selegiline versus L-acetylcarnitine in the treatment of Alzheimer-type dementia. *Clin Ther* **12**:306–314.
- Campono M, Berton-Rigaud D, Joly-Lobbedez F, Baurain JF, Rolland F, Stenzl A, Fabbro M, van Dijk M, Pinkert J, Schmelter T, et al. (2013) A double-blind, randomized phase II study to evaluate the safety and efficacy of acetyl-L-carnitine in the prevention of sagopilone-induced peripheral neuropathy. *Oncologist* **18**:1190–1191.
- Cao B, Wang D, Pan Z, Brietzke E, McIntyre RS, Musial N, Mansur RB, Subramaniepillai M, Zeng J, Huang N, et al. (2019) Characterizing acylcarnitine biosignatures for schizophrenia: a longitudinal pre- and post-treatment study. *Transl Psychiatry* **9**:19.
- Cao B, Wang D, Pan Z, McIntyre RS, Brietzke E, Subramaniepillai M, Nozari Y, and Wang J (2020) Metabolic profiling for water-soluble metabolites in patients with schizophrenia and healthy controls in a Chinese population: a case-control study. *World J Biol Psychiatry* **21**:357–367.
- Capecchi PL, Laghi Pasini F, Quartarolo E, and Di Perri T (1997) Carnitines increase plasma levels of adenosine and ATP in humans. *Vasc Med* **2**:77–81.
- Carrasco P, Sahún I, McDonald J, Ramirez S, Jacas J, Gratacós E, Sierra AY, Serra D, Herrero L, Acker-Palmer A, et al. (2012) Ceramide levels regulated by carnitine palmitoyltransferase 1C control dendritic spine maturation and cognition. *J Biol Chem* **287**:21224–21232.
- Catanzaro F, Ombrone D, Di Stefano C, Rossi A, Nosari N, Scolamiero E, Tandurella I, Frisso G, Parenti G, Ruoppolo M, et al. (2010) The first case of mitochondrial acetoacetyl-CoA thiolase deficiency identified by expanded newborn metabolic screening in Italy: the importance of an integrated diagnostic approach. *J Inher Metab Dis* **33** (Suppl 3):S91–S94.
- Cavallini G, Biagiotti G, Koverech A, and Vitali G (2002) Oral propionyl-L-carnitine and intraplaque verapamil in the therapy of advanced and resistant Peyronie's disease. *BJU Int* **89**:895–900.
- Cavallini G, Caracciolo S, Vitali G, Modenini F, and Biagiotti G (2004) Carnitine versus androgen administration in the treatment of sexual dysfunction, depressed mood, and fatigue associated with male aging. *Urology* **63**:641–646.
- Cavallini G, Modenini F, Vitali G, and Koverech A (2005) Acetyl-L-carnitine plus propionyl-L-carnitine improve efficacy of sildenafil in treatment of erectile dysfunction after bilateral nerve-sparing radical retropubic prostatectomy. *Urology* **66**:1080–1085.
- Chace DH, DiPerna JC, Mitchell BL, Sgroi B, Hofman LF, and Naylor EW (2001) Electrospray tandem mass spectrometry for analysis of acylcarnitines in dried postmortem blood specimens collected at autopsy from infants with unexplained cause of death. *Clin Chem* **47**:1166–1182.
- Chan A, Paskavitz J, Remington R, Rasmussen S, and Shea TB (2008) Efficacy of a vitamin/nutriceutical formulation for early-stage Alzheimer's disease: a 1-year, open-label pilot study with an 16-month caregiver extension. *Am J Alzheimers Dis Other Demen* **23**:571–585.
- Chan A, Remington R, Kotyla E, Lepore A, Zemianek J, and Shea TB (2010) A vitamin/nutriceutical formulation improves memory and cognitive performance in community-dwelling adults without dementia. *J Nutr Health Aging* **14**:224–230.
- Chang KH, Cheng ML, Tang HY, Huang CY, Wu YR, and Chen CM (2018) Alternations of metabolic profile and kynurenine metabolism in the plasma of Parkinson's disease. *Mol Neurobiol* **55**:6319–6328.
- Chao de la Barca JM, Rondet-Courbis B, Ferré M, Müller J, Buisset A, Leruez S, Plubeau G, Macé T, Moureauxzeau L, Chupin S, et al. (2020) A plasma metabolomic profiling of exudative age-related macular degeneration showing carnosine and mitochondrial deficiencies. *J Clin Med* **9**:631.
- Chatterjee P, Cheong YJ, Bhatnagar A, Goozee K, Wu Y, McKay M, Martins IJ, Lim WLF, Pedrini S, Tegg M, et al. (2021) Plasma metabolites associated with biomarker evidence of neurodegeneration in cognitively normal older adults. *J Neurochem* **159**:389–402.
- Chegary M, Brinke Ht, Ruitter JP, Wijburg FA, Stoll MS, Minkler PE, van Weeghel M, Schulz H, Hoppel CL, Wanders RJ, et al. (2009) Mitochondrial long chain fatty acid beta-oxidation in man and mouse. *Biochim Biophys Acta* **1791**:806–815.
- Chen C, Hou G, Zeng C, Ren Y, Chen X, and Peng C (2021) Metabolomic profiling reveals amino acid and carnitine alterations as metabolic signatures in psoriasis. *Theranostics* **11**:754–767.
- Chen Y, Li C, Liu L, Guo F, Li S, Huang L, Sun C, and Feng R (2016) Serum metabolomics of NAFLD plus T2DM based on liquid chromatography-mass spectrometry. *Clin Biochem* **49**:962–966.
- Chen Z, Berquez M, and Luciani A (2020) Mitochondria, mitophagy, and metabolic disease: towards assembling the puzzle. *Cell Stress* **4**:147–150.
- Cheng JF, Chen M, Wallace D, Tith S, Haramura M, Liu B, Mak CC, Arrhenius T, Reily S, Brown S, et al. (2006) Synthesis and structure-activity relationship of small-molecule malonyl coenzyme A decarboxylase inhibitors. *J Med Chem* **49**:1517–1525.
- Cheng ML, Wang CH, Shiao MS, Liu MH, Huang YY, Huang CY, Mao CT, Lin JF, Ho HY, and Yang NI (2015) Metabolic disturbances identified in plasma are associated with outcomes in patients with heart failure: diagnostic and prognostic value of metabolomics. *J Am Coll Cardiol* **65**:1509–1520.
- Chiddo A, Gaglione A, Musci S, Troito G, Grimaldi N, Locuratolo N, and Rizzon P (1991) Hemodynamic study of intravenous propionyl-L-carnitine in patients with ischemic heart disease and normal left ventricular function. *Cardiovasc Drugs Ther* **5** (Suppl 1):107–111.
- Chintapalli SV, Anishkin A, and Adams SH (2018) Exploring the entry route of palmitic acid and palmitoylcarnitine into myoglobin. *Arch Biochem Biophys* **655**:56–66.
- Chintapalli SV, Jayanthi S, Mallipeddi PL, Gundampati R, Suresh Kumar TK, van Rossum DB, Anishkin A, and Adams SH (2016) Novel molecular interactions of acylcarnitines and fatty acids with myoglobin. *J Biol Chem* **291**:25133–25143.
- Cho K, Moon JS, Kang JH, Jang HB, Lee HJ, Park SI, Yu KS, and Cho JY (2017a) Combined untargeted and targeted metabolomic profiling reveals urinary biomarkers for discriminating obese from normal-weight adolescents. *Pediatr Obes* **12**:93–101.
- Cho K, Yoon DW, Lee M, So D, Hong IH, Rhee CS, Park JW, Cho JY, and Shin HW (2017b) Urinary metabolomic signatures in obstructive sleep apnea through targeted metabolomic analysis: a pilot study. *Metabolomics* **13**:88.
- Ciborowski M, Adamska E, Rusak M, Godzien J, Wilk J, Citko A, Bauer W, Gorska M, and Kretowski A (2015) CE-MS-based serum fingerprinting to track evolution of type 2 diabetes mellitus. *Electrophoresis* **36**:2286–2293.
- Cipolli C and Chiari G (1990) Effects of L-acetylcarnitine on mental deterioration in the aged: initial results. *Clin Ther* **132** (Suppl 6):479–510.
- Cittanti C, Colamussi P, Giganti M, Orlandi C, Uccelli L, Manfrini S, Azzena G, and Piffanelli A (1997) Technetium-99m sestamibi leg scintigraphy for non-invasive assessment of propionyl-L-carnitine induced changes in skeletal muscle metabolism. *Eur J Nucl Med* **24**:762–766.
- Clayton PT, Eaton S, Aynsley-Green A, Edginton M, Hussain K, Krywawych S, Datta V, Malingre HE, Berger R, and van den Berg IE (2001) Hyperinsulinism in short-chain L-3-hydroxyacyl-CoA dehydrogenase deficiency reveals the importance of beta-oxidation in insulin secretion. *J Clin Invest* **108**:457–465.
- Condorelli RA, Calogero AE, Cannarella R, Giaccone F, Mongioi' LM, Cimino L, Aversa A, and La Vignera S (2019) Poor efficacy of L-acetylcarnitine in the treatment of asthenozoospermia in patients with type 1 diabetes. *J Clin Med* **8**:585.
- Consitt LA, Koves TR, Muoio DM, Nakazawa M, Newton CA, and Houmard JA (2016) Plasma acylcarnitines during insulin stimulation in humans are reflective of age-related metabolic dysfunction. *Biochem Biophys Res Commun* **479**:868–874.
- Console L, Giangregorio N, Indiveri C, and Tonazzi A (2014) Carnitine/acylcarnitine translocase and carnitine palmitoyltransferase 2 form a complex in the inner mitochondrial membrane. *Mol Cell Biochem* **394**:307–314.
- Corbucci GG, Menichetti A, Cogliatti A, Nicoli P, Arduini A, Damonti W, Marchionni A, and Calvani M (1992) Metabolic aspects of acute cerebral hypoxia during extracorporeal circulation and their modification induced by acetylcarnitine treatment. *Int J Clin Pharmacol Res* **12**:89–98.
- Corr PB, Gross RW, and Sobel BE (1984) Amphiphilic metabolites and membrane dysfunction in ischemic myocardium. *Circ Res* **55**:135–154.
- Costa CG, Struys EA, Bootsma A, ten Brink HJ, Dorland L, Tavares de Almeida I, Duran M, and Jakobs C (1997) Quantitative analysis of plasma acylcarnitines using gas chromatography chemical ionization mass fragmentography. *J Lipid Res* **38**:173–182.
- Couce ML, Aldamiz-Echevarria L, Bueno MA, Barros P, Belanger-Quintana A, Blasco J, Garcia-Silva MT, Márquez-Armenteros AM, Vitoria I, Vives I, et al. (2017) Genotype and phenotype characterization in a Spanish cohort with isovaleric acidemia. *J Hum Genet* **62**:355–360.
- Couce Pico ML, Castiñeiras Ramos DE, López Sousa M, Fernández Seara MJ, Eiris Puñal J, and Cocho de Juan JA (2008) Importance of early diagnosis and treatment in the prognosis of type I glutaric acidemia. *Am J Pediatr (Barc)* **69**:239–243.
- Cree-Green M, Carreau AM, Rahat H, Garcia-Reyes Y, Bergman BC, Pyle L, and Nadeau KJ (2019) Amino acid and fatty acid metabolomic profile during fasting and hyperinsulinemia in girls with polycystic ovarian syndrome. *Am J Physiol Endocrinol Metab* **316**:E707–E718.
- Cristofano A, Sapere N, La Marca G, Angiolillo A, Vitale M, Corbi G, Scapagnini G, Intrieri M, Russo C, Corso G, et al. (2016) Serum levels of acyl-carnitines along the continuum from normal to Alzheimer's dementia. *PLoS One* **11**:e0155694.
- Crown SB, Marze N, and Antoniewicz MR (2015) Catabolism of branched chain amino acids contributes significantly to synthesis of odd-chain and even-chain fatty acids in 3T3-L1 adipocytes. *PLoS One* **10**:e0145850.
- Crucci G, Di Stefano G, Fattapposta F, Jann S, Padua L, Schenone A, and Truini A (2017) L-Acetyl-carnitine in patients with carpal tunnel syndrome: effects on nerve protection, hand function and pain. *CNS Drugs* **31**:1103–1111.
- Curnock R, Heaton ND, Vilca-Melendez H, Dhawan A, Hadzic N, and Vara R (2020) Liver transplantation in children with propionic acidemia: medium-term outcomes. *Liver Transpl* **26**:419–430.

- Curran MW, Olson J, Morhart M, Sample D, and Chan KM (2016) Acetyl-L-carnitine (ALCAR) to enhance nerve regeneration in carpal tunnel syndrome: study protocol for a randomized, placebo-controlled trial. *Trials* **17**:200.
- Curran MWT, Morhart MJ, Olson JL, Hachisuka A, and Chan KM (2019) Acetyl-L-carnitine to enhance nerve regeneration in carpal tunnel syndrome: a double-blind, randomized, controlled trial. *Plast Reconstr Surg* **143**:111e–120e.
- Dal Lago A, De Martini D, Flore R, Gaetani E, Gasbarrini A, Gerardino L, Pola R, Santoliquido A, Serricchio M, Tondi P, et al. (1999) Effects of propionyl-L-carnitine on peripheral arterial obliterative disease of the lower limbs: a double-blind clinical trial. *Drugs Exp Clin Res* **25**:29–36.
- Dambrova M, Zuurbier CJ, Borutaite V, Liepinsh E, and Makrecka-Kuka M (2021) Energy substrate metabolism and mitochondrial oxidative stress in cardiac ischemia/reperfusion injury. *Free Radic Biol Med* **165**:24–37.
- Danese C, Cirene M, Colotto M, Aratari A, Amato S, Di Bona S, and Curione M (2011) Cardiac involvement in inflammatory bowel disease: role of acylcarnitine esters. *Clin Ter* **162**:e105–e109.
- Das AM, Illsinger S, Lücke T, Hartmann H, Ruiter JP, Steuerwald U, Waterham HR, Duran M, and Wanders RJ (2006) Isolated mitochondrial long-chain ketoacyl-CoA thiolase deficiency resulting from mutations in the HADHB gene. *Clin Chem* **52**:530–534.
- Davies SK, Ang JE, Revell VL, Holmes B, Mann A, Robertson FP, Cui N, Middleton B, Ackermann K, Kayser M, et al. (2014) Effect of sleep deprivation on the human metabolome. *Proc Natl Acad Sci USA* **111**:10761–10766.
- Dawson DB, Waber L, Hale DE, and Bennett MJ (1995) Transient organic aciduria and persistent lacticacidemia in a patient with short-chain acyl-coenzyme A dehydrogenase deficiency. *J Pediatr* **126**:69–71.
- De Grandis D and Minardi C (2002) Acetyl-L-carnitine (levaccarnine) in the treatment of diabetic neuropathy. A long-term, randomised, double-blind, placebo-controlled study. *Drugs R D* **3**:223–231.
- De Grandis D, Santoro L, and Di Benedetto P (1995) L-acetylcarnitine in the treatment of patients with peripheral neuropathies: a short term, double-blind clinical study of 426 patients. *Clin Drug Investig* **10**:317–322.
- De Marchi S, Zecchetto S, Rigoni A, Prior M, Fondrieschi L, Scuro A, Rulfo F, and Arosio E (2012) Propionyl-L-carnitine improves endothelial function, microcirculation and pain management in critical limb ischemia. *Cardiovasc Drugs Ther* **26**:401–408.
- Dellow WJ, Chambers ST, Lever M, Lunt H, and Robson RA (1999) Elevated glycine betaine excretion in diabetes mellitus patients is associated with proximal tubular dysfunction and hyperglycemia. *Diabetes Res Clin Pract* **43**:91–99.
- Derrick JP and Ramsay RR (1989) L-carnitine acyltransferase in intact peroxisomes is inhibited by malonyl-CoA. *Biochem J* **262**:801–806.
- Dhaunsi GS and Bitar MS (2004) Antioxidants attenuate diabetes-induced activation of peroxisomal functions in the rat kidney. *J Biomed Sci* **11**:566–570.
- Di Marzo L, Micheli A, Sapienza P, Tedesco M, Mingoli A, Capuani G, Aureli T, Giuliani A, Conti F, and Cavallaro A (1999) ³¹P-magnetic resonance spectroscopy to evaluate medical therapy efficacy in peripheral arterial disease. A pilot study. *Panminerva Med* **41**:283–290.
- Distler AM, Kerner J, and Hoppel CL (2009) Mass spectrometric demonstration of the presence of liver carnitine palmitoyltransferase-I (CPT-I) in heart mitochondria of adult rats. *Biochim Biophys Acta* **1794**:431–437.
- Divakaruni AS, Hsieh WY, Minarretta L, Duong TN, Kim KKO, Desousa BR, Andreyev AY, Bowman CE, Caradonna K, Dranka BP, et al. (2018) Etomoxir inhibits macrophage polarization by disrupting CoA homeostasis. *Cell Metab* **28**:490–503.e7.
- Donti TR, Blackburn PR, and Atwal PS (2016) Holocarboxylase synthetase deficiency pre and post newborn screening. *Mol Genet Metab Rep* **7**:40–44.
- Dos Santos Mello M, Ribas GS, Wayhs CA, Hammerschmidt T, Guerreiro GB, Favanzani JL, Sitta A, de Moura Coelho D, Wajner M, and Vargas CR (2015) Increased oxidative stress in patients with 3-hydroxy-3-methylglutaric aciduria. *Mol Cell Biochem* **402**:149–155.
- Drousiotou A, DiMeo I, Mineri R, Georgiou T, Stylianidou G, and Tiranti V (2011) Ethylmalonic encephalopathy: application of improved biochemical and molecular diagnostic approaches. *Clin Genet* **79**:385–390.
- Dumonteil E, Barré H, and Meissner G (1994) Effects of palmitoyl carnitine and related metabolites on the avian Ca(2+)-ATPase and Ca2+ release channel. *J Physiol* **479**:29–39.
- Duran M, De Klerk JB, Wadman SK, Bruinvis L, and Ketting D (1984) The differential diagnosis of dicarboxylic aciduria. *J Inherit Metab Dis* **7** (Suppl 1): 48–51.
- Duran M, Mitchell G, de Klerk JB, de Jager JP, Hofkamp M, Bruinvis L, Ketting D, Saudubray JM, and Wadman SK (1985) Octanoic acidemia and octanoylcarnitine excretion with dicarboxylic aciduria due to defective oxidation of medium-chain fatty acids. *J Pediatr* **107**:397–404.
- Duranti G, Boenzi S, Rizzo C, Rava L, Di Ciommo V, Carozzo R, Meschini MC, Johnson DW, and Dionisi-Vici C (2008) Urine acylcarnitine analysis by ESI-MS/MS: a new tool for the diagnosis of peroxisomal biogenesis disorders. *Clin Chim Acta* **398**:86–89.
- Dyck JR and Lopaschuk GD (2006) AMPK alterations in cardiac physiology and pathology: enemy or ally? *J Physiol* **574**:95–112.
- Elizondo G, Matern D, Vockley J, Harding CO, and Gillingham MB (2020) Effects of fasting, feeding and exercise on plasma acylcarnitines among subjects with CPT2D, VLCADD and LCHADD/TFPD. *Mol Genet Metab* **131**:90–97.
- Esperanza MG, Wrobel K, Ojeda AG, Garay-Sevilla ME, Escobosa ARC, Barrientos EY, and Wrobel K (2020) Liquid chromatography-mass spectrometry untargeted metabolomics reveals increased levels of tryptophan indole metabolites in urine of metabolic syndrome patients. *Eur J Mass Spectrom (Chichester)* **26**:379–387.
- Famularo G, Moretti S, Alessi E, Trinchieri V, Angelucci A, Santini G, Cifone G, and De Simone C (1999) Reduction of glutamate levels in HIV-infected subjects treated with acylcarnitine. *J Neuro-Aids* **2**:65–73.
- Famularo G, Moretti S, Marcellini S, Trinchieri V, Tzantzoglou S, Santini G, Longo A, and De Simone C (1997) Acetyl-carnitine deficiency in AIDS patients with neurotoxicity on treatment with antiretroviral nucleoside analogues. *AIDS* **11**:185–190.
- Farook VS, Reddivari L, Chittoor G, Puppala S, Arya R, Fowler SP, Hunt KJ, Curran JE, Comuzzie AG, Lehman DM, et al. (2015) Metabolites as novel biomarkers for childhood obesity-related traits in Mexican-American children. *Pediatr Obes* **10**:320–327.
- Farrell SO, Fiol CJ, Reddy JK, and Bieber LL (1984) Properties of purified carnitine acyltransferases of mouse liver peroxisomes. *J Biol Chem* **259**:13089–13095.
- Ferdinandusse S, Denis S, Van Roermund CW, Wanders RJ, and Dacremont G (2004) Identification of the peroxisomal beta-oxidation enzymes involved in the degradation of long-chain dicarboxylic acids. *J Lipid Res* **45**:1104–1111.
- Ferdinandusse S, Mulders J, IJlst L, Denis S, Dacremont G, Waterham HR, and Wanders RJ (1999) Molecular cloning and expression of human carnitine octanoyltransferase: evidence for its role in the peroxisomal beta-oxidation of branched-chain fatty acids. *Biochem Biophys Res Commun* **263**:213–218.
- Fernandez IC, Del Carmen Camberos M, Passicot GA, Martucci LC, and Cresto JC (2013) Children at risk of diabetes type 1. Treatment with acetyl-L-carnitine plus nicotinamide - case reports. *J Pediatr Endocrinol Metab* **26**:347–355.
- Ferro F, Ouilé A, Tran TA, Fontanaud P, Bois P, Babuty D, Labarthe F, and Le Guennec JY (2012) Long-chain acylcarnitines regulate the hERG channel. *PLoS One* **7**:e41686.
- Ficiocioglu C, Chrisant MR, Payan I, and Chace DH (2005) Cardiomyopathy and hypotonia in a 5-month-old infant with malonyl-coa decarboxylase deficiency: potential for preclinical diagnosis with expanded newborn screening. *Pediatr Cardiol* **26**:881–883.
- Fillmore N and Lopaschuk GD (2014) Malonyl CoA: a promising target for the treatment of cardiac disease. *IUBMB Life* **66**:139–146.
- Fillmore N, Mori J, and Lopaschuk GD (2014) Mitochondrial fatty acid oxidation alterations in heart failure, ischaemic heart disease and diabetic cardiomyopathy. *Br J Pharmacol* **171**:2080–2090.
- Fingerhut R, Röschinger W, Muntau AC, Dame T, Kreischer J, Arnecke R, Superti-Furga A, Troxler H, Liebl B, Olgemöller B, et al. (2001) Hepatic carnitine palmitoyltransferase I deficiency: acylcarnitine profiles in blood spots are highly specific. *Clin Chem* **47**:1763–1768.
- Finocchiaro G, Colombo I, and DiDonato S (1990) Purification, characterization and partial amino acid sequences of carnitine palmitoyl-transferase from human liver. *FEBS Lett* **274**:163–166.
- Flatters SJ, Xiao WH, and Bennett GJ (2006) Acetyl-L-carnitine prevents and reduces paclitaxel-induced painful peripheral neuropathy. *Neurosci Lett* **397**:219–223.
- Fontaine M, Briand G, Largillière C, Degand P, Divry P, Vianey-Saban C, Mousson B, and Vamecq J (1998) Metabolic studies in a patient with severe carnitine palmitoyltransferase type II deficiency. *Clin Chim Acta* **273**:161–170.
- Ford DA, Han X, Horner CC, and Gross RW (1996) Accumulation of unsaturated acylcarnitine molecular species during acute myocardial ischemia: metabolic compartmentalization of products of fatty acyl chain elongation in the acylcarnitine pool. *Biochemistry* **35**:7903–7909.
- Forni S, Fu X, Palmer SE, and Sweetman L (2010) Rapid determination of C4-acylcarnitine and C5-acylcarnitine isomers in plasma and dried blood spots by UPLC-MS/MS as a second tier test following flow-injection MS/MS acylcarnitine profile analysis. *Mol Genet Metab* **101**:25–32.
- Fritz IB (1959) Action of carnitine on long chain fatty acid oxidation by liver. *Am J Physiol* **197**:297–304.
- Frye RE, Melnyk S, and Macfabe DF (2013) Unique acyl-carnitine profiles are potential biomarkers for acquired mitochondrial disease in autism spectrum disorder. *Transl Psychiatry* **3**:e220.
- Fukao T, Zhang GX, Sakura N, Kubo T, Yamaga H, Hazama A, Kohno Y, Matsuo N, Kondo M, Yamaguchi S, et al. (2003) The mitochondrial acetoacetyl-CoA thiolase (T2) deficiency in Japanese patients: urinary organic acid and blood acylcarnitine profiles under stable conditions have subtle abnormalities in T2-deficient patients with some residual T2 activity. *J Inherit Metab Dis* **26**:423–431.
- Gallant NM, Leydiker K, Tang H, Feuchtbau L, Lorey F, Puckett R, Deignan JL, Neidich J, Dorrani N, Chang E, et al. (2012) Biochemical, molecular, and clinical characteristics of children with short chain acyl-CoA dehydrogenase deficiency detected by newborn screening in California. *Mol Genet Metab* **106**:55–61.
- Gambi D, Onofri M, Calvani M, Farielli A, Del Re ML, Bazzano S, Cutarella R, Fulgente T, and Colangelo U (1989) Neurophysiological studies of L-acetylcarnitine administration in man. *Drugs Exp Clin Res* **15**:435–446.
- Garzya G, Corallo D, Fiore A, Lecciso G, Petrelli G, and Zotti C (1990) Evaluation of the effects of L-acetylcarnitine on senile patients suffering from depression. *Drugs Exp Clin Res* **16**:101–106.
- Gasbarrini G, Mingrone G, Giancaterini A, De Gaetano A, Scarfone A, Capristo E, Calvani M, Caso V, and Greco AV (2003) Effects of propionyl-L-carnitine topical irrigation in distal ulcerative colitis: a preliminary report. *Hepato gastroenterology* **50**:1385–1389.
- Gasparetto A, Corbucci GG, De Blasi RA, Antonelli M, Bagliella E, D'Iddio S, and Trevisani C (1991) Influence of acetyl-L-carnitine infusion on haemodynamic parameters and survival of circulatory-shock patients. *Int J Clin Pharmacol Res* **11**:83–92.
- Gavino VC, Cordeau S, and Gavino G (2003) Kinetic analysis of the selectivity of acylcarnitine synthesis in rat mitochondria. *Lipids* **38**:485–490.
- Gavrilova SI, Kalya L B, Kolykhalov IV, Roshchina IF, and Selezneva ND (2011). Acetyl-L-carnitine (carnitine) in the treatment of early stages of Alzheimer's disease and vascular dementia. *Zh Neurol Psikhiatr Im S S Korsakova* **111**:16–22.
- Gelaye B, Sumner SJ, McRitchie S, Carlson JE, Ananth CV, Enquobahrie DA, Qiu C, Sorensen TK, and Williams MA (2016) Maternal early pregnancy serum metabolomics profile and abnormal vaginal bleeding as predictors of placental abruption: a prospective study. *PLoS One* **11**:e0156755.

- Gempel K, Kiechl S, Hofmann S, Lochmüller H, Kiechl-Kohlendorfer U, Willeit J, Sperl W, Rettinger A, Bieger I, Pongratz D, et al. (2002) Screening for carnitine palmitoyltransferase II deficiency by tandem mass spectrometry. *J Inherit Metab Dis* **25**:17–27.
- Gempel K, von Praun C, Baumkötter J, Lehnert W, Ensenauer R, Gerbitz KD, and Bauer MF (2001) “Adult” form of muscular carnitine palmitoyltransferase II deficiency: manifestation in a 2-year-old child. *Eur J Pediatr* **160**:548–551.
- Gentile V, Antonini G, Antonella Bertozzi M, Dinelli N, Rizzo C, Ashraf Virmani M, and Koverech A (2009) Effect of propionyl-L-carnitine, L-arginine and nicotinic acid on the efficacy of vardenafil in the treatment of erectile dysfunction in diabetes. *Curr Med Res Opin* **25**:2223–2228.
- Gentile V, Vicini P, Prigiotti G, Koverech A, and Di Silverio F (2004) Preliminary observations on the use of propionyl-L-carnitine in combination with sildenafil in patients with erectile dysfunction and diabetes. *Curr Med Res Opin* **20**:1377–1384.
- Ghirardi O, Lo Giudice P, Pisano C, Vertechy M, Bellucci A, Vesce L, Cundari S, Miloso M, Rigamonti LM, Nicolini G, et al. (2005a) Acetyl-L-carnitine prevents and reverts experimental chronic neurotoxicity induced by oxaliplatin, without altering its antitumor properties. *Anticancer Res* **25**:2681–2687.
- Ghirardi O, Vertechy M, Vesce L, Canta A, Nicolini G, Galbiati S, Ciogli C, Quattrini G, Pisano C, Cundari S et al. (2005b) Chemotherapy-induced allodinia: neuroprotective effect of acetyl-L-carnitine. *In Vivo* **19**:631–637.
- Ghoraba DA, Mohammed MM, and Zaki OK (2015) Mutation analysis of methylmalonyl CoA mutase gene exon 2 in Egyptian families: identification of 25 novel allelic variants. *Meta Gene* **3**:71–88.
- Giancaterini A, De Gaetano A, Mingrone G, Gniuli D, Liverani E, Capristo E, and Greco AV (2000) Acetyl-L-carnitine infusion increases glucose disposal in type 2 diabetic patients. *Metabolism* **49**:704–708.
- Gianfrilli D, Lauretta R, Di Dato C, Graziadio C, Pozza C, De Larichaudy J, Giannetta E, Isidori AM, and Lenzi A (2012) Propionyl-L-carnitine, L-arginine and niacin in sexual medicine: a nutraceutical approach to erectile dysfunction. *Andrologia* **44** (Suppl 1):600–604.
- Gillingham MB, Heitner SB, Martin J, Rose S, Goldstein A, El-Gharbawy AH, Deward S, Lasarev MR, Pollaro J, DeLany JP, et al. (2017) Triheptanoin versus trioctanoin for long-chain fatty acid oxidation disorders: a double blinded, randomized controlled trial. *J Inherit Metab Dis* **40**:831–843.
- Glatz JFC and vanderVusse GJ (1996) Cellular fatty acid-binding proteins: their function and physiological significance. *Prog Lipid Res* **35**:243–282.
- Gnoni A, Longo S, Gnoni GV, and Giudetti AM (2020) Carnitine in human muscle bioenergetics: can carnitine supplementation improve physical exercise? *Molecules* **25**:182.
- Gobin S, Thuillier L, Jogl G, Faye A, Tong L, Chi M, Bonnefont JP, Girard J, and Prip-Buus C (2003) Functional and structural basis of carnitine palmitoyltransferase 1A deficiency. *J Biol Chem* **278**:50428–50434.
- Goety CG, Tanner CM, Cohen JA, Thelen JA, Carroll VS, Klawans HL, and Fariello RG (1990) L-acetyl-carnitine in Huntington's disease: double-blind placebo controlled crossover study of drug effects on movement disorder and dementia. *Mov Disord* **5**:263–265.
- Golpich M, Amini E, Mohamed Z, Azman Ali R, Mohamed Ibrahim N, and Ahmadiani A (2017) Mitochondrial dysfunction and biogenesis in neurodegenerative diseases: pathogenesis and treatment. *CNS Neurosci Ther* **23**:5–22.
- Gong LL, Yang S, Zhang W, Han FF, Xuan LL, Lv YL, Liu H, and Liu LH (2020) Targeted metabolomics for plasma amino acids and carnitines in patients with metabolic syndrome using HPLC-MS/MS. *Dis Markers* **2020**:8842320.
- Goodpaster BH and Sparks LM (2017) Metabolic flexibility in health and disease. *Cell Metab* **25**:1027–1036.
- Grandis DD (1998) Tolerability and efficacy of L-acetylcarnitine in patients with peripheral neuropathies: a short-term, open multicentre study. *Clin Drug Investig* **15**:73–79.
- Greco AV, Mingrone G, Bianchi M, and Ghirlanda G (1992) Effect of propionyl-L-carnitine in the treatment of diabetic angiopathy: controlled double blind trial versus placebo. *Drugs Exp Clin Res* **18**:69–80.
- Grevengoed TJ, Klett EL, and Coleman RA (2014) Acyl-CoA metabolism and partitioning. *Annu Rev Nutr* **34**:1–30.
- Grünert SC, Schlatter SM, Schmitt RN, Gemperle-Britschgi C, Mrázová L, Balci MC, Bischof F, Çoker M, Das AM, Demirkol M, et al. (2017) 3-Hydroxy-3-methylglutaryl-coenzyme A lyase deficiency: clinical presentation and outcome in a series of 37 patients. *Mol Genet Metab* **121**:206–215.
- Guarnaschelli C, Fugazza G, and Pistarini C (1988) Pathological brain ageing: evaluation of the efficacy of a pharmacological aid. *Drugs Exp Clin Res* **14**:715–718.
- Guasch-Ferré M, Zheng Y, Ruiz-Canela M, Hruby A, Martínez-González MA, Clish CB, Corella D, Estruch R, Ros E, Fitó M, et al. (2016) Plasma acylcarnitines and risk of cardiovascular disease: effect of Mediterranean diet interventions. *Am J Clin Nutr* **103**:1408–1416.
- Hameed A, Mojsak P, Buczynska A, Suleria HAR, Kretowski A, and Ciborowski M (2020) Altered metabolome of lipids and amino acids species: a source of early signaling biomarkers of T2DM. *J Clin Med* **9**:2257.
- Han LS, Huang Z, Han F, Ye J, Qiu WJ, Zhang HW, Wang Y, Gong ZW, and Gu XF (2015) Clinical features and MUT gene mutation spectrum in Chinese patients with isolated methylmalonic acidemia: identification of ten novel allelic variants. *World J Pediatr* **11**:358–365.
- Hart AM, Wiberg M, Youle M, and Terenghi G (2002) Systemic acetyl-L-carnitine eliminates sensory neuronal loss after peripheral axotomy: a new clinical approach in the management of peripheral nerve trauma. *Exp Brain Res* **145**:182–189.
- Hart AM, Wilson AD, Montovani C, Smith C, Johnson M, Terenghi G, and Youle M (2004) Acetyl-L-carnitine: a pathogenesis based treatment for HIV-associated antiretroviral toxic neuropathy. *AIDS* **18**:1549–1560.
- Heggermont WA, Papageorgiou A-P, Heymans S, and Van Bilsen M (2016) Metabolic support for the heart: complementary therapy for heart failure? *Eur J Heart Fail* **18**:1420–1429.
- Hellgren LI (2010) Phytanic acid—an overlooked bioactive fatty acid in dairy fat? *Ann N Y Acad Sci* **1190**:42–49.
- Hennermann JB, Roloff S, Gellermann J, Grütters A, and Klein J (2009) False-positive newborn screening mimicking glutaric aciduria type I in infants with renal insufficiency. *J Inherit Metab Dis* **32** (Suppl 1):S355–S359.
- Herrmann WM, Dietrich B, and Hiersemazel R (1990) Pharmacoelectroencephalographic and clinical effects of the cholinergic substance-acetyl-L-carnitine in patients with organic brain syndrome. *Int J Clin Pharmacol Res* **10**:81–84.
- Hershman DL, Unger JM, Crew KD, Minasian LM, Awad D, Moinpour CM, Hansen L, Lew DL, Greenlee H, Fehrenbacher L, et al. (2013) Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy. *J Clin Oncol* **31**:2627–2633.
- Hershman DL, Unger JM, Crew KD, Till C, Greenlee H, Minasian LM, Moinpour CM, Lew DL, Fehrenbacher L, Wade 3rd JL, et al. (2018) Two-year trends of taxane-induced neuropathy in women enrolled in a randomized trial of acetyl-L-carnitine (SWOG S0715). *J Natl Cancer Inst* **110**:669–676.
- Herzmann C, Johnson MA, and Youle M (2005) Long-term effect of acetyl-L-carnitine for antiretroviral toxic neuropathy. *HIV Clin Trials* **6**:344–350.
- Herzog K, van Lenthe H, Wanders RJA, Vaz FM, Waterham HR, and Ferdinandusse S (2017) Identification and diagnostic value of phytanoyl- and pristanoyl-carnitine in plasma from patients with peroxisomal disorders. *Mol Genet Metab* **121**:279–282.
- Hiatt WR, Creager MA, Amato A, and Brass EP (2011) Effect of propionyl-L-carnitine on a background of monitored exercise in patients with claudication secondary to peripheral artery disease. *J Cardiopulm Rehabil Prev* **31**:125–132.
- Hiatt WR, Regensteiner JG, Creager MA, Hirsch AT, Cooke JP, Olin JW, Gorbunov GN, Isner J, Lukjanov YV, Tstsiashvili MS, et al. (2001) Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication. *Am J Med* **110**:616–622.
- Hiltunen JK, Mursula AM, Rottensteiner H, Wierenga RK, Kastaniotis AJ, and Gurvitz A (2003) The biochemistry of peroxisomal beta-oxidation in the yeast *Saccharomyces cerevisiae*. *FEMS Microbiol Rev* **27**:35–64.
- Hinder LM, Figueroa-Romero C, Pacut C, Hong Y, Vivekanandan-Giri A, Pennathur S, and Feldman EL (2014) Long-chain acyl coenzyme A synthetase 1 overexpression in primary cultured Schwann cells prevents long chain fatty acid-induced oxidative stress and mitochondrial dysfunction. *Antioxid Redox Signal* **21**:588–600.
- Hirschey MD, Shimazu T, Goetzman E, Jing E, Schwer B, Lombard DB, Grueter CA, Harris C, Biddinger S, Ilkayeva OR, et al. (2010) SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation. *Nature* **464**:121–125.
- Hisahara S, Matsushita T, Furuyama H, Tajima G, Shigematsu Y, Imai T, and Shimohama S (2015) A heterozygous missense mutation in adolescent-onset very long-chain acyl-CoA dehydrogenase deficiency with exercise-induced rhabdomyolysis. *Tohoku J Exp Med* **235**:305–310.
- Hoffman JR, Ratames NA, Gonzalez A, Beller NA, Hoffman MW, Olson M, Purpura M, and Jäger R (2010) The effects of acute and prolonged CRAM supplementation on reaction time and subjective measures of focus and alertness in healthy college students. *J Int Soc Sports Nutr* **7**:39.
- Hori T, Fukao T, Kobayashi H, Teramoto T, Takayanaagi M, Hasegawa Y, Yasuno T, Yamaguchi S, and Kondo N (2010) Carnitine palmitoyltransferase 2 deficiency: the time-course of blood and urinary acylcarnitine levels during initial L-carnitine supplementation. *Tohoku J Exp Med* **221**:191–195.
- Houten SM, Violante S, Ventura FV, and Wanders RJ (2016) The biochemistry and physiology of mitochondrial fatty acid β -oxidation and its genetic disorders. *Annu Rev Physiol* **78**:23–44.
- Hozyasz KK, Oltarzewski M, and Dudkiewicz Z (2010) Malonylcarnitine in newborns with non-syndromic cleft lip with or without cleft palate. *Int J Oral Sci* **2**:136–141.
- Hsiao YS, Jogl G, and Tong L (2004) Structural and biochemical studies of the substrate selectivity of carnitine acetyltransferase. *J Biol Chem* **279**:31584–31589.
- Huang HJ, Zhang AY, Cao HC, Lu HF, Wang BH, Xie Q, Xu W, and Li LJ (2013) Metabolomic analyses of faeces reveals malabsorption in cirrhotic patients. *Dig Liver Dis* **45**:677–682.
- Huang Y, Xiao M, Ou J, Lv Q, Wei Q, Chen Z, Wu J, Tu L, Jiang Y, Zhang X, et al. (2020) Identification of the urine and serum metabolomics signature of gout. *Rheumatology (Oxford)* **59**:2960–2969.
- Hull FE, Radloff JF, and Sweeley CC (1975) Fatty acid oxidation by ischemic myocardium. *Recent Adv Stud Cardiac Struct Metab* **8**:153–165.
- Hung PL, Lin LJ, Chen C, Hung KY, Hsieh TY, Hsu MH, Kuo HC, and Lin YJ (2020) An examination of serum acylcarnitine and amino acid profiles at different time point of ketogenic diet therapy and their association of ketogenic diet effectiveness. *Nutrients* **13**:21.
- Hunt MC, Siponen MI, and Alexson SE (2012) The emerging role of acyl-CoA thioesterases and acyltransferases in regulating peroxisomal lipid metabolism. *Biochim Biophys Acta* **1822**:1397–1410.
- Hunter WG, Kelly JP, McGarrath 3rd RW, Khouri MG, Craig D, Haynes C, Ilkayeva O, Stevens RD, Bain JR, Muehlbauer MJ, et al. (2016) Metabolomic profiling identifies novel circulating biomarkers of mitochondrial dysfunction differentially elevated in heart failure with preserved versus reduced ejection fraction: evidence for shared metabolic impairments in clinical heart failure. *J Am Heart Assoc* **5**:e003190.
- Huo Z, Yu L, Yang J, Zhu Y, Bennett DA, and Zhao J (2020) Brain and blood metabolome for Alzheimer's dementia: findings from a targeted metabolomics analysis. *Neurobiol Aging* **86**:123–133.

- Hussain K, Clayton PT, Krywawych S, Chatziandreou I, Mills P, Ginbey DW, Geboers AJ, Berger R, van den Berg IE, and Eaton S (2005) Hyperinsulinism of infancy associated with a novel splice site mutation in the SCHAD gene. *J Pediatr* **146**:706–708.
- Iacobazzi V, Pasquali M, Singh R, Matern D, Rinaldo P, Amat di San Filippo C, Palmieri F, and Longo N (2004) Response to therapy in carnitine/acylcarnitine translocase (CACT) deficiency due to a novel missense mutation. *Am J Med Genet A* **126A**:150–155.
- Idell-Wenger JA, Grotyhohn LW, and Neely JR (1978) Coenzyme A and carnitine distribution in normal and ischemic hearts. *J Biol Chem* **253**:4310–4318.
- Igal RA and Sinner DI (2021) Stearoyl-CoA desaturase 5 (SCD5), a Δ -9 fatty acyl desaturase in search of a function. *Biochim Biophys Acta Mol Cell Biol Lipids* **1866**:158840.
- Illsinger S, Lücke T, Peter M, Rüter JP, Wanders RJ, Deschauer M, Handig I, Wuys W, and Das AM (2008) Carnitine-palmitoyltransferase 2 deficiency: novel mutations and relevance of newborn screening. *Am J Med Genet A* **146A**:2925–2928.
- Indiveri C, Iacobazzi V, Tonazzi A, Giangregorio N, Infantino V, Convertini P, Console L, and Palmieri F (2011) The mitochondrial carnitine/acylcarnitine carrier: function, structure and physiopathology. *Mol Aspects Med* **32**:223–233.
- Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, and Matthews DR (2015) Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care* **38**:140–149.
- Jaberi E, Chitsazian F, Ali Shahidi G, Rohani M, Sina F, Safari I, Malakouti Nejad M, Houshmand M, Klotzle B, and Elahi E (2013) The novel mutation p.Asp251Asn in the β -subunit of succinate-CoA ligase causes encephalomyopathy and elevated succinylcarnitine. *J Hum Genet* **58**:526–530.
- Jagannathan R, Neves JS, Dorcely B, Chung ST, Tamura K, Rhee M, and Bergman M (2020) The oral glucose tolerance test: 100 years later. *Diabetes Metab Syndr Obes* **13**:3787–3805.
- Jain P, Singh S, and Arya A (2021) A student centric method for calculation of fatty acid energetics: Integrated formula and web tool. *Biochem Mol Biol Educ* **49**:492–499.
- Jakobs BS and Wanders RJ (1995) Fatty acid beta-oxidation in peroxisomes and mitochondria: the first, unequivocal evidence for the involvement of carnitine in shuttling propionyl-CoA from peroxisomes to mitochondria. *Biochem Biophys Res Commun* **213**:1035–1041.
- James JS (1997) Drug-related neuropathy: low acylcarnitine levels found. *AIDS Treat News* **265**:6–7.
- Janiri L, Martinotti G, Tonioni F, Ghelardini C, Nicolai R, Galeotti N, Mosconi L, Calvani M, Bartolini A, and Iannoni E (2009) Acetyl-L-carnitine in the management of pain during methadone withdrawal syndrome. *Clin Neuropharmacol* **32**:35–40.
- Jaswal JS, Keung W, Wang W, Ussher JR, and Lopaschuk GD (2011) Targeting fatty acid and carbohydrate oxidation—a novel therapeutic intervention in the ischemic and failing heart. *Biochim Biophys Acta* **1813**:1333–1350.
- Jeong HS, Park JS, Yang Y, Na SH, Chung YA, and Song IU (2017) Cerebral perfusion changes after acetyl-L-carnitine treatment in early Alzheimer's disease using single photon emission computed tomography. *Dement Neurocognitive Disord* **16**:26–31.
- Jernberg JN, Bowman CE, Wolfgang MJ, and Scafidi S (2017) Developmental regulation and localization of carnitine palmitoyltransferases (CPTs) in rat brain. *J Neurochem* **142**:407–419.
- Jeter CB, Hergenroeder GW, Ward 3rd NH, Moore AN, and Dash PK (2013) Human mild traumatic brain injury decreases circulating branched-chain amino acids and their metabolite levels. *J Neurotrauma* **30**:671–679.
- Jogl G, Hsiao YS, and Tong L (2005) Crystal structure of mouse carnitine octanoyltransferase and molecular determinants of substrate selectivity. *J Biol Chem* **280**:738–744.
- Jones LL, McDonald DA, and Borum PR (2010) Acylcarnitines: role in brain. *Prog Lipid Res* **49**:61–75.
- Jooste S, Erasmus E, Mienie LJ, de Wet WJ, and Gibson KM (1994) The detection of 3-methylglutaryl carnitine and a new dicarboxylic conjugate, 3-methylglutaconyl carnitine, in 3-methylglutaconic aciduria. *Clin Chim Acta* **230**:1–8.
- Joshi PR, Deschauer M, and Zierz S (2014) Carnitine palmitoyltransferase II (CPT II) deficiency: genotype-phenotype analysis of 50 patients. *J Neurol Sci* **338**:107–111.
- Joshi PR and Zierz S (2020) Muscle carnitine palmitoyltransferase II (CPT II) deficiency: a conceptual approach. *Molecules* **25**:1784.
- Jung S, Kim OY, Kim M, Song J, Lee SH, and Lee JH (2014) Age-related increase in alanine aminotransferase correlates with elevated levels of plasma amino acids, decanoylcarnitine, Lp-PLA2 activity, oxidative stress, and arterial stiffness. *J Proteome Res* **13**:3467–3475.
- Kalhan SC, Guo L, Edmison J, Dasarathy S, McCullough AJ, Hanson RW, and Milburn M (2011) Plasma metabolomic profile in nonalcoholic fatty liver disease. *Metabolism* **60**:404–413.
- Kalim S, Chish CB, Wenger J, Elmariash S, Yeh RW, Deferio JJ, Pierce K, Deik A, Gerszten RE, Thadhani R, et al. (2013) A plasma long-chain acylcarnitine predicts cardiovascular mortality in incident dialysis patients. *J Am Heart Assoc* **2**:e000542.
- Kang L, Liu Y, Shen M, Liu Y, He R, Song J, Jin Y, Li M, Zhang Y, Dong H, et al. (2020) A study on a cohort of 301 Chinese patients with isolated methylmalonic acidemia. *J Inherit Metab Dis* **43**:409–423.
- Kang M, Yoo HJ, Kim M, Kim M, and Lee JH (2018) Metabolomics identifies increases in the acylcarnitine profiles in the plasma of overweight subjects in response to mild weight loss: a randomized, controlled design study. *Lipids Health Dis* **17**:237.
- Karall D, Brunner-Krainz M, Kogelnig K, Konstantopoulou V, Maier EM, Möslinger D, Plecko B, Sperl W, Volkmar B, and Scholl-Bürgi S (2015) Clinical outcome, biochemical and therapeutic follow-up in 14 Austrian patients with long-chain 3-hydroxy acyl CoA dehydrogenase deficiency (LCHADD). *Orphanet J Rare Dis* **10**:21.
- Karlic H and Lohninger A (2004) Supplementation of L-carnitine in athletes: does it make sense? *Nutrition* **20**:709–715.
- Karwi QG, Wagg CS, Altamimi TR, Uddin GM, Ho KL, Darwesh AM, Seubert JM, and Lopaschuk GD (2020) Insulin directly stimulates mitochondrial glucose oxidation in the heart. *Cardiovasc Diabetol* **19**:207.
- Kasumov T, Adams JE, Bian F, David F, Thomas KR, Jobbins KA, Minkler PE, Hoppel CL, and Brunengraber H (2005) Probing peroxisomal beta-oxidation and the labelling of acetyl-CoA proxies with [1-(13C)]octanoate and [3-(13C)]octanoate in the perfused rat liver. *Biochem J* **389**:397–401.
- Keyfi F, Abbaszadegan MR, Sankian M, Rolfs A, Orolicki S, Pournasrollah M, Alijanpour M, and Varasteh A (2019) Mutation analysis of genes related to methylmalonic acidemia: identification of eight novel mutations. *Mol Biol Rep* **46**:271–285.
- Kennedy JA, Kiosoglou AJ, Murphy GA, Pelle MA, and Horowitz JD (2000) Effect of perhexiline and oxfenicine on myocardial function and metabolism during low-flow ischemia/reperfusion in the isolated rat heart. *J Cardiovasc Pharmacol* **36**:794–801.
- Kępka A, Ochocińska A, Chojnowska S, Borzym-Kluczyk M, Skorupa E, Knaś M, and Waszkiewicz N (2021) Potential role of L-carnitine in autism spectrum disorder. *J Clin Med* **10**:1202.
- Khalid JM, Oerton J, Besley G, Dalton N, Downing M, Green A, Henderson M, Krywawych S, Wiley V, Wilcken B, et al.; UK Collaborative Study of Newborn Screening for MCADD (2010) Relationship of octanoylcarnitine concentrations to age at sampling in unaffected newborns screened for medium-chain acyl-CoA dehydrogenase deficiency. *Clin Chem* **56**:1015–1021.
- Kido Y, Tamai I, Ohnari A, Sai Y, Kagami T, Nezu J, Nikaido H, Hashimoto N, Asano M, and Tsuji A (2001) Functional relevance of carnitine transporter OCTN2 to brain distribution of L-carnitine and acetyl-L-carnitine across the blood-brain barrier. *J Neurochem* **79**:959–969.
- Kidouchi K, Niwa T, Nohara D, Asai K, Sugiyama N, Morishita H, Kobayashi M, and Wada Y (1988) Urinary acylcarnitines in a patient with neonatal multiple acyl-CoA dehydrogenation deficiency, quantified by a carboxylic acid analyzer with a reversed-phase column. *Clin Chim Acta* **173**:263–272.
- Kiykim E, Aktuğlu Zeybek AC, Barut K, Zübarioğlu T, Cansever MS, Alsancak S, and Kasapçopur Ö (2016) Screening of free carnitine and acylcarnitine status in children with familial Mediterranean fever. *Arch Rheumatol* **31**:133–138.
- Kim DJ, Cho EJ, Yu KS, Jang IJ, Yoon JH, Park T, and Cho JY (2019) Comprehensive metabolomic search for biomarkers to differentiate early stage hepatocellular carcinoma from cirrhosis. *Cancers (Basel)* **11**:1497.
- Kim HI, Raffler J, Lu W, Lee JJ, Abbey D, Salehen D, Rabinowitz JD, Bennett MJ, Hand NJ, Brown C, et al. (2017) Fine mapping and functional analysis reveal a role of SLC22A1 in acylcarnitine transport. *Am J Hum Genet* **101**:489–502.
- Kim HS, Yu HJ, Lee J, Park HD, Kim JH, Shin HJ, Jin DK, and Lee M (2014) A Korean patient with glutaric aciduria type 1 with a novel mutation in the glutaryl CoA dehydrogenase gene. *Ann Clin Lab Sci* **44**:213–216.
- Kim M, Jung S, Lee SH, and Lee JH (2015) Association between arterial stiffness and serum L-octanoylcarnitine and lactosylceramide in overweight middle-aged subjects: 3-year follow-up study. *PLoS One* **10**:e0119519.
- Kimura C, Mizugaki M, Yamanaka H, Fujino M, and Morishima T (2004) 2,4-Dienoyl-CoA reductases: from discovery toward pathophysiological significance. *Nihon Rinsho* **62**:1577–1583.
- Kimura I, Ichimura A, Ohue-Kitano R, and Igarashi M (2020) Free fatty acid receptors in health and disease. *Physiol Rev* **100**:171–210.
- Kirby T, Walters DC, Shi X, Turgeon C, Rinaldo P, Arning E, Ashcraft P, Bottiglieri T, DiBacco M, Pearl PL, et al. (2020) Novel biomarkers and age-related metabolite correlations in plasma and dried blood spots from patients with succinic semialdehyde dehydrogenase deficiency. *Orphanet J Rare Dis* **15**:261.
- Klouwer FCC, Ferdinandusse S, van Lenthe H, Kulik W, Wanders RJA, Poll-The BT, Waterham HR, and Vaz FM (2017) Evaluation of C26:0-lipid phosphatidylcholine and C26:0-carnitine as diagnostic markers for Zellweger spectrum disorders. *J Inherit Metab Dis* **40**:875–881.
- Knabb MT, Saffitz JE, Corr PB, and Sobel BE (1986) The dependence of electrophysiological derangements on accumulation of endogenous long-chain acyl carnitine in hypoxic neonatal rat myocytes. *Circ Res* **58**:230–240.
- Knottnerus SJG, Bleeker JC, Wüst RCI, Ferdinandusse S, IJlst L, Wijburg FA, Wanders RJA, Visser G, and Houtkooper RH (2018) Disorders of mitochondrial long-chain fatty acid oxidation and the carnitine shuttle. *Rev Endocr Metab Disord* **19**:93–106.
- Knottnerus SJG, Mengarelli I, Wüst RCI, Baartscheer A, Bleeker JC, Coronel R, Ferdinandusse S, Guan K, IJlst L, Li W, et al. (2020) Electrophysiological abnormalities in VLCAD deficient hiPSC-cardiomyocytes can be improved by lowering accumulation of fatty acid oxidation intermediates. *Int J Mol Sci* **21**:2589.
- Kobayashi D, Tamai I, Sai Y, Yoshida K, Wakayama T, Kido Y, Nezu J, Iseki S, and Tsuji A (2007) Transport of carnitine and acetyl carnitine by carnitine/organic cation transporter (OCTN) 2 and OCTN3 into epididymal spermatozoa. *Reproduction* **134**:651–658.
- Kolho KL, Pessia A, Jaakkola T, de Vos WM, and Velagapudi V (2017) Faecal and serum metabolomics in paediatric inflammatory bowel disease. *J Crohn's Colitis* **11**:321–334.
- Korge P, Honda HM, and Weiss JN (2003) Effects of fatty acids in isolated mitochondria: implications for ischemic injury and cardioprotection. *Am J Physiol Heart Circ Physiol* **285**:H259–H269.
- Korman SH, Jakobs C, Darmin PS, Gutman A, van der Knaap MS, Ben-Neriah Z, Dweikat I, Wexler ID and Salomons GS (2007) Glutaric aciduria type 1: clinical, biochemical and molecular findings in patients from Israel. *Eur J Paediatr Neurol* **11**:81–89.

- Koves TR, Ussher JR, Noland RC, Slentz D, Mosedale M, Ilkayeva O, Bain J, Stevens R, Dyck JR, Newgard CB, et al. (2008) Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance. *Cell Metab* 7:45–56.
- Kriisa K, Leppik L, Balõtsõv R, Ottas A, Soomets U, Koido K, Volke V, Innos J, Haring L, Vasar E, et al. (2017) Profiling of acylcarnitines in first episode psychosis before and after antipsychotic treatment. *J Proteome Res* 16:3558–3566.
- Kukhareenko A, Brito A, Kozhevnikova MV, Moskaleva N, Markin PA, Bochkareva N, Korobkova EO, Belenkov YN, Privalova EV, Larocva EV, et al. (2020) Relationship between the plasma acylcarnitine profile and cardiometabolic risk factors in adults diagnosed with cardiovascular diseases. *Clin Chim Acta* 507:250–256.
- Kuratsune H, Yamaguti K, Lindh G, Evengard B, Takahashi M, Machii T, Matsumura K, Takaishi J, Kawata S, Långström B, et al. (1998) Low levels of serum acylcarnitine in chronic fatigue syndrome and chronic hepatitis type C, but not seen in other diseases. *Int J Mol Med* 2:51–56.
- Ladep NG, Dona AC, Lewis MR, Crossey MM, Lemoine M, Okeke E, Shimakaya Y, Duguru M, Njai HF, Fye HK, et al. (2014) Discovery and validation of urinary metabolites for the diagnosis of hepatocellular carcinoma in West Africans. *Hepatology* 60:1291–1301.
- Laforet P, Acquaviva-Bourdain C, Rigal O, Brivet M, Penisson-Besnier I, Chabrol B, Chaigne D, Boespflug-Tanguy O, Laroche C, Bedat-Millet AL, et al. (2009) Diagnostic assessment and long-term follow-up of 13 patients with very long-chain acyl-coenzyme A dehydrogenase (VLCAD) deficiency. *Neuromuscul Disord* 19:324–329.
- Lagioia R, Scrutinio D, Mangini SG, Ricci A, Mastropasqua F, Valentini G, Ramunni G, Totaro Fila G, and Rizzon P (1992) Propionyl-L-carnitine: a new compound in the metabolic approach to the treatment of effort angina. *Int J Cardiol* 34:167–172.
- Lamers JM, Stinis HT, Montfoort A, and Hülsman WC (1984) The effect of lipid intermediates on Ca²⁺ and Na⁺ permeability and (Na⁺ + K⁺)-ATPase of cardiac sarcolemma. A possible role in myocardial ischemia. *Biochim Biophys Acta* 774:127–137.
- Lampret BR, Murko S, Debeljak M, Tansek MZ, Fister P, and Battelino T (2015) A case report of short-chain acyl-CoA dehydrogenase deficiency (SCADD). *Biochem Med (Zagreb)* 25:279–284.
- Langley RJ, Tsalik EL, van Velkinburgh JC, Glickman SW, Rice BJ, Wang C, Chen B, Carin L, Suarez A, Mohnney RP, et al. (2013) An integrated clinico-metabolomic model improves prediction of death in sepsis. *Sci Transl Med* 5:195ra95.
- Lango R, Smoleński RT, Rogowski J, Siebert J, Wujtewicz M, Słomińska EM, Lysiak-Szydłowska W, and Yacoub MH (2005) Propionyl-L-carnitine improves hemodynamics and metabolic markers of cardiac perfusion during coronary surgery in diabetic patients. *Cardiovasc Drugs Ther* 19:267–275.
- Le Borgne F, Ben Mohamed A, Logerot M, Garnier E, and Demarquoy J (2011) Changes in carnitine octanoyltransferase activity induce alteration in fatty acid metabolism. *Biochem Biophys Res Commun* 409:699–704.
- Ledinek AH, Sajko MC, and Rot U (2013) Evaluating the effects of amantadin, modafinil and acetyl-L-carnitine on fatigue in multiple sclerosis—result of a pilot randomized, blind study. *Clin Neurol Neurosurg* 115 (Suppl 1):S86–S89.
- Lee CS, Chien YH, Peng SF, Cheng PW, Chang LM, Huang AC, Hwu WL, and Lee NC (2013) Promising outcomes in glutaric aciduria type I patients detected by newborn screening. *Metab Brain Dis* 28:61–67.
- Lee J, Choi J, Scafidi S, and Wolfgang MJ (2016) Hepatic fatty acid oxidation restrains systemic catabolism during starvation. *Cell Rep* 16:201–212.
- Leombruni P, Miniotti M, Colonna F, Sica C, Castelli L, Bruzzone M, Parisi S, Fusaro E, Sarzi-Puttini P, Atzeni F, et al. (2015) A randomised controlled trial comparing duloxetine and acetyl L-carnitine in fibromyalgic patients: preliminary data. *Clin Exp Rheumatol* 33 (1 Suppl 88):S82–S85.
- Lepori V, Mühlhause F, Sewell AC, Jagannathan V, Janzen N, Rosati M, Alves de Sousa FMM, Tschopp A, Schüpbach G, Matiassek K, et al. (2018) A nonsense variant in the ACADVL gene in German hunting terriers with exercise induced metabolic myopathy. *G3 (Bethesda)* 8:1545–1554.
- Leruez S, Bresson T, Chao de la Barca JM, Marill A, de Saint Martin G, Buisset A, Muller J, Tessier L, Gadras C, VERNY C, et al. (2018) A plasma metabolomic signature of the exfoliation syndrome involves amino acids, acylcarnitines, and polyamines. *Invest Ophthalmol Vis Sci* 59:1025–1032.
- Li LO, Ellis JM, Paich HA, Wang S, Gong N, Altshuler G, Thresher RJ, Koves TR, Watkins SM, Muoio DM, et al. (2009) Liver-specific loss of long chain acyl-CoA synthetase-1 decreases triacylglycerol synthesis and beta-oxidation and alters phospholipid fatty acid composition. *J Biol Chem* 284:27816–27826.
- Li S, Chen X, Li Q, Du J, Liu Z, Peng Y, Xu M, Li Q, Lei M, Wang C, et al. (2016) Effects of acetyl-L-carnitine and methylcobalamin for diabetic peripheral neuropathy: a multicenter, randomized, double-blind, controlled trial. *J Diabetes Investig* 7:777–785.
- Li S, Gao D, and Jiang Y (2019) Function, detection and alteration of acylcarnitine metabolism in hepatocellular carcinoma. *Metabolites* 9:36.
- Liao Y and Hung MC (2010) Physiological regulation of Akt activity and stability. *Am J Transl Res* 2:19–42.
- Libert DM, Nowacki AS, and Natowicz MR (2018) Metabolomic analysis of obesity, metabolic syndrome, and type 2 diabetes: amino acid and acylcarnitine levels change along a spectrum of metabolic wellness. *PeerJ* 6:e5410.
- Liepinsh E, Makrečka-Kuka M, Kuka J, Makarova E, Vilskersts R, Cirule H, Sevostjanovs E, Grinberga S, Pugovics O, and Dambrova M (2014) The heart is better protected against myocardial infarction in the fed state compared to the fasted state. *Metabolism* 63:127–136.
- Liepinsh E, Makrečka-Kuka M, Kuka J, Vilskersts R, Makarova E, Cirule H, Loza E, Lola D, Grinberga S, Pugovics O, et al. (2015) Inhibition of L-carnitine biosynthesis and transport by methyl- γ -butyrobetaine decreases fatty acid oxidation and protects against myocardial infarction. *Br J Pharmacol* 172:1319–1332.
- Liepinsh E, Makrečka-Kuka M, Makarova E, Volska K, Vilks K, Sevostjanovs E, Antone U, Kuka J, Vilskersts R, Lola D, et al. (2017) Acute and long-term administration of palmitoylecarnitine induces muscle-specific insulin resistance in mice. *Biofactors* 43:718–730.
- Liepinsh E, Makrečka-Kuka M, Volska K, Kuka J, Makarova E, Antone U, Sevostjanovs E, Vilskersts R, Strods A, Tars K, et al. (2016) Long-chain acylcarnitines determine ischaemia/reperfusion-induced damage in heart mitochondria. *Biochem J* 473:1191–1202.
- Liepinsh E, Skapare E, Kuka J, Makrečka M, Cirule H, Vavers E, Sevostjanovs E, Grinberga S, Pugovics O, and Dambrova M (2013) Activated peroxisomal fatty acid metabolism improves cardiac recovery in ischemia-reperfusion. *Naunyn-Schmiedeberg's Arch Pharmacol* 386:541–550.
- Lin Y, Chen D, Peng W, Wang K, Lin W, Zhuang J, Zheng Z, Li M, and Fu Q (2020) Newborn screening for isovaleric acidemia in Quanzhou, China. *Clin Chim Acta* 509:25–29.
- Lino A, Boccia MM, Rusconi AC, Bellomonte L, and Cocuocchia B (1992) Psycho-functional changes in attention and learning under the action of L-acetylcarnitine in 17 young subjects. A pilot study of its use in mental deterioration. *Clin Ter* 140:569–573.
- Liu E, Goldhaber JI, and Weiss JN (1991) Effects of lysophosphatidylcholine on electrophysiological properties and excitation-contraction coupling in isolated guinea pig ventricular myocytes. *J Clin Invest* 88:1819–1832.
- Liu H, Tan D, Han L, Ye J, Qiu W, Gu X, and Zhang H (2016) A new case of malonyl-CoA decarboxylase deficiency with mild clinical features. *Am J Med Genet A* 170A:1347–1351.
- Loffredo L, Carnevale R, Cangemi R, Angelico F, Augelletti T, Di Santo S, Calabrese CM, Della Volpe L, Pignatelli P, Perri L, et al. (2013) NOX2 up-regulation is associated with artery dysfunction in patients with peripheral artery disease. *Int J Cardiol* 165:184–192.
- Loffredo L, Pignatelli P, Cangemi R, Andreozzi P, Panico MA, Meloni V, and Violi F (2006) Imbalance between nitric oxide generation and oxidative stress in patients with peripheral arterial disease: effect of an antioxidant treatment. *J Vasc Surg* 44:525–530.
- Longo N, Frigeni M, and Pasquali M (2016) Carnitine transport and fatty acid oxidation. *Biochim Biophys Acta* 1863:2422–2435.
- Lopaschuk GD, Wall SR, Olley PM, and Davies NJ (1988) Etomoxir, a carnitine palmitoyltransferase I inhibitor, protects hearts from fatty acid-induced ischemic injury independent of changes in long chain acylcarnitine. *Circ Res* 63:1036–1043.
- Lopes-Marques M, Delgado IL, Ruivo R, Torres Y, Sainath SB, Rocha E, Cunha I, Santos MM, and Castro LF (2015) The origin and diversity of Cpt1 genes in vertebrate species. *PLoS One* 10:e0138447.
- López M, Lelliott CJ, Tovar S, Kimber W, Gallego R, Virtue S, Blount M, Vázquez MJ, Finer N, Powles TJ, et al. (2006) Tamoxifen-induced anorexia is associated with fatty acid synthase inhibition in the ventromedial nucleus of the hypothalamus and accumulation of malonyl-CoA. *Diabetes* 55:1327–1336.
- Lu Y, Li N, Gao L, Xu YJ, Huang C, Yu K, Ling Q, Cheng Q, Chen S, Zhu M, et al. (2016) Acetylcarnitine is a candidate diagnostic and prognostic biomarker of hepatocellular carcinoma. *Cancer Res* 76:2912–2920.
- Lucas SM, Rothwell NJ, and Gibson RM (2006) The role of inflammation in CNS injury and disease. *Br J Pharmacol* 147 (Suppl 1):S232–S240.
- Luo T, Li J, Li L, Yang B, Liu C, Zheng Q, Jin B, Chen Z, Li K, Zhang X, et al. (2013) A study on the efficacy and safety assessment of propionyl-L-carnitine tablets in treatment of intermittent claudication. *Thromb Res* 132:427–432.
- Luong TV, Pedersen MGB, Kjærulf MLBG, Madsen S, Lauritsen KM, Tolbod LP, Søndergaard E, and Gormsen LC (2021) Ischemic heart failure mortality is not predicted by cardiac insulin resistance but by diabetes per se and coronary flow reserve: a retrospective dynamic cardiac ¹⁸F-FDG PET study. *Metabolism* 123:154862.
- Ma YY, Song JQ, Wu TF, Liu YP, Xiao JX, Jiang YW and Yang YL (2011) Leucodystrophy induced by late onset 3-hydroxy-3-methylglutaric aciduria. *Zhongguo Dang Dai Er Ke Za Zhi* 13:392–395.
- Madsen PP, Kibaek M, Roca X, Sachidanandam R, Krainer AR, Christensen E, Steiner RD, Gibson KM, Corydon TJ, Knudsen I, et al. (2006) Short/branched-chain acyl-CoA dehydrogenase deficiency due to an IVS3 + 3A>G mutation that causes exon skipping. *Hum Genet* 118:680–690.
- Maeda Y, Ito T, Ohmi H, Yokoi K, Nakajima Y, Ueta A, Kurono Y, Togari H, and Sugiyama N (2008) Determination of 3-hydroxyisovalerylcarnitine and other acylcarnitine levels using liquid chromatography-tandem mass spectrometry in serum and urine of a patient with multiple carboxylase deficiency. *J Chromatogr B Analyt Technol Biomed Life Sci* 870:154–159.
- Maeda Y, Ito T, Suzuki A, Kurono Y, Ueta A, Yokoi K, Sumi S, Togari H, and Sugiyama N (2007) Simultaneous quantification of acylcarnitine isomers containing dicarboxylic acylcarnitines in human serum and urine by high-performance liquid chromatography/electrospray ionization tandem mass spectrometry. *Rapid Commun Mass Spectrom* 21:799–806.
- Maestri A, De Pasquale Ceratti A, Cundari S, Zanna C, Cortesi E, and Crinò L (2005) A pilot study on the effect of acetyl-L-carnitine in paclitaxel- and cisplatin-induced peripheral neuropathy. *Tumori* 91:135–138.
- Mai M, Tönjes A, Kovacs P, Stumvoll M, Fiedler GM, and Leichle AB (2013) Serum levels of acylcarnitines are altered in prediabetic conditions. *PLoS One* 8:e82459.
- Makarova E, Makrečka-Kuka M, Vilks K, Volska K, Sevostjanovs E, Grinberga S, Zarkova-Malkova O, Dambrova M, and Liepinsh E (2019) Decreases in circulating concentrations of long-chain acylcarnitines and free fatty acids during the glucose tolerance test represent tissue-specific insulin sensitivity. *Front Endocrinol (Lausanne)* 10:870.
- Makrečka M, Kuka J, Volska K, Antone U, Sevostjanovs E, Cirule H, Grinberga S, Pugovics O, Dambrova M, and Liepinsh E (2014) Long-chain acylcarnitine content determines the pattern of energy metabolism in cardiac mitochondria. *Mol Cell Biochem* 395:1–10.

- Makrecka-Kuka M, Korzh S, Videja M, Vilks K, Cirule H, Kuka J, Dambrova M, and Liepinsh E (2020a) Empagliflozin protects cardiac mitochondrial fatty acid metabolism in a mouse model of diet-induced lipid overload. *Cardiovasc Drugs Ther* **34**:791–797.
- Makrecka-Kuka M, Korzh S, Videja M, Vilskersts R, Sevostjanovs E, Zharkova-Malkova O, Arsenyan P, Kuka J, Dambrova M, and Liepinsh E (2020b) Inhibition of CPT2 exacerbates cardiac dysfunction and inflammation in experimental endotoxaemia. *J Cell Mol Med* **24**:11903–11911.
- Makrecka-Kuka M, Liepinsh E, Murray AJ, Lemieux H, Dambrova M, Tepp K, Puurand M, Käämbre T, Han WH, de Goede P, et al. (2020c) Altered mitochondrial metabolism in the insulin-resistant heart. *Acta Physiol (Oxf)* **228**:e13430.
- Makrecka-Kuka M, Sevostjanovs E, Vilks K, Volska K, Antone U, Kuka J, Makarova E, Pugovics O, Dambrova M, and Liepinsh E (2017) Plasma acylcarnitine concentrations reflect the acylcarnitine profile in cardiac tissues. *Sci Rep* **7**:17528.
- Malaguarnera G, Pennisi M, Gagliano C, Vacante M, Malaguarnera M, Salomone S, Drago F, Bertino G, Caraci F, Nunnari G, et al. (2014) Acetyl-L-carnitine supplementation during HCV therapy with pegylated interferon- α 2b plus ribavirin: effect on work performance; a randomized clinical trial. *Hepat Mon* **14**:e11608.
- Malaguarnera M, Bella R, Vacante M, Giordano M, Malaguarnera G, Gargante MP, Motta M, Mistretta A, Rampello L, and Pennisi G (2011a) Acetyl-L-carnitine reduces depression and improves quality of life in patients with minimal hepatic encephalopathy. *Scand J Gastroenterol* **46**:750–759.
- Malaguarnera M, Gargante MP, Cristaldi E, Colonna V, Messano M, Koverech A, Neri S, Vacante M, Cammalleri L, and Motta M (2008) Acetyl-L-carnitine (ALC) treatment in elderly patients with fatigue. *Arch Gerontol Geriatr* **46**:181–190.
- Malaguarnera M, Vacante M, Bertino G, Neri S, Gargante MP, Motta M, Lupo L, Chisari G, Bruno CM, Pennisi G and Bella R (2011b) The supplementation of acetyl-L-carnitine decreases fatigue and increases quality of life in patients with hepatitis C treated with pegylated interferon-alpha 2b plus ribavirin. *J Interferon Cytokine Res* **31**:653–659.
- Malaguarnera M, Vacante M, Giordano M, Pennisi G, Bella R, Rampello L, Malaguarnera M, Li Volti G, and Galvano F (2011c) Oral acetyl-L-carnitine therapy reduces fatigue in overt hepatic encephalopathy: a randomized, double-blind, placebo-controlled study. *Am J Clin Nutr* **93**:799–808.
- Malandrino MI, Fucho R, Weber M, Calderon-Dominguez M, Mir JF, Valcarcel L, Escoté X, Gómez-Serrano M, Peral B, Salvadó L, et al. (2015) Enhanced fatty acid oxidation in adipocytes and macrophages reduces lipid-induced triglyceride accumulation and inflammation. *Am J Physiol Endocrinol Metab* **308**:E756–E769.
- Maldonado C, Vázquez M, and Fagioliño P (2020) Potential therapeutic role of carnitine and acetylcarnitine in neurological disorders. *Curr Pharm Des* **26**:1277–1285.
- Mancini M, Rengo F, Lingetti M, Sorrentino GP, and Nolfi G (1992) Controlled study on the therapeutic efficacy of propionyl-L-carnitine in patients with congestive heart failure. *Arzneimittelforschung* **42**:1101–1104.
- Markwell MA, McGroarty EJ, Bieber LL, and Tolbert NE (1973) The subcellular distribution of carnitine acyltransferases in mammalian liver and kidney. A new peroxisomal enzyme. *J Biol Chem* **248**:3426–3432.
- Marsden D, Bedrosian CL, and Vockley J (2021) Impact of newborn screening on the reported incidence and clinical outcomes associated with medium- and long-chain fatty acid oxidation disorders. *Genet Med* **23**:816–829.
- Martí-Carvajal AJ, Glud C, Arevalo-Rodríguez I, and Martí-Amarista CE (2019) Acetyl-L-carnitine for patients with hepatic encephalopathy. *Cochrane Database Syst Rev* **1**:CD011451.
- Martinotti G, Andreoli S, Reina D, Di Nicola M, Ortolani I, Tedeschi D, Fanella F, Pozzi G, Iannoni E, D'Idio S, et al. (2011) Acetyl-L-carnitine in the treatment of anhedonia, melancholic and negative symptoms in alcohol dependent subjects. *Prog Neuropsychopharmacol Biol Psychiatry* **35**:953–958.
- Matsui S, Sugita T, Matoba M, Murakami E, Takekoshi N, Shinka T, and Matsumoto I (1994) Urinary carnitine excretion in patients with heart failure. *Clin Cardiol* **17**:301–305.
- Matsumoto M, Matsumoto I, Shinka T, Kuhara T, Imamura H, Shimao S, and Okada T (1990) Organic acid and acylcarnitine profiles of glutaric aciduria type I. *Acta Paediatr Jpn* **32**:76–82.
- Matsushima S and Sadoshima J (2015) The role of sirtuins in cardiac disease. *Am J Physiol Heart Circ Physiol* **309**:H1375–H1389.
- McCann MR, George De la Rosa MV, Rosania GR, and Stringer KA (2021) L-carnitine and acylcarnitines: mitochondrial biomarkers for precision medicine. *Metabolites* **11**:51.
- McCoin CS, Gillingham MB, Knotts TA, Vockley J, Ono-Moore KD, Blackburn ML, Norman JE, and Adams SH (2019) Blood cytokine patterns suggest a modest inflammation phenotype in subjects with long-chain fatty acid oxidation disorders. *Physiol Rep* **7**:e14037.
- McCoin CS, Knotts TA, and Adams SH (2015a) Acylcarnitines—old actors auditioning for new roles in metabolic physiology. *Nat Rev Endocrinol* **11**:617–625.
- McCoin CS, Knotts TA, Ono-Moore KD, Oort PJ, and Adams SH (2015b) Long-chain acylcarnitines activate cell stress and myokine release in C2C12 myotubes: calcium-dependent and -independent effects. *Am J Physiol Endocrinol Metab* **308**:E990–E1000.
- McGarry JD and Brown NF (1997) The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis. *Eur J Biochem* **244**:1–14.
- McGarry JD, Mannaerts GP, and Foster DW (1977) A possible role for malonyl-CoA in the regulation of hepatic fatty acid oxidation and ketogenesis. *J Clin Invest* **60**:265–270.
- McGarry JD, Mills SE, Long CS, and Foster DW (1983) Observations on the affinity for carnitine, and malonyl-CoA sensitivity, of carnitine palmitoyltransferase I in animal and human tissues. Demonstration of the presence of malonyl-CoA in non-hepatic tissues of the rat. *Biochem J* **214**:21–28.
- McHugh D, Cameron CA, Abdenur JE, Abdulrahman M, Adair O, Al Nuaimi SA, Ahlman H, Allen JJ, Antonozzi I, Archer S, et al. (2011) Clinical validation of cutoff target ranges in newborn screening of metabolic disorders by tandem mass spectrometry: a worldwide collaborative project. *Genet Med* **13**:230–254.
- Meister R, von Wolff A, Mohr H, Härter M, Nestoriciu Y, Hölzel L, and Kriston L (2016) Comparative safety of pharmacologic treatments for persistent depressive disorder: a systematic review and network meta-analysis. *PLoS One* **11**:e0153380.
- Memeo A and Loiero M (2008) Thioctic acid and acetyl-L-carnitine in the treatment of sciatic pain caused by a herniated disc: a randomized, double-blind, comparative study. *Clin Drug Investig* **28**:495–500.
- Mészáros J and Pappano AJ (1990) Electrophysiological effects of L-palmitoylcarnitine in single ventricular myocytes. *Am J Physiol* **258**:H931–H938.
- Mey JT, Hari A, Axelrod CL, Fealy CE, Erickson ML, Kirwan JP, Dweik RA, and Heresi GA (2020) Lipids and ketones dominate metabolism at the expense of glucose control in pulmonary arterial hypertension: a hyperglycaemic clamp and metabolomics study. *Eur Respir J* **55**:1901700.
- Mihalik SJ, Goodpaster BH, Kelley DE, Chace DH, Vockley J, Toledo FG, and DeLany JP (2010) Increased levels of plasma acylcarnitines in obesity and type 2 diabetes and identification of a marker of glucolipotoxicity. *Obesity (Silver Spring)* **18**:1695–1700.
- Miinalainen IJ, Schmitz W, Huotari A, Autio KJ, Soiminen R, Ver Loren van Themaat E, Baes M, Herzig KH, Conzelmann E, and Hiltunen JK (2009) Mitochondrial 2,4-dienoyl-CoA reductase deficiency in mice results in severe hypoglycemia with stress intolerance and unimpaired ketogenesis. *PLoS Genet* **5**:e1000543.
- Mikhailova TL, Sishkova E, Poniewierka E, Zhidkov KP, Bakulin IG, Kupcinkas L, Lesniakowski K, Grinevich VB, Malecka-Panas E, Ardizzone S, et al. (2011) Randomised clinical trial: the efficacy and safety of propionyl-L-carnitine therapy in patients with ulcerative colitis receiving stable oral treatment. *Aliment Pharmacol Ther* **34**:1088–1097.
- Millington DS, Roe CR, and Maltby DA (1987) Characterization of new diagnostic acylcarnitines in patients with beta-ketothiolase deficiency and glutaric aciduria type I using mass spectrometry. *Biomed Environ Mass Spectrom* **14**:711–716.
- Minkler PE and Hoppel CL (1993) Quantification of free carnitine, individual short- and medium-chain acylcarnitines, and total carnitine in plasma by high-performance liquid chromatography. *Anal Biochem* **212**:510–518.
- Minkler PE, Kerner J, North KN, and Hoppel CL (2005) Quantitation of long-chain acylcarnitines by HPLC/fluorescence detection: application to plasma and tissue specimens from patients with carnitine palmitoyltransferase-II deficiency. *Clin Chim Acta* **352**:81–92.
- Miyaaki H, Kobayashi H, Miuma S, Fukusima M, Sasaki R, Haraguchi M, and Nakao K (2020) Blood carnitine profiling on tandem mass spectrometry in liver cirrhotic patients. *BMC Gastroenterol* **20**:41.
- Miyazawa S, Ozasa H, Osumi T, and Hashimoto T (1983) Purification and properties of carnitine octanoyltransferase and carnitine palmitoyltransferase from rat liver. *J Biochem* **94**:529–542.
- Mohamed S, Hamad MH, Hassan HH, and Salih MA (2015) Glutaric aciduria type I as a cause of dystonic cerebral palsy. *Saudi Med J* **36**:1354–1357.
- Molsberry S, Bjornevik K, Hughes KC, Zhang ZJ, Jeanfavre S, Clish C, Healy B, Schwarzschild M, and Ascherio A (2020) Plasma metabolomic markers of insulin resistance and diabetes and rate of incident Parkinson's disease. *J Parkinsons Dis* **10**:1011–1021.
- Monostori P, Klinke K, Richter S, Baráth Á, Fingerhut R, Baumgartner MR, Kölker S, Hoffmann GF, Gramer G, and Okun JG (2017) Simultaneous determination of 3-hydroxypropionic acid, methylmalonic acid and methylcitric acid in dried blood spots: Second-tier LC-MS/MS assay for newborn screening of propionic acidemia, methylmalonic acidemias and combined remethylation disorders. *PLoS One* **12**:e0184897.
- Morano S, Mandosi E, Fallarino M, Gatti A, Tiberti C, Sensi M, Gandini L, Buchetti B, Lenti L, Jannini EA, et al. (2007) Antioxidant treatment associated with sildenafil reduces monocyte activation and markers of endothelial damage in patients with diabetic erectile dysfunction: a double-blind, placebo-controlled study. *Eur Urol* **52**:1768–1774.
- Morillas M, Gómez-Puertas P, Rubi B, Clotet J, Ariño J, Valencia A, Hegardt FG, Serra D, and Asins G (2002) Structural model of a malonyl-CoA-binding site of carnitine octanoyltransferase and carnitine palmitoyltransferase I: mutational analysis of a malonyl-CoA affinity domain. *J Biol Chem* **277**:11473–11480.
- Munday MR (2002) Regulation of mammalian acetyl-CoA carboxylase. *Biochem Soc Trans* **30**:1059–1064.
- Murthy MS and Pande SV (1984) Mechanism of carnitine acylcarnitine translocase-catalyzed import of acylcarnitines into mitochondria. *J Biol Chem* **259**:9082–9089.
- Mutomba MC, Yuan H, Konyavko M, Adachi S, Yokoyama CB, Esser V, McGarry JD, Babior BM, and Gottlieb RA (2000) Regulation of the activity of caspases by L-carnitine and palmitoylcarnitine. *FEBS Lett* **478**:19–25.
- Nakanishi T and Shimizu A (1993) Identification of 3-hydroxyisovalerylcarnitine in the urine of a patient with multiple carboxylase deficiency. *Ann Clin Biochem* **30**:318–320.
- Nalecz KA, Miecz D, Berezowski V, and Cecchelli R (2004) Carnitine: transport and physiological functions in the brain. *Mol Aspects Med* **25**:551–567.
- Namgaladze D and Brüne B (2014) Fatty acid oxidation is dispensable for human macrophage IL-4-induced polarization. *Biochim Biophys Acta* **1841**:1329–1335.
- Nasca C, Bigio B, Lee FS, Young SP, Kautz MM, Albright A, Beasley J, Millington DS, Mathé AA, Kocsis JH, et al. (2018) Acetyl-l-carnitine deficiency in patients with major depressive disorder. *Proc Natl Acad Sci USA* **115**:8627–8632.
- Neely JR and Feuvray D (1981) Metabolic products and myocardial ischemia. *Am J Pathol* **102**:282–291.
- Neess D, Bek S, Engelsby H, Gallego SF, and Færgeman NJ (2015) Long-chain acyl-CoA esters in metabolism and signaling: role of acyl-CoA binding proteins. *Prog Lipid Res* **59**:1–25.

- Neinast M, Murashige D, and Arany Z (2019) Branched chain amino acids. *Annu Rev Physiol* **81**:139–164.
- Ngu LH, Zabadah MY, Shanti B, and Teh SH (2008) Biochemical profiling in two siblings with mitochondrial 2-methylacetoacetyl-CoA thiolase deficiency. *Malays J Pathol* **30**:109–114.
- Nguyen PJ, Ripa S, Rossez Y, and Perrin Y (2016) Acylcarnitines participate in developmental processes associated to lipid metabolism in plants. *Planta* **243**:1011–1022.
- Ni Y, Xie G, and Jia W (2014) Metabonomics of human colorectal cancer: new approaches for early diagnosis and biomarker discovery. *J Proteome Res* **13**:3857–3870.
- Nicholas DA, Proctor EA, Agrawal M, Belkina AC, Van Nostrand SC, Panneerseelan-Bharath L, Jones 4th AR, Raval F, Ip BC, Zhu M, et al. (2019) Fatty acid metabolites combine with reduced β oxidation to activate Th17 inflammation in human type 2 diabetes. *Cell Metab* **30**:447–461.e5.
- Nizioł J, Bonifay V, Ossoliński K, Ossolińska T, Ossolińska A, Sunner J, Beech I, Arendowski A, and Ruman T (2018) Metabolomic study of human tissue and urine in clear cell renal carcinoma by LC-HRMS and PLS-DA. *Anal Bioanal Chem* **410**:3859–3869.
- Noland RC, Koves TR, Seiler SE, Lum H, Lust RM, Ilkayeva O, Stevens RD, Hegardt FG, and Muoio DM (2009) Carnitine insufficiency caused by aging and overnutrition compromises mitochondrial performance and metabolic control. *J Biol Chem* **284**:22840–22852.
- Nomura M, Liu J, Rovira II, Gonzalez-Hurtado E, Lee J, Wolfgang MJ, and Finkel T (2016) Fatty acid oxidation in macrophage polarization. *Nat Immunol* **17**:216–217.
- Numata-Uematsu Y, Sakamoto O, Kakisaka Y, Okubo Y, Oikawa Y, Arai-Ichinoi N, Kure S, and Uematsu M (2017) Reversible brain atrophy in glutaric aciduria type 1. *Brain Dev* **39**:532–535.
- Obici S, Feng Z, Arduini A, Conti R, and Rossetti L (2003) Inhibition of hypothalamic carnitine palmitoyltransferase-1 decreases food intake and glucose production. *Nat Med* **9**:756–761.
- Ohtani Y, Ohyanagi K, Yamamoto S, and Matsuda I (1988) Secondary carnitine deficiency in hyperammonemic attacks of ornithine transcarbamylase deficiency. *J Pediatr* **112**:409–414.
- Onofrij M, Ciccioppo F, Varanese S, di Muzio A, Calvani M, Chiechio S, Osio M, and Thomas A (2013) Acetyl-L-carnitine: from a biological curiosity to a drug for the peripheral nervous system and beyond. *Expert Rev Neurother* **13**:925–936.
- Onofrij M, Fulgente T, Melchionda D, Marchionni A, Tomasello F, Salpietro FM, Alafaci C, De Sanctis E, Pennisi G, Bella R, et al. (1995) L-acetylcarnitine as a new therapeutic approach for peripheral neuropathies with pain. *Int J Clin Pharmacol Res* **15**:9–15.
- Osio M, Muscia F, Zampini L, Nascimbene C, Mailland E, Cargnel A, and Mariani C (2006) Acetyl-L-carnitine in the treatment of painful antiretroviral toxic neuropathy in human immunodeficiency virus patients: an open label study. *J Peripher Nerv Syst* **11**:72–76.
- Ottas A, Fishman D, Okas TL, Kingo K, and Soomets U (2017) The metabolic analysis of psoriasis identifies the associated metabolites while providing computational models for the monitoring of the disease. *Arch Dermatol Res* **309**:519–528.
- Pajares S, López RM, Gort L, Argudo-Ramírez A, Marín JL, González de Aledo-Castillo JM, García-Villoria J, Arranz JA, Del Toro M, Tort F, et al. (2020) An incidental finding in newborn screening leading to the diagnosis of a patient with *ECHS1* mutations. *Mol Genet Metab Rep* **22**:100553.
- Pak VM, Dai F, Keenan BT, Gooneratne NS, and Pack AI (2018) Lower plasma choline levels are associated with sleepiness symptoms. *Sleep Med* **44**:89–96.
- Pallares-Méndez R, Aguilar-Salinas CA, Cruz-Bautista I, and Del Bosque-Plata L (2016) Metabonomics in diabetes, a review. *Ann Med* **48**:89–102.
- Palmieri F (1994) Mitochondrial carrier proteins. *FEBS Lett* **346**:48–54.
- Palomo-Guerrero M, Fadó R, Casas M, Pérez-Montero M, Baena M, Helmer PO, Domínguez JL, Roig A, Serra D, Hayden H, et al. (2019) Sensing of nutrients by CPT1C regulates late endosome/lysosome anterograde transport and axon growth. *eLife* **8**:e51063.
- Park HD, Kim SR, Ki CS, Lee SY, Chang YS, Jin DK, and Park WS (2009) Two novel HADHB gene mutations in a Korean patient with mitochondrial trifunctional protein deficiency. *Ann Clin Lab Sci* **39**:399–404.
- Park J, Shin Y, Kim TH, Kim DH, and Lee A (2019) Plasma metabolites as possible biomarkers for diagnosis of breast cancer. *PLoS One* **14**:e0225129.
- Park TY, Jeong HG, Park JJ, Chae JY, Kim JW, Oh MM, Park HS, Kim JJ, and Moon G (2016) The efficacy of medical treatment of Peyronie's disease: potassium para-aminobenzoate monotherapy vs. combination therapy with tamoxifen, L-carnitine, and phosphodiesterase type 5 inhibitor. *World J Mens Health* **34**:40–46.
- Parnetti L, Abate G, Bartorelli L, Cucinotta D, Cuzzupoli M, Maggioni M, Villardita C, and Senin U (1993) Multicentre study of L-alpha-glycerylphosphorylcholine vs ST200 among patients with probable senile dementia of Alzheimer's type. *Drugs Aging* **3**:159–164.
- Parvanova A, Trillini M, Podestà MA, Iliev IP, Aparicio C, Perna A, Peraro F, Rubis N, Gaspari F, Cannata A, et al. (2018) Blood pressure and metabolic effects of acetyl-L-carnitine in type 2 diabetes: DIABASI randomized controlled trial. *J Endocr Soc* **2**:420–436.
- Passeri M, Cucinotta D, Bonati PA, Iannuccelli M, Parnetti L, and Senin U (1990) Acetyl-L-carnitine in the treatment of mildly demented elderly patients. *Int J Clin Pharmacol Res* **10**:75–79.
- Passeri M, Iannuccelli M, Ciotti G, Bonati PA, Nolfé G, and Cucinotta D (1988) Mental impairment in aging: selection of patients, methods of evaluation and therapeutic possibilities of acetyl-L-carnitine. *Int J Clin Pharmacol Res* **8**:367–376.
- Paternostro G, Camici PG, Lammerstma AA, Marinho N, Baliga RR, Kooner JS, Radda GK, and Ferrannini E (1996) Cardiac and skeletal muscle insulin resistance in patients with coronary heart disease. A study with positron emission tomography. *J Clin Invest* **98**:2094–2099.
- Paulson DJ, Ward KM, and Shug AL (1984) Malonyl CoA inhibition of carnitine palmitoyltransferase in rat heart mitochondria. *FEBS Lett* **176**:381–384.
- Pedersen CB, Bischoff C, Christensen E, Simonsen H, Lund AM, Young SP, Koerber DD, Millington DS, Roe CR, Roe DS, et al. (2006) Variations in IBD (ACAD8) in children with elevated C4-carnitine detected by tandem mass spectrometry newborn screening. *Pediatr Res* **60**:315–320.
- Peng M, Liu L, Jiang M, Liang C, Zhao X, Cai Y, Sheng H, Ou Z, and Luo H (2013) Measurement of free carnitine and acylcarnitines in plasma by HILIC-ESI-MS/MS without derivatization. *J Chromatogr B Analyt Technol Biomed Life Sci* **932**:12–18.
- Pennisi M, Lanza G, Cantone M, D'Amico E, Fiscaro F, Puglisi V, Vinciguerra L, Bella R, Vicari E, and Malaguarnera G (2020) Acetyl-L-carnitine in dementia and other cognitive disorders: a critical update. *Nutrients* **12**:1389.
- Pereira PTVT, Reis AD, Diniz RR, Lima FA, Leite RD, da Silva MCP, Guerra RNM, de Moraes Vieira EB, and Garcia JBS (2018) Dietary supplements and fatigue in patients with breast cancer: a systematic review. *Breast Cancer Res Treat* **171**:515–526.
- Pereyra AS, Hasek LY, Harris KL, Berman AG, Damen FW, Goergen CJ, and Ellis JM (2017) Loss of cardiac carnitine palmitoyltransferase 2 results in rapamycin-resistant, acetylation-independent hypertrophy. *J Biol Chem* **292**:18443–18456.
- Pereyra AS, Rajan A, Ferreira CR, and Ellis JM (2020) Loss of muscle carnitine palmitoyltransferase 2 prevents diet-induced obesity and insulin resistance despite long-chain acylcarnitine accumulation. *Cell Rep* **33**:108374.
- Peters SA, Huxley RR, Sattar N, and Woodward M (2015) Sex differences in the excess risk of cardiovascular diseases associated with type 2 diabetes: potential explanations and clinical implications. *Curr Cardiovasc Risk Rep* **9**:36.
- Pettegrew JW, Klunk WE, Panchalingam K, Kanfer JN, and McClure RJ (1995) Clinical and neurochemical effects of acetyl-L-carnitine in Alzheimer's disease. *Neurobiol Aging* **16**:1–4.
- Pettegrew JW, Levine J, Gershon S, Stanley JA, Servan-Schreiber D, Panchalingam K, and McClure RJ (2002) 31P-MRS study of acetyl-L-carnitine treatment in geriatric depression: preliminary results. *Bipolar Disord* **4**:61–66.
- Pietrocola F, Galluzzi L, Bravo-San Pedro JM, Madeo F, and Kroemer G (2015) Acetyl coenzyme A: a central metabolite and second messenger. *Cell Metab* **21**:805–821.
- Polá P, De Martini D, Gerardino L, De Rossi S, and Tondi P (1992) The action of propionyl-L-carnitine on the basal endothelium: increased t-PA synthesis and a decrease in the activity of PAI-1. A preliminary study. *Drugs Exp Clin Res* **18**:343–348.
- Porta F, Chiesa N, Martinelli D, and Spada M (2019) Clinical, biochemical, and molecular spectrum of short/branched-chain acyl-CoA dehydrogenase deficiency: two new cases and review of literature. *J Pediatr Endocrinol Metab* **32**:101–108.
- Postiglione A, Cicerano U, Soricelli A, De Chiara S, Gallotta G, Salvatore M, and Mancini M (1990) Cerebral blood flow in patients with chronic cerebrovascular disease: effect of acetyl L-carnitine. *Int J Clin Pharmacol Res* **10**:129–132.
- Postiglione A, Soricelli A, Cicerano U, Mansi L, De Chiara S, Gallotta G, Schettini G, and Salvatore M (1991) Effect of acute administration of L-acetyl carnitine on cerebral blood flow in patients with chronic cerebral infarct. *Pharmacol Res* **23**:241–246.
- Prasad M and Hussain S (2015) Glutaric aciduria type II presenting as myopathy and rhabdomyolysis in a teenager. *J Child Neurol* **30**:96–99.
- Price ER, Staples JF, Milligan CL, and Guglielmo CG (2011) Carnitine palmitoyl transferase activity and whole muscle oxidation rates vary with fatty acid substrate in avian flight muscles. *J Comp Physiol B* **181**:565–573.
- Price N, van der Leij F, Jackson V, Corstorphine C, Thomson R, Sorensen A, and Zammit V (2002) A novel brain-expressed protein related to carnitine palmitoyltransferase I. *Genomics* **80**:433–442.
- Pueschel SM (2006) The effect of acetyl-L-carnitine administration on persons with Down syndrome. *Res Dev Disabil* **27**:599–604.
- Puskasik MA, Evans CR, Karnovsky A, Das AK, Jones AE, and Stringer KA (2018) Septic shock nonsurvivors have persistently elevated acylcarnitines following carnitine supplementation. *Shock* **49**:412–419.
- Qiu G, Zheng Y, Wang H, Sun J, Ma H, Xiao Y, Li Y, Yuan Y, Yang H, Li X, et al. (2016) Plasma metabolomics identified novel metabolites associated with risk of type 2 diabetes in two prospective cohorts of Chinese adults. *Int J Epidemiol* **45**:1507–1516.
- Rahbeeni Z, Vaz FM, Al-Hussein K, Bucknall MP, Ruiter J, Wanders RJ, and Rashed MS (2002) Identification of two novel mutations in OCTN2 from two Saudi patients with systemic carnitine deficiency. *J Inher Metab Dis* **25**:363–369.
- Rahmandar MH, Bawcom A, Romano ME, and Hamid R (2014) Cobalamin C deficiency in an adolescent with altered mental status and anorexia. *Pediatrics* **134**:e1709–e1714.
- Rai G, Wright G, Scott L, Beston B, Rest J, and Exton-Smith AN (1990) Double-blind, placebo controlled study of acetyl-L-carnitine in patients with Alzheimer's dementia. *Curr Med Res Opin* **11**:638–647.
- Ramos-Roman MA, Sweetman L, Valdez MJ, and Parks EJ (2012) Postprandial changes in plasma acylcarnitine concentrations as markers of fatty acid flux in overweight and obesity. *Metabolism* **61**:202–212.
- Ramsay RR, Gandour RD, and van der Leij FR (2001) Molecular enzymology of carnitine transfer and transport. *Biochim Biophys Acta* **1546**:21–43.
- Rardin MJ, He W, Nishida Y, Newman JC, Carrico C, Danielson SR, Guo A, Gut P, Sahu AK, Li B, et al. (2013) SIRT5 regulates the mitochondrial lysine succinylome and metabolic networks. *Cell Metab* **18**:920–933.
- Ratnayake WM and Galli C (2009) Fat and fatty acid terminology, methods of analysis and fat digestion and metabolism: a background review paper. *Ann Nutr Metab* **55**:8–43.

- Raud B, Roy DG, Divakaruni AS, Tarasenko TN, Franke R, Ma EH, Samborska B, Hsieh WY, Wong AH, Stüve P, et al. (2018) Etomoxir actions on regulatory and memory T cells are independent of Cpt1a-mediated fatty acid oxidation. *Cell Metab* **28**:504–515.e7.
- Ravindran AV, Balneaves LG, Faulkner G, Ortiz A, McIntosh D, Morehouse RL, Ravindran L, Yatham LN, Kennedy SH, Lam RW, et al.; CANMAT Depression Work Group (2016) Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 5. Complementary and alternative medicine treatments. *Can J Psychiatry* **61**:576–587.
- Rebouche CJ (2004) Kinetics, pharmacokinetics, and regulation of L-carnitine and acetyl-L-carnitine metabolism. *Ann N Y Acad Sci* **1033**:30–41.
- Remington R, Bechtel C, Larsen D, Samar A, Doshanjh L, Fishman P, Luo Y, Smyers K, Page R, Morrell C, et al. (2015a) A phase II randomized clinical trial of a nutritional formulation for cognition and mood in Alzheimer's disease. *J Alzheimers Dis* **45**:395–405.
- Remington R, Bechtel C, Larsen D, Samar A, Page R, Morrell C, and Shea TB (2016) Maintenance of cognitive performance and mood for individuals with Alzheimer's disease following consumption of a nutraceutical formulation: a one-year, open-label study. *J Alzheimers Dis* **51**:991–995.
- Remington R, Chan A, Paskavitz J, and Shea TB (2009) Efficacy of a vitamin/nutraceutical formulation for moderate-stage to later-stage Alzheimer's disease: a placebo-controlled pilot study. *Am J Alzheimers Dis Other Demen* **24**:27–33.
- Remington R, Lortie JJ, Hoffmann H, Page R, Morrell C, and Shea TB (2015b) A nutritional formulation for cognitive performance in mild cognitive impairment: a placebo-controlled trial with an open-label extension. *J Alzheimers Dis* **48**:591–595.
- Reszko AE, Kasumov T, David F, Jobbins KA, Thomas KR, Hoppel CL, Brunengraber H, and Des Rosiers C (2004) Peroxisomal fatty acid oxidation is a substantial source of the acetyl moiety of malonyl-CoA in rat heart. *J Biol Chem* **279**:19574–19579.
- Reubsaet FA, Veerkamp JH, Trijbels JM, and Monnens LA (1989) Total and peroxisomal oxidation of various saturated and unsaturated fatty acids in rat liver, heart and m. quadriceps. *Lipids* **24**:945–950.
- Reuter SE and Evans AM (2011) Long-chain acylcarnitine deficiency in patients with chronic fatigue syndrome. Potential involvement of altered carnitine palmitoyltransferase-I activity. *J Intern Med* **270**:76–84.
- Reuter SE and Evans AM (2012) Carnitine and acylcarnitines: pharmacokinetic, pharmacological and clinical aspects. *Clin Pharmacokinet* **51**:553–572.
- Reuter SE, Evans AM, Chace DH, and Fornasini G (2008) Determination of the reference range of endogenous plasma carnitines in healthy adults. *Ann Clin Biochem* **45**:585–592.
- Rhead WJ (2006) Newborn screening for medium-chain acyl-CoA dehydrogenase deficiency: a global perspective. *J Inherit Metab Dis* **29**:370–377.
- Ribel-Madsen A, Ribel-Madsen R, Brøns C, Newgard CB, Vaag AA, and Hellgren LI (2016) Plasma acylcarnitine profiling indicates increased fatty acid oxidation relative to tricarboxylic acid cycle capacity in young, healthy low birth weight men. *Physiol Rep* **4**:e12977.
- Riccioni C, Sarcinella R, Palermo G, Izzo A, Liguori M, Koverech A, Messano M and Virmani A (2008) Evaluation of the efficacy of propionyl-L-carnitine versus pulsed muscular compressions in diabetic and non-diabetic patients affected by obliterating arteriopathy Leriche stage II. *Int Angiol* **27**:253–259.
- Rinaldo P, Cowan TM, and Matern D (2008) Acylcarnitine profile analysis. *Genet Med* **10**:151–156.
- Rizza S, Copetti M, Rossi C, Cianfarani MA, Zucchelli M, Luzzi A, Pecchioli C, Porzio O, Di Cola G, Urbani A, et al. (2014) Metabolomics signature improves the prediction of cardiovascular events in elderly subjects. *Atherosclerosis* **232**:260–264.
- Rizzo C, Boenzi S, Inglese R, la Marca G, Muraca M, Martinez TB, Johnson DW, Zelli E, and Dionisi-Vici C (2014) Measurement of succinyl-carnitine and methylmalonyl-carnitine on dried blood spot by liquid chromatography-tandem mass spectrometry. *Clin Chim Acta* **429**:30–33.
- Rizzo C, Boenzi S, Wanders RJ, Duran M, Caruso U, and Dionisi-Vici C (2003) Characteristic acylcarnitine profiles in inherited defects of peroxisome biogenesis: a novel tool for screening diagnosis using tandem mass spectrometry. *Pediatr Res* **53**:1013–1018.
- Roe CR, Millington DS, and Maltby DA (1986) Identification of 3-methylglutaryl-carnitine. A new diagnostic metabolite of 3-hydroxy-3-methylglutaryl-coenzyme A lyase deficiency. *J Clin Invest* **77**:1391–1394.
- Roe CR, Millington DS, Maltby DA, Kahler SG, and Bohan TP (1984) L-carnitine therapy in isovaleric acidemia. *J Clin Invest* **74**:2290–2295.
- Roe CR, Millington DS, Norwood DL, Kodo N, Sprecher H, Mohammed BS, Nada M, Schulz H, and McVie R (1990) 2,4-Dienoyl-coenzyme A reductase deficiency: a possible new disorder of fatty acid oxidation. *J Clin Invest* **85**:1703–1707.
- Rolim LC, da Silva EM, Flumignan RL, Abreu MM, and Dib SA (2019) Acetyl-L-carnitine for the treatment of diabetic peripheral neuropathy. *Cochrane Database Syst Rev* **6**:CD011265.
- Rossini M, Di Munno O, Valentini G, Bianchi G, Biasi G, Cacace E, Malesci D, La Montagna G, Viapiana O, and Adami S (2007) Double-blind, multicenter trial comparing acetyl l-carnitine with placebo in the treatment of fibromyalgia patients. *Clin Exp Rheumatol* **25**:182–188.
- Roy C, Tremblay PY, Anassour-Laouan-Sidi E, Lucas M, Forest JC, Giguère Y, and Ayotte P (2018) Risk of gestational diabetes mellitus in relation to plasma concentrations of amino acids and acylcarnitines: a nested case-control study. *Diabetes Res Clin Pract* **140**:183–190.
- Rubio-Gozalbo ME, Bakker JA, Waterham HR, and Wanders RJ (2004) Carnitine-acylcarnitine translocase deficiency, clinical, biochemical and genetic aspects. *Mol Aspects Med* **25**:521–532.
- Rufer AC, Thoma R, and Hennig M (2009) Structural insight into function and regulation of carnitine palmitoyltransferase. *Cell Mol Life Sci* **66**:2489–2501.
- Ruggenenti P, Cattaneo D, Loriga G, Ledda F, Motterlini N, Gherardi G, Orisio S, and Remuzzi G (2009) Ameliorating hypertension and insulin resistance in subjects at increased cardiovascular risk: effects of acetyl-L-carnitine therapy. *Hypertension* **54**:567–574.
- Ruiz M, Labarthe F, Fortier A, Bouchard B, Thompson Legault J, Bolduc V, Rigal O, Chen J, Ducharme A, Crawford PA, et al. (2017) Circulating acylcarnitine profile in human heart failure: a surrogate of fatty acid metabolic dysregulation in mitochondria and beyond. *Am J Physiol Heart Circ Physiol* **313**:H768–H781.
- Ruiz-Canela M, Hruba C, Clish CB, Liang L, Martínez-González MA, and Hu FB (2017) Comprehensive metabolomic profiling and incident cardiovascular disease: a systematic review. *J Am Heart Assoc* **6**:e005705.
- Rutkowski JM, Knotts TA, Ono-Moore KD, McCain CS, Huang S, Schneider D, Singh S, Adams SH, and Hwang DH (2014) Acylcarnitines activate proinflammatory signaling pathways. *Am J Physiol Endocrinol Metab* **306**:E1378–E1387.
- Safarinejad MR, Hosseini SY, and Kolahi AA (2007) Comparison of vitamin E and propionyl-L-carnitine, separately or in combination, in patients with early chronic Peyronie's disease: a double-blind, placebo controlled, randomized study. *J Urol* **178**:1398–1403, discussion 1403.
- Saiki S, Hatano T, Fujimaki M, Ishikawa KI, Mori A, Oji Y, Okuzumi A, Fukuhara T, Koimura T, Imamichi Y, et al. (2017) Decreased long-chain acylcarnitines from insufficient β -oxidation as potential early diagnostic markers for Parkinson's disease. *Sci Rep* **7**:7328.
- Sakuma T, Sugiyama N, Ichiki T, Kobayashi M, Wada Y, and Nohara D (1991) Analysis of acylcarnitines in maternal urine for prenatal diagnosis of glutaric aciduria type 2. *Prenat Diagn* **11**:77–82.
- Salvioli G and Neri M (1994) L-acetylcarnitine treatment of mental decline in the elderly. *Drugs Exp Clin Res* **20**:169–176.
- Sánchez-Martínez R, Cruz-Gil S, García-Álvarez MS, Reglero G, and Ramírez de Molina A (2017) Complementary ACSL isoforms contribute to a non-Warburg advantageous energetic status characterizing invasive colon cancer cells. *Sci Rep* **7**:11143.
- Santarelli F, Cassanello M, Enea A, Poma F, D'Onofrio V, Guala G, Garrone G, Puccinelli P, Caruso U, Porta F, et al. (2013) A neonatal case of 3-hydroxy-3-methylglutaric-coenzyme A lyase deficiency. *Ital J Pediatr* **39**:33.
- Santer R, Fingerhut R, Lässker U, Wightman PJ, Fitzpatrick DR, Olgemöller B, and Roscher AA (2003) Tandem mass spectrometric determination of malonylcarnitine: diagnosis and neonatal screening of malonyl-CoA decarboxylase deficiency. *Clin Chem* **49**:660–662.
- Santo SS, Sergio N, Luigi DP, Giuseppe M, Margherita F, Gea OC, Roberto F, Gabriella C, Giuseppe P, and Massimiliano A (2006) Effect of PLC on functional parameters and oxidative profile in type 2 diabetes-associated PAD. *Diabetes Res Clin Pract* **72**:231–237.
- Santos GA, Pereira VD, Roman EA, Ignacio-Souza L, Vitorino DC, de Moura RF, Razolli DS, Torsoni AS, Velloso LA, and Torsoni MA (2013) Hypothalamic inhibition of acetyl-CoA carboxylase stimulates hepatic counter-regulatory response independent of AMPK activation in rats. *PLoS One* **8**:e62669.
- Santra S and Hendriks C (2010) How to use acylcarnitine profiles to help diagnose inborn errors of metabolism. *Arch Dis Child Educ Pract Ed* **95**:151–156.
- Saral NY, Aksungar FB, Aktuglu-Zeybek C, Coskun J, Demirele O, and Serteser M (2018) Glutaric acidemia type II patient with thalassemia minor and novel electron transfer flavoprotein-A gene mutations: a case report and review of literature. *World J Clin Cases* **6**:786–790.
- Sassa T and Kihara A (2014) Metabolism of very long-chain fatty acids: genes and pathophysiology. *Biomol Ther (Seoul)* **22**:83–92.
- Sawicka AK, Renzi G, and Olek RA (2020) The bright and the dark sides of L-carnitine supplementation: a systematic review. *J Int Soc Sports Nutr* **17**:49.
- Scanlon PJ (1985) The training for and practice of percutaneous transluminal coronary angioplasty: results of two surveys. *Cathet Cardiovasc Diagn* **11**:561–570.
- Scarpini E, Sacilotto G, Baron P, Cusini M, and Scarlato G (1997) Effect of acetyl-L-carnitine in the treatment of painful peripheral neuropathies in HIV+ patients. *J Peripher Nerv Syst* **2**:250–252.
- Schaefer J, Jackson S, Taroni F, Swift P, and Turnbull DM (1997) Characterisation of carnitine palmitoyltransferases in patients with a carnitine palmitoyltransferase deficiency: implications for diagnosis and therapy. *J Neurol Neurosurg Psychiatry* **62**:169–176.
- Schlueter RJ, Al-Akwaq FM, Benny PA, Gurary A, Xie G, Jia W, Chun SJ, Chern I, and Garmire LX (2020) Prepregnant obesity of mothers in a multiethnic cohort is associated with cord blood metabolomic changes in offspring. *J Proteome Res* **19**:1361–1374.
- Schmidt-Sommerfeld E, Penn D, Duran M, Bennett MJ, Santer R, and Stanley CA (1993) Detection of inborn errors of fatty acid oxidation from acylcarnitine analysis of plasma and blood spots with the radioisotopic exchange-high-performance liquid chromatographic method. *J Pediatr* **122**:708–714.
- Schmidt-Sommerfeld E, Penn D, Rinaldo P, Kossak D, Li BU, Huang ZH, and Gage DA (1992) Urinary medium-chain acylcarnitines in medium-chain acyl-CoA dehydrogenase deficiency, medium-chain triglyceride feeding and valproic acid therapy: sensitivity and specificity of the radioisotopic exchange/high performance liquid chromatography method. *Pediatr Res* **31**:545–551.
- Schönfeld P and Reiser G (2013) Why does brain metabolism not favor burning of fatty acids to provide energy? Reflections on disadvantages of the use of free fatty acids as fuel for brain. *J Cereb Blood Flow Metab* **33**:1493–1499.
- Schönfeld P and Wojtczak L (2016) Short- and medium-chain fatty acids in energy metabolism: the cellular perspective. *J Lipid Res* **57**:943–954.
- Schooneman MG, Achterkamp N, Argmann CA, Soeters MR, and Houten SM (2014) Plasma acylcarnitines inadequately reflect tissue acylcarnitine metabolism. *Biochim Biophys Acta* **1841**:987–994.
- Schooneman MG, Ten Have GA, van Vlies N, Houten SM, Deutz NE, and Soeters MR (2015) Transorgan fluxes in a porcine model reveal a central role for liver in acylcarnitine metabolism. *Am J Physiol Endocrinol Metab* **309**:E256–E264.

- Schooneman MG, Vaz FM, Houten SM, and Soeters MR (2013) Acylcarnitines: reflecting or inflicting insulin resistance? *Diabetes* **62**:1–8.
- Scioli MG, Stasi MA, Passeri D, Doldo E, Costanza G, Camerini R, Fociani P, Arcuri G, Lombardo K, Pace S, et al. (2014) Propionyl-L-carnitine is efficacious in ulcerative colitis through its action on the immune function and microvasculature. *Clin Transl Gastroenterol* **5**:e55.
- See WK, Jo G, Shin MJ, and Oh K (2018) Medium-chain acylcarnitines are associated with cardioembolic stroke and stroke recurrence. *Arterioscler Thromb Vasc Biol* **38**:2245–2253.
- Shah SH, Bain JR, Muehlbauer MJ, Stevens RD, Crosslin DR, Haynes C, Dungan J, Newby LK, Hauser ER, Ginsburg GS, et al. (2010) Association of a peripheral blood metabolic profile with coronary artery disease and risk of subsequent cardiovascular events. *Circ Cardiovasc Genet* **3**:207–214.
- Shah SH, Sun JL, Stevens RD, Bain JR, Muehlbauer MJ, Pieper KS, Haynes C, Hauser ER, Kraus VE, Granger CB, et al. (2012) Baseline metabolomic profiles predict cardiovascular events in patients at risk for coronary artery disease. *Am Heart J* **163**:844–850.e1.
- Shigematsu Y, Hata I, and Tanaka Y (2007) Stable-isotope dilution measurement of isovalerylglycine by tandem mass spectrometry in newborn screening for isovaleric acidemia. *Clin Chim Acta* **386**:82–86.
- Shigematsu Y, Hirano S, Hata I, Tanaka Y, Sudo M, Tajima T, Sakura N, Yamaguchi S, and Takayanagi M (2003) Selective screening for fatty acid oxidation disorders by tandem mass spectrometry: difficulties in practical discrimination. *J Chromatogr B Analyt Technol Biomed Life Sci* **792**:63–72.
- Shimizu N, Yamaguchi S, Orii T, Previs SF, and Rinaldo P (1991) Mass spectrometric analysis of metabolite excretion in five Japanese patients with the late-onset form of glutaric aciduria type II. *Biol Mass Spectrom* **20**:479–483.
- Shirley M (2020) Triheptanoin: First Approval. *Drugs* **80**:1595–1600.
- Siciliano M, Annicchiarico BE, Lucchese F, and Bombardieri G (2006) Effects of a single, short intravenous dose of acetyl-L-carnitine on pattern-reversal visual-evoked potentials in cirrhotic patients with hepatic encephalopathy. *Clin Exp Pharmacol Physiol* **33**:76–80.
- Sierra AY, Gratacós E, Carrasco P, Clotet J, Ureña J, Serra D, Asins G, Hegardt FG, and Casals N (2008) CPT1c is localized in endoplasmic reticulum of neurons and has carnitine palmitoyltransferase activity. *J Biol Chem* **283**:6878–6885.
- Signorelli SS, Fatuzzo P, Rapisarda F, Neri S, Ferrante M, Oliveri Conti G, Fallico R, Di Pino L, Pennisi G, Celotta G, et al. (2006a) Propionyl-L-carnitine therapy: effects on endothelin-1 and homocysteine levels in patients with peripheral arterial disease and end-stage renal disease. *Kidney Blood Press Res* **29**:100–107.
- Signorelli SS, Fatuzzo P, Rapisarda F, Neri S, Ferrante M, Oliveri Conti G, Fallico R, Di Pino L, Pennisi G, Celotta G, et al. (2006b) A randomised, controlled clinical trial evaluating changes in therapeutic efficacy and oxidative parameters after treatment with propionyl L-carnitine in patients with peripheral arterial disease requiring haemodialysis. *Drugs Aging* **23**:263–270.
- Siliprandi D, Biban C, Testa S, Toninello A, and Siliprandi N (1992) Effects of palmitoyl CoA and palmitoyl carnitine on the membrane potential and Mg²⁺ content of rat heart mitochondria. *Mol Cell Biochem* **116**:117–123.
- Sima AA, Calvani M, Mehra M, and Amato A; Acetyl-L-Carnitine Study Group (2005) Acetyl-L-carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo-controlled trials. *Diabetes Care* **28**:89–94.
- Sinforiani E, Iannuccelli M, Mauri M, Costa A, Merlo P, Bono G, and Nappi G (1990) Neuropsychological changes in demented patients treated with acetyl-L-carnitine. *Int J Clin Pharmacol Res* **10**:69–74.
- Singh H and Poulos A (1995) Substrate specificity of rat liver mitochondrial carnitine palmitoyl transferase I: evidence against alpha-oxidation of pyruvic acid in rat liver mitochondria. *FEBS Lett* **359**:179–183.
- Skaper SD, Facci L, Zusso M, and Giusti P (2018) An inflammation-centric view of neurological disease: beyond the neuron. *Front Cell Neurosci* **12**:72.
- Skottene E, Tarrant AM, Olsen AJ, Altin D, Istenens MA, Hansen BH, Choquet M, Jessen BM, and Olsen RE (2019) The β -oxidation pathway is downregulated during diapause termination in Calanus copepods. *Sci Rep* **9**:16686.
- Smeland OB, Meisingset TW, Borges K, and Sonnewald U (2012) Chronic acetyl-L-carnitine alters brain energy metabolism and increases noradrenaline and serotonin content in healthy mice. *Neurochem Int* **61**:100–107.
- Smith RL, Soeters MR, Wüst RCI, and Houtkooper RH (2018) Metabolic flexibility as an adaptation to energy resources and requirements in health and disease. *Endocr Rev* **39**:489–517.
- Soeters MR, Sauerwein HP, Duran M, Wanders RJ, Ackermans MT, Fliers E, Houten SM, and Serlie MJ (2009) Muscle acylcarnitines during short-term fasting in lean healthy men. *Clin Sci (Lond)* **116**:585–592.
- Soeters MR, Serlie MJ, Sauerwein HP, Duran M, Ruiters JP, Kulik W, Ackermans MT, Minkler PE, Hoppel CL, Wanders RJ, et al. (2012) Characterization of D-3-hydroxybutyrylcarnitine (ketocarnitine): an identified ketosis-induced metabolite. *Metabolism* **61**:966–973.
- Soni MS, Rabaglia ME, Bhatnagar S, Shang J, Ilkayeva O, Mynatt R, Zhou YP, Schadt EE, Thornberry NA, Muoio DM, et al. (2014) Downregulation of carnitine acyl-carnitine translocase by miRNAs 132 and 212 amplifies glucose-stimulated insulin secretion. *Diabetes* **63**:3805–3814.
- Sorensen A, Travers MT, Vernon RG, Price NT, and Barber MC (2002) Localization of messenger RNAs encoding enzymes associated with malonyl-CoA metabolism in mouse brain. *Brain Res Gene Expr Patterns* **1**:167–173.
- Spagnoli A, Lucca U, Menasse G, Bandera L, Cizza G, Forloni G, Tettamanti M, Frattura L, Tiraboschi P, Comelli M, et al. (1991) Long-term acetyl-L-carnitine treatment in Alzheimer's disease. *Neurology* **41**:1726–1732.
- Spiekerkoetter U, Lindner M, Santer R, Grotzke M, Baumgartner MR, Boehles H, Das A, Haase C, Hennermann JB, Karall D, et al. (2009) Management and outcome in 75 individuals with long-chain fatty acid oxidation defects: results from a workshop. *J Inheret Metab Dis* **32**:488–497.
- Srinivasan NT and Schilling RJ (2018) Sudden cardiac death and arrhythmias. *Arrhythm Electrophysiol Rev* **7**:111–117.
- Stanley WC, Recchia FA, and Lopaschuk GD (2005) Myocardial substrate metabolism in the normal and failing heart. *Physiol Rev* **85**:1093–1129.
- Steiner N, Müller U, Hajek R, Sevcikova S, Borjan B, Jöhner K, Göbel G, Pircher A, and Günsilius E (2018) The metabolomic plasma profile of myeloma patients is considerably different from healthy subjects and reveals potential new therapeutic targets. *PLoS One* **13**:e0202045.
- Stephens FB, Constantin-Teodosiu D, and Greenhaff PL (2007) New insights concerning the role of carnitine in the regulation of fuel metabolism in skeletal muscle. *J Physiol* **581**:431–444.
- Stepien KM, Abidin Z, Lee G, Cullen R, Logan P, and Pastores GM (2018) Metallosis mimicking a metabolic disorder: a case report. *Mol Genet Metab Rep* **17**:38–41.
- Stoler JM, Sabry MA, Hanley C, Hoppel CL, and Shih VE (2004) Successful long-term treatment of hepatic carnitine palmitoyltransferase I deficiency and a novel mutation. *J Inheret Metab Dis* **27**:679–684.
- Strano A (2002) Propionyl-L-carnitine versus pentoxifylline: improvement in walking capacity in patients with intermittent claudication. *Clin Drug Investig* **22** (Suppl 1):1–6.
- Stratton SL, Horvath TD, Bogusiewicz A, Matthews NI, Henrich CL, Spencer HJ, Moran JH, and Mock DM (2011) Urinary excretion of 3-hydroxyisovaleryl carnitine is an early and sensitive indicator of marginal biotin deficiency in humans. *J Nutr* **141**:353–358.
- Strijbis K, Vaz FM, and Distel B (2010) Enzymology of the carnitine biosynthesis pathway. *IUBMB Life* **62**:357–362.
- Sugiyama N, Kidouchi K, Kobayashi M, and Wada Y (1990) Carnitine deficiency in inherited organic acid disorders and Reye syndrome. *Acta Paediatr Jpn* **32**:410–416.
- Sun Y, Gao HY, Fan ZY, He Y, and Yan YX (2020) Metabolomics signatures in type 2 diabetes: a systematic review and integrative analysis. *J Clin Endocrinol Metab* **105**:1000–1008.
- Sun Y, Kim JH, Vangipuram K, Hayes DF, Smith EML, Yeomans L, Henry NL, Stringer KA, and Hertz DL (2018) Pharmacometabolomics reveals a role for histidine, phenylalanine, and threonine in the development of paclitaxel-induced peripheral neuropathy. *Breast Cancer Res Treat* **171**:657–666.
- Sun Y, Shu Y, Liu B, Liu P, Wu C, Zheng R, Zhang X, Zhuang Z, Deng Y, Zheng L, et al. (2016a) A prospective study to evaluate the efficacy and safety of oral acetyl-L-carnitine for the treatment of chemotherapy-induced peripheral neuropathy. *Exp Ther Med* **12**:4017–4024.
- Sun ZJ, Jia HM, Qiu GX, Zhou C, Guo S, Zhang JG, Shen JX, Zhao Y, and Zou ZM (2016b) Identification of candidate diagnostic biomarkers for adolescent idiopathic scoliosis using UPLC/QTOF-MS analysis: a first report of lipid metabolism profiles. *Sci Rep* **6**:22274.
- Suzuki H, Hibino H, Inoue Y, Mikami A, Matsumoto H, and Mikami K (2017) Effect of acetyl-L-carnitine in elderly patient who presented with hyperammonemia associated with administration of sodium valproate. *Asian J Psychiatr* **30**:179.
- Suzuki H, Hibino H, Inoue Y, and Mikami K (2019) The benefits of the concomitant use of antidepressants and acetyl-L-carnitine in the treatment of moderate depression. *Asian J Psychiatr* **41**:84–85.
- Tajima G, Hara K, Tsumura M, Kagawa R, Okada S, Sakura N, Maruyama S, Noguchi A, Awaya T, Ishige M, et al. (2017) Newborn screening for carnitine palmitoyltransferase II deficiency using (C16+C18:1)/C2: evaluation of additional indices for adequate sensitivity and lower false-positivity. *Mol Genet Metab* **122**:67–75.
- Tajima G, Sakura N, Shirao K, Okada S, Tsumura M, Nishimura Y, Ono H, Hasegawa Y, Hata I, Naito E, et al. (2008) Development of a new enzymatic diagnosis method for very-long-chain acyl-CoA dehydrogenase deficiency by detecting 2-hexadecenoyl-CoA production and its application in tandem mass spectrometry-based selective screening and newborn screening in Japan. *Pediatr Res* **64**:667–672.
- Takaya H, Namisaki T, Kitade M, Shimozato N, Kaji K, Tsuji Y, Nakanishi K, Noguchi R, Fujinaga Y, Sawada Y, et al. (2019) Acylcarnitine: useful biomarker for early diagnosis of hepatocellular carcinoma in non-steatohepatitis patients. *World J Gastrointest Oncol* **11**:887–897.
- Tan B, Qiu Y, Zou X, Chen T, Xie G, Cheng Y, Dong T, Zhao L, Feng B, Hu X, et al. (2013) Metabonomics identifies serum metabolite markers of colorectal cancer. *J Proteome Res* **12**:3000–3009.
- Tavasoli AR, Shervin Badv R, Zschocke J, Ashrafi MR, and Rostami P (2017) Early infantile presentation of 3-methylglutaconic aciduria type 1 with a novel mutation in AUH gene: a case report and literature review. *Brain Dev* **39**:714–716.
- Taylor DJ, Amato A, Hands LJ, Kemp GJ, Ramaswami G, Nicolaidis A, and Radda GK (1996) Changes in energy metabolism of calf muscle in patients with intermittent claudication assessed by 31P magnetic resonance spectroscopy: a phase II open study. *Vasc Med* **1**:241–245.
- Tempesta E, Casella L, Pirrongelli C, Janiri L, Calvani M, and Ancona L (1987) L-acetylcarnitine in depressed elderly subjects. A cross-over study vs placebo. *Drugs Exp Clin Res* **13**:417–423.
- Thal LJ, Calvani M, Amato A, and Carta A (2000) A 1-year controlled trial of acetyl-L-carnitine in early-onset AD. *Neurology* **55**:805–810.
- Thal LJ, Carta A, Clarke WR, Ferris SH, Friedland RP, Petersen RC, Pettegrew JW, Pfeiffer E, Raskind MA, Sano M, et al. (1996) A 1-year multicenter placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer's disease. *Neurology* **47**:705–711.
- The Investigators of the Study on Propionyl-L-Carnitine in Chronic Heart Failure (1999) Study on propionyl-L-carnitine in chronic heart failure. *Eur Heart J* **20**:70–76.

- Thomsen JA, Lund AM, Olesen JH, Mohr M, and Rasmussen J (2015) Is L-carnitine supplementation beneficial in 3-methylcrotonyl-CoA carboxylase deficiency? *JIMD Rep* **21**:79–88.
- Toledo JB, Arnold M, Kastenmüller G, Chang R, Baillie RA, Han X, Thambisetty M, Tenenbaum JD, Suhre K, Thompson JW, et al.; Alzheimer's Disease Neuroimaging Initiative and the Alzheimer Disease Metabolomics Consortium (2017) Metabolic network failures in Alzheimer's disease: a biochemical road map. *Alzheimers Dement* **13**:965–984.
- Tomassini V, Pozzilli C, Onesti E, Pasqualetti P, Marinelli F, Pisani A, and Fieschi C (2004) Comparison of the effects of acetyl L-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: results of a pilot, randomised, double-blind, crossover trial. *J Neurol Sci* **218**:103–108.
- Tominaga H, Katoh H, Odagiri K, Takeuchi Y, Kawashima H, Saotome M, Urushida T, Satoh H, and Hayashi H (2008) Different effects of palmitoyl-L-carnitine and palmitoyl-CoA on mitochondrial function in rat ventricular myocytes. *Am J Physiol Heart Circ Physiol* **295**:H105–H112.
- Tonin R, Caciotti A, Funghini S, Pasquini E, Mooney SD, Cai B, Proncopio E, Donati MA, Baronio F, Bettocchi I, et al. (2016) Clinical relevance of short-chain acyl-CoA dehydrogenase (SCAD) deficiency: exploring the role of new variants including the first SCAD-disease-causing allele carrying a synonymous mutation. *BBA Clin* **5**:114–119.
- Topping DL and Clifton PM (2001) Short-chain fatty acids and human colonic function: roles of resistant starch and nonstarch polysaccharides. *Physiol Rev* **81**:1031–1064.
- Traina G (2016) The neurobiology of acetyl-L-carnitine. *Front Biosci* **21**:1314–1329.
- Traina G, Federighi G, Brunelli M, and Scuri R (2009) Cytoprotective effect of acetyl-L-carnitine evidenced by analysis of gene expression in the rat brain. *Mol Neurobiol* **39**:101–106.
- Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, McGrath PJ, et al.; STAR*D Study Team (2006) Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. *Am J Psychiatry* **163**:28–40.
- Tserng KY, Jin SJ, Kerr DS, and Hoppel CL (1990) Abnormal urinary excretion of unsaturated dicarboxylic acids in patients with medium-chain acyl-CoA dehydrogenase deficiency. *J Lipid Res* **31**:763–771.
- Tuncel AT, Boy N, Morath MA, Hörster F, Mütze U, and Kölker S (2018) Organic acidurias in adults: late complications and management. *J Inherit Metab Dis* **41**:765–776.
- Turpeinen AK, Kuikka JT, Vanninen E, Yang J and Uusitupa MI (2000) Long-term effect of acetyl-L-carnitine on myocardial 123I-MIBG uptake in patients with diabetes. *Clin Auton Res* **10**:13–16.
- Ueland T, Svardal A, Ie E, Askevold ET, Nymoeh SH, Bjørndal B, Dahl CP, Gullestad L, Berge RK, and Aukrust P (2013) Disturbed carnitine regulation in chronic heart failure—increased plasma levels of palmitoyl-carnitine are associated with poor prognosis. *Int J Cardiol* **167**:1892–1899.
- Ussher JR, Kovacs TR, Jaswal JS, Zhang L, Ilkayeva O, Dyck JR, Muoio DM, and Lopaschuk GD (2009) Insulin-stimulated cardiac glucose oxidation is increased in high-fat diet-induced obese mice lacking malonyl CoA decarboxylase. *Diabetes* **58**:1766–1775.
- Václavík J, Mádrová L, Kouřil Š, de Sousa J, Brumarová R, Janečková H, Jácová J, Friedecký D, Knapková M, Kluijtmans LAJ, et al. (2020) A newborn screening approach to diagnose 3-hydroxy-3-methylglutaryl-CoA lyase deficiency. *JIMD Rep* **54**:79–86.
- Valcour V, Yeh TM, Bartt R, Clifford D, Gerschenson M, Evans SR, Cohen BA, Ebenezer GJ, Hauer P, Millar L, et al.; AIDS Clinical Trials Group (ACTG) 5157 protocol team (2009) Acetyl-L-carnitine and nucleoside reverse transcriptase inhibitor-associated neuropathy in HIV infection. *HIV Med* **10**:103–110.
- Vallée L, Fontaine M, Nuyts JP, Ricart G, Krivosic I, Divry P, Vianey-Saban C, Lhermitte M, and Vamecq J (1994) Stroke, hemiparesis and deficient mitochondrial beta-oxidation. *Eur J Pediatr* **153**:598–603.
- van de Beek MC, Dijkstra IM, van Lenthe H, Ofman R, Goldhaber-Pasillas D, Schauer N, Schackmann M, Engelen-Lee JY, Vaz FM, Kulik W, et al. (2016) C26:0-carnitine is a new biomarker for X-linked adrenoleukodystrophy in mice and man. *PLoS One* **11**:e0154597.
- van der Hooft JJ, Ridder L, Barrett MP, and Burgess KE (2015) Enhanced acylcarnitine annotation in high-resolution mass spectrometry data: fragmentation analysis for the classification and annotation of acylcarnitines. *Front Bioeng Biotechnol* **3**:26.
- van der Velpen V, Teav T, Gallart-Ayala H, Mehl F, Konz I, Clark C, Oikonomidi A, Peyratout G, Henry H, Delorenzi M, et al. (2019) Systemic and central nervous system metabolic alterations in Alzheimer's disease. *Alzheimers Res Ther* **11**:93.
- van Hove JL, Rutledge SL, Nada MA, Kahler SG, and Millington DS (1995) 3-Hydroxyisovalerylcarnitine in 3-methylcrotonyl-CoA carboxylase deficiency. *J Inherit Metab Dis* **18**:592–601.
- Van Hove JL, Saenz MS, Thomas JA, Gallagher RC, Lovell MA, Fenton LZ, Shanske S, Myers SM, Wanders RJ, Ruiters J, et al. (2010) Succinyl-CoA ligase deficiency: a mitochondrial hepatocerebralopathy. *Pediatr Res* **68**:159–164.
- van Maldegem BT, Duran M, Wanders RJ, Niezen-Koning KE, Hogeveen M, Ijlst L, Waterham HR, and Wijburg FA (2006) Clinical, biochemical, and genetic heterogeneity in short-chain acyl-coenzyme A dehydrogenase deficiency. *JAMA* **296**:943–952.
- van Maldegem BT, Duran M, Wanders RJ, Waterham HR, and Wijburg FA (2010) Flavin adenine dinucleotide status and the effects of high-dose riboflavin treatment in short-chain acyl-CoA dehydrogenase deficiency. *Pediatr Res* **67**:304–308.
- Van Oudheusden LJ and Scholte HR (2002) Efficacy of carnitine in the treatment of children with attention-deficit hyperactivity disorder. *Prostaglandins Leukot Essent Fatty Acids* **67**:33–38.
- van Weeghel M, Abdurrachim D, Nederlof R, Arghmann CA, Houtkooper RH, Hagen J, Nabben M, Denis S, Ciapaite J, Kolwicz Jr SC, et al. (2018) Increased cardiac fatty acid oxidation in a mouse model with decreased malonyl-CoA sensitivity of CPT1B. *Cardiovasc Res* **114**:1324–1334.
- Vats D, Mukundan L, Odegaard JI, Zhang L, Smith KL, Morel CR, Wagner RA, Greaves DR, Murray PJ, and Chawla A (2006) Oxidative metabolism and PGC-1 β attenuate macrophage-mediated inflammation. *Cell Metab* **4**:13–24.
- Ventura FV, Ijlst L, Ruiters J, Ofman R, Costa CG, Jakobs C, Duran M, Tavares de Almeida I, Bieber LL, and Wanders RJ (1998) Carnitine palmitoyltransferase II specificity towards beta-oxidation intermediates—evidence for a reverse carnitine cycle in mitochondria. *Eur J Biochem* **253**:614–618.
- Vermeulen RC and Scholte HR (2004) Exploratory open label, randomized study of acetyl- and propionylcarnitine in chronic fatigue syndrome. *Psychosom Med* **66**:276–282.
- Vernez L, Wenk M, and Krähenbühl S (2004) Determination of carnitine and acylcarnitines in plasma by high-performance liquid chromatography/electrospray ionization ion trap tandem mass spectrometry. *Rapid Commun Mass Spectrom* **18**:1233–1238.
- Veronese N, Stubbs B, Solmi M, Ajnakina O, Carvalho AF, and Maggi S (2018) Acetyl-L-carnitine supplementation and the treatment of depressive symptoms: a systematic review and meta-analysis. *Psychosom Med* **80**:154–159.
- Vilks K, Videja M, Makrečka-Kuka M, Katkevics M, Sevostjanovs E, Grandane A, Dambrova M, and Liepinsh E (2021) Long-chain acylcarnitines decrease the phosphorylation of the insulin receptor at Tyr1151 through a PTP1B-dependent mechanism. *Int J Mol Sci* **22**:6470.
- Vilskersts R, Kuka J, Liepinsh E, Makrečka-Kuka M, Volska K, Makarova E, Sevostjanovs E, Cirule H, Grinberga S, and Dambrova M (2015) Methyl- γ -butyrobetaine decreases levels of acylcarnitines and attenuates the development of atherosclerosis. *Vascul Pharmacol* **72**:101–107.
- Violante S, Achetib N, van Roermund CWT, Hagen J, Dodatko T, Vaz FM, Waterham HR, Chen H, Baes M, Yu C, et al. (2019) Peroxisomes can oxidize medium- and long-chain fatty acids through a pathway involving ABCD3 and HSD17B4. *FASEB J* **33**:4355–4364.
- Violante S, Ijlst L, Ruiters J, Koster J, van Lenthe H, Duran M, de Almeida IT, Wanders RJ, Houten SM, and Ventura FV (2013a) Substrate specificity of human carnitine acetyltransferase: implications for fatty acid and branched-chain amino acid metabolism. *Biochim Biophys Acta* **1832**:773–779.
- Violante S, Ijlst L, Te Brinke H, Koster J, Tavares de Almeida I, Wanders RJ, Ventura FV, and Houten SM (2013b) Peroxisomes contribute to the acylcarnitine production when the carnitine shuttle is deficient. *Biochim Biophys Acta* **1831**:1467–1474.
- Violante S, Ijlst L, van Lenthe H, de Almeida IT, Wanders RJ, and Ventura FV (2010) Carnitine palmitoyltransferase 2: new insights on the substrate specificity and implications for acylcarnitine profiling. *Biochim Biophys Acta* **1802**:728–732.
- Virmanani A and Binienda Z (2004) Role of carnitine esters in brain neuropathology. *Mol Aspects Med* **25**:533–549.
- Vishwanath VA (2016) Fatty acid beta-oxidation disorders: a brief review. *Ann Neurosci* **23**:51–55.
- Vitoria I, Martín-Hernández E, Peña-Quintana L, Bueno M, Quijada-Fraile P, Dalmáu J, Molina-Marrero S, Pérez B, and Merinero B (2015) Carnitine-acylcarnitine translocase deficiency: experience with four cases in Spain and review of the literature. *JIMD Rep* **20**:11–20.
- Vockley J, Burton B, Berry G, Longo N, Phillips J, Sanchez-Valle A, Chapman K, Tanpaiboon P, Grunewald S, Murphy E, et al. (2021) Effects of triheptanoin (UX007) in patients with long-chain fatty acid oxidation disorders: results from an open-label, long-term extension study. *J Inherit Metab Dis* **44**:253–263.
- Waagsbø B, Svardal A, Ueland T, Landrø L, Iktdalen O, Berge RK, Flo TH, Aukrust P, and Damås JK (2016) Low levels of short- and medium-chain acylcarnitines in HIV-infected patients. *Eur J Clin Invest* **46**:408–417.
- Wahl S, Yu Z, Kleber M, Singmann P, Holzapfel C, He Y, Mittelstrass K, Polonikov A, Prehn C, Römisch-Margl W, et al. (2012) Childhood obesity is associated with changes in the serum metabolite profile. *Obes Facts* **5**:660–670.
- Wan X, Li X, Wang Q, Zheng B, Zhou C, Kang X, Hu D, Bao H, and Peng A (2019) Metabolic profiling of amino acids in paraquat-induced acute kidney injury. *Clin Exp Nephrol* **23**:474–483.
- Wanders RJ, Komen J, and Kemp S (2011) Fatty acid omega-oxidation as a rescue pathway for fatty acid oxidation disorders in humans. *FEBS J* **278**:182–194.
- Wanders RJA, Visser G, Ferdinandusse S, Vaz FM, and Houtkooper RH (2020) Mitochondrial fatty acid oxidation disorders: laboratory diagnosis, pathogenesis, and the complicated route to treatment. *J Lipid Atheroscler* **9**:313–333.
- Wang C, Feng R, Sun D, Li Y, Bi X, and Sun C (2011) Metabolic profiling of urine in young obese men using ultra performance liquid chromatography and Q-TOF mass spectrometry (UPLC/Q-TOF MS). *J Chromatogr B Analyt Technol Biomed Life Sci* **879**:2871–2876.
- Wang JM, Xu R, Di QN, Fu HW, and Xu Q (2020) Determination of urinary carnitine levels as a potential indicator of uterine fibroids caused by nonylphenol exposure. *J Chromatogr B Analyt Technol Biomed Life Sci* **1152**:122248.
- Wang Y, Sun W, Zheng J, Xu C, Wang X, Li T, Tang Y, and Li Z (2018) Urinary metabolomic study of patients with acute coronary syndrome using UPLC-QTOF/MS. *J Chromatogr B Analyt Technol Biomed Life Sci* **1100–1101**:122–130.
- Wang-Sattler R, Yu Z, Herder C, Messias AC, Floegel A, He Y, Heim K, Campillos M, Holzapfel C, Thorand B, et al. (2012) Novel biomarkers for pre-diabetes identified by metabolomics. *Mol Syst Biol* **8**:615.
- Wasant P, Matsumoto I, Naylor E, and Liammongkolkul S (2002) Mitochondrial fatty acid oxidation disorders in Thai infants: a report of 3 cases. *J Med Assoc Thai* **85** (Suppl 2):S710–S719.
- Waters PJ, Thuriot F, Clarke JT, Gravel S, Watkins D, Rosenblatt DS, and Lévesque S (2016) Methylmalonyl-coA epimerase deficiency: a new case, with an acute metabolic presentation and an intronic splicing mutation in the *MCEE* gene. *Mol Genet Metab Rep* **9**:19–24.

- Weigel C, Kiener C, Meier N, Schmid P, Rauh M, Rascher W, and Knerr I (2008) Carnitine status in early-treated children, adolescents and young adults with phenylketonuria on low phenylalanine diets. *Ann Nutr Metab* **53**:91–95.
- Wen P, Chen Z, Wang G, Su Z, Zhang X, Tang G, Cui D, Liu X, and Li C (2016) Analysis of clinical phenotype and ACAT1 gene mutation in a family affected with beta-ketothiolase deficiency. *Zhonghua Yi Xue Yi Chuan Xue Za Zhi* **33**:286–291.
- Westin MA, Hunt MC, and Alexson SE (2008) Short- and medium-chain carnitine acyltransferases and acyl-CoA thioesterases in mouse provide complementary systems for transport of beta-oxidation products out of peroxisomes. *Cell Mol Life Sci* **65**:982–990.
- Whitmer JT, Idell-Wenger JA, Rovetto MJ, and Neely JR (1978) Control of fatty acid metabolism in ischemic and hypoxic hearts. *J Biol Chem* **253**:4305–4309.
- Wicks SE, Vandanmagsar B, Haynie KR, Fuller SE, Warfel JD, Stephens JM, Wang M, Han X, Zhang J, Noland RC, et al. (2015) Impaired mitochondrial fat oxidation induces adaptive remodeling of muscle metabolism. *Proc Natl Acad Sci USA* **112**:E3300–E3309.
- Wierzbicki AS (2007) Peroxisomal disorders affecting phytanic acid alpha-oxidation: a review. *Biochem Soc Trans* **35**:881–886.
- Wiseman LR and Brogden RN (1998) Propionyl-L-carnitine. *Drugs & Aging* **12**:243–248.
- Wishart DS, Feunang YD, Marcu A, Guo AC, Liang K, Vázquez-Fresno R, Sajed T, Johnson D, Li C, Karu N, et al. (2018) HMDB 4.0: the human metabolome database for 2018. *Nucleic Acids Res* **46** (D1):D608–D617.
- Wishart DS, Guo A, Oler E, Wang F, Anjum A, Peters H, Dizon R, Sayeeda Z, Tian S, Lee BL, et al. (2022) HMDB 5.0: the human metabolome database for 2022. *Nucleic Acids Res* **50**:D622–D631.
- Witters LA and Kemp BE (1992) Insulin activation of acetyl-CoA carboxylase accompanied by inhibition of the 5'-AMP-activated protein kinase. *J Biol Chem* **267**:2864–2867.
- Wolf A, Weir P, Segar P, Stone J, and Shield J (2001) Impaired fatty acid oxidation in propofol infusion syndrome. *Lancet* **357**:606–607.
- Wolfgang MJ, Cha SH, Millington DS, Cline G, Shulman GI, Suwa A, Asaumi M, Kurama T, Shimokawa T, and Lane MD (2008) Brain-specific carnitine palmitoyl-transferase-1c: role in CNS fatty acid metabolism, food intake, and body weight. *J Neurochem* **105**:1550–1559.
- Wolfgang MJ, Kurama T, Dai Y, Suwa A, Asaumi M, Matsumoto S, Cha SH, Shimokawa T, and Lane MD (2006) The brain-specific carnitine palmitoyltransferase-1c regulates energy homeostasis. *Proc Natl Acad Sci USA* **103**:7282–7287.
- Woo HI, Park HD, Lee YW, Lee DH, Ki CS, Lee SY, and Kim JW (2011) Clinical, biochemical and genetic analyses in two Korean patients with medium-chain acyl-CoA dehydrogenase deficiency. *Korean J Lab Med* **31**:54–60.
- Wood JC, Magera MJ, Rinaldo P, Seashore MR, Strauss AW, and Friedman A (2001) Diagnosis of very long chain acyl-dehydrogenase deficiency from an infant's newborn screening card. *Pediatrics* **108**:E19.
- Wright EL and Baker PR (2020) Neonatal macrosomia is an interfering factor for analytes on the Colorado state newborn screen. *J Clin Endocrinol Metab* **105**:e1561–e1568.
- Wu D, Govindasamy L, Lian W, Gu Y, Kukar T, Agbandje-McKenna M, and McKenna R (2003) Structure of human carnitine acetyltransferase. Molecular basis for fatty acyl transfer. *J Biol Chem* **278**:13159–13165.
- Wu H, Chen Y, Li Z, and Liu X (2018) Untargeted metabolomics profiles delineate metabolic alterations in mouse plasma during lung carcinoma development using UPLC-QTOF/MS in MS^B mode. *R Soc Open Sci* **5**:181143.
- Wu J and Corr PB (1992) Influence of long-chain acylcarnitines on voltage-dependent calcium current in adult ventricular myocytes. *Am J Physiol* **263**:H410–H417.
- Wu X, Huang W, Prasad PD, Seth P, Rajan DP, Leibach FH, Chen J, Conway SJ, and Ganapathy V (1999) Functional characteristics and tissue distribution pattern of organic cation transporter 2 (OCTN2), an organic cation/carnitine transporter. *J Pharmacol Exp Ther* **290**:1482–1492.
- Xiao WH and Bennett GJ (2008) Chemotherapy-evoked neuropathic pain: abnormal spontaneous discharge in A-fiber and C-fiber primary afferent neurons and its suppression by acetyl-L-carnitine. *Pain* **135**:262–270.
- Xiao WH, Zheng H, and Bennett GJ (2012) Characterization of oxaliplatin-induced chronic painful peripheral neuropathy in the rat and comparison with the neuropathy induced by paclitaxel. *Neuroscience* **203**:194–206.
- Xu G, Hansen JS, Zhao XJ, Chen S, Hoene M, Wang XL, Clemmesen JO, Secher NH, Häring HU, Pedersen BK, et al. (2016) Liver and muscle contribute differently to the plasma acylcarnitine pool during fasting and exercise in humans. *J Clin Endocrinol Metab* **101**:5044–5052.
- Xu J, Chen Y, Zhang R, Song Y, Cao J, Bi N, Wang J, He J, Bai J, Dong L et al. (2013) Global and targeted metabolomics of esophageal squamous cell carcinoma discovers potential diagnostic and therapeutic biomarkers. *Mol Cell Proteomics* **12**:1306–1318.
- Yamada K, Shiraiishi H, Oki E, Ishige M, Fukao T, Hamada Y, Sakai N, Ochi F, Watanabe A, Kawakami S, et al. (2018) Open-label clinical trial of bezafibrate treatment in patients with fatty acid oxidation disorders in Japan. *Mol Genet Metab Rep* **15**:55–63.
- Yamada KA, Kanter EM, and Newatia A (2000) Long-chain acylcarnitine induces Ca²⁺ efflux from the sarcoplasmic reticulum. *J Cardiovasc Pharmacol* **36**:14–21.
- Yamada KA, McHowat J, Yan GX, Donahue K, Peirick J, Kléber AG, and Corr PB (1994) Cellular uncoupling induced by accumulation of long-chain acylcarnitine during ischemia. *Circ Res* **74**:83–95.
- Yan X, Markey SP, Marupaka R, Dong Q, Cooper BT, Mirokhin YA, Wallace WE, and Stein SE (2020) Mass spectral library of acylcarnitines derived from human urine. *Anal Chem* **92**:6521–6528.
- Yang Y, Choi H, Lee CN, Kim YB, and Kwak YT (2018) A multicenter, randomized, double-blind, placebo-controlled clinical trial for efficacy of acetyl-L-carnitine in patients with dementia associated with cerebrovascular disease. *Dement Neurocognitive Disord* **17**:1–10.
- Yano S, Sweetman L, Thorburn DR, Mofidi S, and Williams JC (1997) A new case of malonyl coenzyme A decarboxylase deficiency presenting with cardiomyopathy. *Eur J Pediatr* **156**:382–383.
- Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Bond DJ, Frey BN, Sharma V, Goldstein BI, Rej S, Beaulieu S, et al. (2018) Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. *Bipolar Disord* **20**:97–170.
- Yi WJ, Chen J, Li ZB, Jiang TT, Bi DQ, Liu CM, Yang S, Hu YT, Gan L, Tu HH, et al. (2020) Screening of potential biomarkers for Yin-deficiency-heat syndrome based on UHPLC-MS method and the mechanism of Zhibai Dihuang granule therapeutic effect. *Anat Rec (Hoboken)* **303**:2095–2108.
- Yokoi K, Ito T, Maeda Y, Nakajima Y, Kurono Y, Sugiyama N, and Togari H (2009) A case of holocarboxylase synthetase deficiency with insufficient response to prenatal biotin therapy. *Brain Dev* **31**:775–778.
- Yoon DW, Kwon HN, Jin X, Kim JK, Lee SK, Park S, Yun CH, and Shin C (2019) Untargeted metabolomics analysis of rat hippocampus subjected to sleep fragmentation. *Brain Res Bull* **153**:74–83.
- Youle M and Osio M; ALCAR Study Group (2007) A double-blind, parallel-group, placebo-controlled, multicentre study of acetyl L-carnitine in the symptomatic treatment of antiretroviral toxic neuropathy in patients with HIV-1 infection. *HIV Med* **8**:241–250.
- Young SP, Matern D, Gregersen N, Stevens RD, Bali D, Liu HM, Koeberl DD, and Millington DS (2003) A comparison of in vitro acylcarnitine profiling methods for the diagnosis of classical and variant short chain acyl-CoA dehydrogenase deficiency. *Clin Chim Acta* **337**:103–113.
- Yu D, Zhou L, Xuan Q, Wang L, Zhao X, Lu X, and Xu G (2018) Strategy for comprehensive identification of acylcarnitines based on liquid chromatography-high-resolution mass spectrometry. *Anal Chem* **90**:5712–5718.
- Yu XX, Drackley JK, and Odle J (1997) Rates of mitochondrial and peroxisomal β -oxidation of palmitate change during postnatal development and food deprivation in liver, kidney and heart of pigs. *The Journal of Nutrition* **127**:1814–1821.
- Yu ZR, Ning Y, Yu H and Tang NJ (2014) A HPLC-Q-TOF-MS-based urinary metabolomic approach to identification of potential biomarkers of metabolic syndrome. *J Huazhong Univ Sci Technol Med Sci* **34**:276–283.
- Zafeiriou DI, Augoustides-Savvopoulou P, Haas D, Smet J, Triantafyllou P, Vargiami E, Tamiolaki M, Gombakis N, van Coster R, Sewell AC, et al. (2007) Ethylmalonic encephalopathy: clinical and biochemical observations. *Neuropediatrics* **38**:78–82.
- Zanardi R and Smeraldi E (2006) A double-blind, randomised, controlled clinical trial of acetyl-L-carnitine vs. amisulpride in the treatment of dysthymia. *Eur Neuropsychopharmacol* **16**:281–287.
- Zhang J, Light AR, Hoppel CL, Campbell C, Chandler CJ, Burnett DJ, Souza EC, Casazza GA, Hughes RW, Keim NL, et al. (2017a) Acylcarnitines as markers of exercise-associated fuel partitioning, xenometabolism, and potential signals to muscle afferent neurons. *Exp Physiol* **102**:48–69.
- Zhang X, Li Y, Liang Y, Sun P, Wu X, Song J, Sun X, Hong M, Gao P, and Deng D (2017b) Distinguishing intracerebral hemorrhage from acute cerebral infarction through metabolomics. *Rev Invest Clin* **69**:319–328.
- Zhang X, Zhang C, Chen L, Han X, and Ji L (2014) Human serum acylcarnitine profiles in different glucose tolerance states. *Diabetes Res Clin Pract* **104**:376–382.
- Zhao S, Feng XF, Huang T, Luo HH, Chen JX, Zeng J, Gu M, Li J, Sun XY, Sun D, et al. (2020) The association between acylcarnitine metabolites and cardiovascular disease in chinese patients with type 2 diabetes mellitus. *Front Endocrinol (Lausanne)* **11**:212.
- Zhong H, Fang C, Fan Y, Lu Y, Wen B, Ren H, Hou G, Yang F, Xie H, Jie Z, et al. (2017) Lipidomic profiling reveals distinct differences in plasma lipid composition in healthy, prediabetic, and type 2 diabetic individuals. *Gigascience* **6**:1–12.
- Ziats MN, Comeaux MS, Yang Y, Scaglia F, Elsea SH, Sun Q, Beaudet AL, and Schaaf CP (2015) Improvement of regressive autism symptoms in a child with TMLHE deficiency following carnitine supplementation. *Am J Med Genet A* **167A**:2162–2167.
- Zoni E, Minoli M, Bovet C, Wehrhan A, Piscuoglio S, Ng CKY, Gray PC, Spahn M, Thalmann GN, and Kruthof-de Julio M (2019) Preoperative plasma fatty acid metabolites inform risk of prostate cancer progression and may be used for personalized patient stratification. *BMC Cancer* **19**:1216.
- Zordoky BN, Sung MM, Ezekowitz J, Mandal R, Han B, Bjorn Dahl TC, Bouatra S, Anderson T, Oudit GY, Wishart DS, et al.; Alberta HEART (2015) Metabolomic fingerprint of heart failure with preserved ejection fraction. *PLoS One* **10**:e0124844.
- Zuniga A and Li L (2011) Ultra-high performance liquid chromatography tandem mass spectrometry for comprehensive analysis of urinary acylcarnitines. *Anal Chim Acta* **689**:77–84.